Cancer evidence library
Breast Cancer
A living PubMed evidence library for breast cancer research, treatment, outcomes, risks, and emerging therapies.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 904 non-retracted PubMed-indexed records for Breast Cancer. The structured collection includes 6 guideline or consensus records, 127 evidence syntheses/systematic reviews/meta-analyses, and 85 randomized or phase III studies. 366 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 697 of 904 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
1
2014
2
2017
1
2019
1
2020
2
2021
21
2022
14
2023
26
2024
56
2025
780
2026
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Reported outcomes
Numerical results extracted from PubMed abstracts
Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.
Non-pooled ratio measures
Reference = 1.0
Hazard, risk, and odds ratios reported in abstracts
0.250.51.02.04.0
View extracted numerical results 60
| Publication | Outcome | Measure | Reported value | Source |
|---|---|---|---|---|
| Relationship between incident cardiovascular disease and quality of life after a breast cancer diagnosis.Journal of cancer survivorship : research and practice · 2026 | not_reported | Hazard Ratio | 1.23 P < 0.001 | PMID 39909978 |
| Curietherapy User eXperience Pilot Study (CurieUx): A Feasibility Study of a Novel Augmented Reality Educational Tool During Radiation Oncology Consultation for Patients With Breast Cancer.International journal of radiation oncology, biology, physics · 2026 | not_reported | Odds Ratio | 5.0 | PMID 41539575 |
| Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 | not_reported | Hazard Ratio | 0.51 | PMID 41587113 |
| Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 | not_reported | Hazard Ratio | 0.44 | PMID 41587113 |
| Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 | not_reported | Hazard Ratio | 0.45 | PMID 41587113 |
| AI software as a third reader in breast cancer screening-a prospective diagnostic observational study.European radiology · 2026 | not_reported | Odds Ratio | 5.0 | PMID 41642301 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 3.91 95% CI 1.439–10.624 | PMID 41658476 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 11.35 95% CI 3.45–37.345 | PMID 41658476 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 0.208 95% CI 0.045–0.967 | PMID 41658476 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 0.676 95% CI 0.506–0.904 | PMID 41658476 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 0.921 95% CI 0.855–0.993 | PMID 41658476 |
| Radiation Dose and Lymphedema Risk After Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection.International journal of radiation oncology, biology, physics · 2026 | not_reported | Percentage Comparison | 89.0percent vs 20.0percent P = .006 | PMID 41666961 |
| Radiation Dose and Lymphedema Risk After Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection.International journal of radiation oncology, biology, physics · 2026 | not_reported | Percentage Comparison | 84.0percent vs 17.0percent P = .006 | PMID 41666961 |
| Radiation Dose and Lymphedema Risk After Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection.International journal of radiation oncology, biology, physics · 2026 | not_reported | Percentage Comparison | 92.0percent vs 30.0percent P = .006 | PMID 41666961 |
| Radiation Dose and Lymphedema Risk After Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection.International journal of radiation oncology, biology, physics · 2026 | not_reported | Percentage Comparison | 92.0percent vs 22.0percent P = .006 | PMID 41666961 |
| Clinical Hypothyroidism After Proton Versus Photon Regional Nodal Irradiation: A Prospective Correlative Study Within the RADCOMP Randomized Trial.International journal of radiation oncology, biology, physics · 2026 | not_reported | Hazard Ratio | 3.02 | PMID 41692352 |
| Clinical Hypothyroidism After Proton Versus Photon Regional Nodal Irradiation: A Prospective Correlative Study Within the RADCOMP Randomized Trial.International journal of radiation oncology, biology, physics · 2026 | not_reported | Hazard Ratio | 8.8 | PMID 41692352 |
| Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.Journal of the National Cancer Institute · 2026 | recurrence | Percentage Comparison | 93.0percent vs 89.0percent | PMID 41712503 |
| Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.Journal of the National Cancer Institute · 2026 | recurrence | Percentage Comparison | 76.0percent vs 66.0percent | PMID 41712503 |
| Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.Journal of the National Cancer Institute · 2026 | recurrence | Percentage Comparison | 72.0percent vs 57.0percent | PMID 41712503 |
| Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.Journal of the National Cancer Institute · 2026 | recurrence | Percentage Comparison | 55.0percent vs 37.0percent | PMID 41712503 |
| Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.Journal of the National Cancer Institute · 2026 | not_reported | Hazard Ratio | 0.68 95% CI 0.46–0.99 | PMID 41712503 |
| Contrast-enhanced mammography versus breast MRI in the preoperative evaluation of the nipple-areola complex: data from a real-world setting.European radiology · 2026 | not_reported | Odds Ratio | 26.3 95% CI 3.9–100.0 p = 0.0007 | PMID 41735676 |
| Contrast-enhanced mammography versus breast MRI in the preoperative evaluation of the nipple-areola complex: data from a real-world setting.European radiology · 2026 | not_reported | Odds Ratio | 14.0 95% CI 1.5–133.5 p = 0.0007 | PMID 41735676 |
| Contrast-enhanced mammography versus breast MRI in the preoperative evaluation of the nipple-areola complex: data from a real-world setting.European radiology · 2026 | not_reported | Odds Ratio | 0.28 95% CI 0.1–0.6 p = 0.0007 | PMID 41735676 |
| Cognitive behavioral stress management and physical activity in breast cancer survivors: A two-part growth model.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2026 | not_reported | Odds Ratio | 1.0 | PMID 41785110 |
| Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.International journal of cancer · 2026 | not_reported | Hazard Ratio | 0.37 | PMID 41787605 |
| Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.International journal of cancer · 2026 | not_reported | Hazard Ratio | 0.35 | PMID 41787605 |
| Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.Annals of medicine · 2026 | not_reported | Odds Ratio | 1.15 95% CI 1.09–1.22 | PMID 41808362 |
| Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.Annals of medicine · 2026 | not_reported | Odds Ratio | 1.44 95% CI 1.26–1.64 | PMID 41808362 |
| Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.Annals of medicine · 2026 | not_reported | Odds Ratio | 1.0 95% CI 0.91–1.1 | PMID 41808362 |
| Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.Annals of medicine · 2026 | not_reported | Odds Ratio | 0.78 95% CI 0.7–0.87 | PMID 41808362 |
| Evaluating the Feasibility of Breast-Conserving Surgery in Breast Cancer Patients with Suspicious Calcifications After Neoadjuvant Chemotherapy: A Retrospective Cohort Study.Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2026 | not_reported | Percentage Comparison | 73.7percent vs 26.3percent p = 0.012 | PMID 41814780 |
| Evaluating the Feasibility of Breast-Conserving Surgery in Breast Cancer Patients with Suspicious Calcifications After Neoadjuvant Chemotherapy: A Retrospective Cohort Study.Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2026 | not_reported | Odds Ratio | 0.26 95% CI 0.08–0.73 | PMID 41814780 |
| Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations.European radiology · 2026 | not_reported | Odds Ratio | 15.4 p < 0.001 | PMID 41832929 |
| Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations.European radiology · 2026 | not_reported | Odds Ratio | 10.2 p < 0.001 | PMID 41832929 |
| Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations.European radiology · 2026 | not_reported | Odds Ratio | 2.49 p < 0.001 | PMID 41832929 |
| Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations.European radiology · 2026 | not_reported | Percentage Comparison | 58.0percent vs 16.0percent p < 0.001 | PMID 41832929 |
| Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations.European radiology · 2026 | not_reported | Percentage Comparison | 50.0percent vs 8.7percent p < 0.001 | PMID 41832929 |
| Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations.European radiology · 2026 | not_reported | Percentage Comparison | 60.7percent vs 38.7percent p < 0.001 | PMID 41832929 |
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
NCI NIH HHS95
NHLBI NIH HHS22
National Natural Science Foundation of China16
NIH HHS16
NIGMS NIH HHS14
National Cancer Institute (NCI)14
The Region of Västmanland13
NCATS NIH HHS7
View records with declared financial or industry relationships 12
Combination Therapy with Cisplatin and Activatable Liposomes on Breast Cancer Cells.
Author K.G. was employed by the company BIOMEDRIC LLC. The authors declare that preliminary studies for this research received funding from Marmara University Scientific Research Projects Unit. The funder had no involvement in the study design, data collection, analysis, interpretation of data, the writing of the manuscript, or the decision to submit the paper for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
PMID 42515734 · 2026Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials.
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FP reports research grants from AstraZeneca, Eisai, and Roche. FP has received consulting fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, Menarini, MSD, Novartis, Pfizer, and Roche; and payments/honoraria from AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, Italfarmaco, Menarini, MSD, Novartis, Pfizer, and Roche. FP has served in advisory roles for Amgen, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Novartis, Pfizer, and Roche. FP has received travel support and accommodation from AstraZeneca, Daiichi Sankyo, Menarini, Pfizer, and Roche, and has participated in advisory boards for AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Menarini, MSD, Novartis, Pfizer, and Roche. MP reports institutional funding from Gilead and travel reimbursement from Ipsen. LDM reports grants from Eli Lilly, Novartis, Roche, Daiichi Sankyo, Seagen, AstraZeneca, Gilead, Pierre Fabre, Pfizer, Menarini Stemline, and MSD. LDM has received consulting fees from Novartis, Roche, Daiichi Sankyo, Eli Lilly, Gilead, Pfizer, Menarini Stemline, Olema, and AstraZeneca; and honoraria from Eli Lilly, Novartis, Roche, Daiichi Sankyo, Seagen, AstraZeneca, Gilead, Pierre Fabre, Pfizer, Menarini Stemline, MSD, Exact Sciences, GSK, Ipsen, and Eisai. LDM has received travel grants from Roche, Gilead, Menarini Stemline, AstraZeneca, and Daiichi Sankyo. LDM has served on advisory boards for Eli Lilly, Novartis, Roche, Daiichi Sankyo, Seagen, AstraZeneca, Gilead, Pierre Fabre, Pfizer, Menarini Stemline, MSD, Exact Sciences, GSK, Ipsen, and Eisai. LDM reports receipt of equipment from FoundationOne.MDL reports relationships with Roche, Novartis, Takeda, Eli Lilly, Pierre Fabre, AstraZeneca, MSD, Seagen, Gilead, Daiichi Sankyo, Tomalab, Genetic, Pfizer, Menarini, Sophos, Istituto Gentili, Sanofi, Ipsen, GSK, and Exact Sciences, including consulting/advisory roles and travel reimbursement. MG reports relationships with AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Celgene, Exact Sciences, Eli Lilly, MSD, Novartis, Pfizer, Roche, and Seagen, including consulting/advisory roles and travel reimbursement. GA reports relationships with Roche, Pfizer, Eli Lilly, MSD, AstraZeneca, and Novartis, including consulting/advisory roles and research funding grants. PV has received honoraria and served in advisory roles for AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Incyte, Istituto Gentili, Novartis, Pfizer, Roche, Seagen, and Teva. PV has received travel support and accommodation from Daiichi Sankyo, Eli Lilly, and Novartis. PV reports research funding to the institution from Novartis and AstraZeneca.CDA reports consulting or advisory relationships with Novartis, GSK, Eli Lilly, and Pfizer. EDA reports honoraria and/or advisory board participation from Roche/GNE, Novartis, Seagen, Zodiac, Libbs, Pierre Fabre, Lilly, AstraZeneca, MSD, and Gilead Sciences; travel grants from AstraZeneca and Gilead; institutional research grants from Roche/GNE, AstraZeneca, GSK/Novartis, Gilead Sciences, and Seagen/Pfizer; and non-financial roles as ESMO Director of Membership (2023–2025) and BSMO President (2023–2026). LA reports travel grants from AstraZeneca and institutional research funding from Gilead Sciences. All other authors declare no competing financial interests or personal relationships that could have influenced the work reported in this paper.
PMID 42285001 · 2026Modeling Cure from Cancer Accounting for Inevitable Mortality.
Conflict of Interest Statement Suchitrita S. Rathmann is an employee and stockholder of Merck & Co., Inc., Rahway, NJ, U.S.A. Qi Jiang is an employee and stockholder of AbbVie Inc., North Chicago, IL, U.S.A. The authors declare that they have no other conflicts of interests. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of their respective institutions/organizations.
PMID 42540647 · 2026ESR1 activating mutations: From structure to clinical application.
Declaration of Competing Interest RJ received research funding from Pfizer and Lilly and is an advisor for GE Health. SWF receives research funding and is a member of the scientific advisory board at Olema Oncology.
PMID 36336145 · 2023A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor-Positive Metastatic Breast Cancer.
A.A. Gabizon reports grants from the Israel Cancer Association and Merck during the conduct of the study. A. Yaacov reports personal fees from Protica Bio outside the submitted work; in addition, A. Yaacov has a patent to “Machine learning identification of mutational signatures” issued. A. Grinshpun reports grants from Merck during the conduct of the study, as well as personal fees from Novartis, Pfizer, AstraZeneca, and Roche and grants from Daichi Sankyo outside the submitted work. No disclosures were reported by the other authors.
PMID 42361329 · 2026First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.
Competing interests: P.S. has received research grants from Astellas Pharma (institution), AstraZeneca (institution), Roche/Genentech, Medivation (institution), Novartis and OncoGenex Pharmaceuticals (institution), consultant fees from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Roche, Merck, Novartis, Pfizer and Puma Biotechnology and data and safety monitoring fees from Novartis. S.-A.I. has received research grants from AstraZeneca (institution), Boryung Corporation (institution), Daewoong Pharmaceutical Company (institution), Daiichi Sankyo Company (institution), Eisai Korea (institution), F. Hoffmann-La Roche (institution) and Pfizer (institution) and consultant fees from AstraZeneca, Bertis, Daiichi Sankyo Company, Eisai, Eli Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Hanmi Pharmaceutical Co., Idience Co. Ltd Consultant, MSD Korea, Novartis and Pfizer. Z.N. has received travel expenses from Roche and research grants from Roche (institution). P.J.W. has received consulting fees from, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Immunicom, Merck, Astellas, Janssen and Ipsen, honoraria from Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Immunicom, Pfizer, Merck, Astellas, Janssen and Ipsen and travel expenses from Bristol-Myers Squibb, AstraZeneca and Pierre Fabre. J.J. has received consultant fees from AstraZeneca, Pfizer, MSD and Bristol-Myers Squibb, honoraria from AstraZeneca, Roche (not compensated) and Pfizer and travel expenses from AstraZeneca, Roche and Pfizer. K.H.J. has received consultant fees from AstraZeneca, BIXINK, Celgene, Daiichi Sankyo, Eisai, Everest Medicines, Gilead Sciences, MSD, Novartis, Pfizer, Roche and Takeda Pharmaceuticals. S.L. has received research funding from CRUK (institution and personal), Boehringer Ingelheim (institution), Piqur Therapeutics (institution), AstraZeneca (institution), Carrick Therapeutics (institution), Sanofi (institution), Merck KGaA (institution), Synthon (institution), Roche (institution), NIHR (institution and personal), Against Breast Cancer (institution and personal) and Pathios Therapeutics (institution and personal), consultant fees from Sanofi, GLG consulting, Rejuversen, Oxford Biodynamics and Exscientia, honoraria from Eisai, Prosigna, Roche, Pfizer, Novartis and Sanofi, travel expenses from Pfizer, Roche, Synthon and Piqur Therapeutics and advisory board fees from Shionogi, Sanofi and Exscientia and has stock or stock options in Mitox Therapeutics. J.A. has stock or stock options and employment with AstraZeneca. R.S. has stock or stock options and employment with AstraZeneca. P.V. has stock or stock options and employment with AstraZeneca. N.D. has stock or stock options and employment with AstraZeneca. Y.H.P. has received research grants from AstraZeneca (institution), Merck (institution) and Pfizer (institution) and consultant fees from Daiichi Sankyo, Eisai, Lilly, Menarini, Helsinn, Novartis and Pfizer.
PMID 42259988 · 2026Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2- Breast Cancer and Palpable Adenopathy: A Nonrandomized Clinical Trial.
Conflict of Interest Disclosures: Dr Barrio reported speaking honoraria from Novartis and MSD outside the submitted work. Dr Kirstein reported professional services and activities for Boston Scientific. Dr Lee reported equity and professional services and activities for Biologica. Dr Plitas reported professional services and activities for Merck & Co, research funding from Paige.AI, and intellectual property rights for Takeda Pharmaceuticals. Dr Sacchini reported professional services and activities for Best Doctors, Brust-Zentrum Zurich, Spital Oberengadin, and the Universita’ degli Studi di Milano. Dr Morrow reported speaking honoraria from Roche. No other disclosures were reported.
PMID 42090164 · 2026A mixed prebiotic/probiotic intervention (MBR-01) for the management of diarrhea during abemaciclib treatment of early breast cancer in postmenopausal patients: A single-center prospective case-control pilot study.
Declaration of competing interest F. Schettini reports honoraria from Novartis, Astra-Zeneca, Gilead, Veracyte and Daiichy-Sankyo for educational events/materials, advisory fees from Astra-Zeneca, Pfizer, Daiichy-Sankyo and Veracyte, and travel expenses from Novartis, Gilead and Daiichy-Sankyo. D. Generali reports honoraria from Novartis, Astra-Zeneca, Pfizer, Lilly, Roche and Daiichy-Sankyo for educational events/materials, advisory fees from Novartis, Astra-Zeneca, Pfizer, Lilly and Roche, travel expenses from Roche and research grants from Novartis, Pfizer and Myriad. All remaining authors have no relevant financial or non-financial interests to disclose.
PMID 42235180 · 2026Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Disclosure: Sherko Kuemmel: Advisory board: AstraZeneca, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Exact Science, Lilly Deutschland, Novartis, Pfizer, Gilead, Seagen Hologic, Stemline, PINK; speaker: F. Hoffmann-La Roche, Lilly Deutschland, Novartis Pharma, Sonoscape; IDMC and Steering Committee: F. Hoffmann-La Roche; Scientific Advisory Board speaking engagement: MSD, Novartis Pharma; Steering Committee: Novartis F. Hoffmann-La Roche; travel grants: Daiichi Sankyo, F. Hoffmann-La Roche, Roche. Peter A. Fasching: Personal fees from from Merck Sharp & Dohme and institutional feed from Merck Sharp & Dohme. Personal fees from Novartis, grants from Biontech, grants and personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from Astra Zeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from SeaGen, personal fees from Roche, personal fees from Agendia, personal fees from Gilead, personal fees from Mylan, personal fees from Menarini, personal fees from Veracyte, personal fees from GuardantHealth, during the conduct of the study; and Translational Research in Oncology (TRIO). Peter Schmid: Consultant to or received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma, Roche, Eisai, and Celgene. Grant funding (to institution) from Astellas, AstraZeneca, Genentech, Novartis, Oncogenex, Roche, Medivation, and Merck. Nadia Harbeck: Consultant to or received honoraria from: AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Novartis, F. Hoffmann-La Roche, Pfizer Pharma GmbH, Pierre Fabre Pharmaceuticals, Inc., Sandoz, Seagen Inc., Viatris, and Zuelligpharma. Business ownership: West German Study Group. Masato Takahashi: Lecture fees from AstraZeneca, Daiichi-Sankyo, Eisai, Eli Lilly, MSD, and Pfizer. Michael Untch: Honoraria for lectures, presentations from Astra Zeneca, Daiichi Sankyo, Lilly, EurBio Scientific, Myriad Genetics, Novartis, Pfizer, Roche, Sanofi Aventis, Menarini Stemline, MSD Merck; honoraria for advisory boards from AstraZeneca, Daiichi Sankyo, Lilly, MSD Merck, Myriad Genetics, Novartis, Pierre Fabre, Pfizer, Gilead, Roche, Sanofi Aventis, Seagen, Menarini Stemline, BeOne Germany. Jean-Francois Boileau: Grant/contract: AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche, Merck, Novartis, Pfizer Canada Inc.; consultant: AstraZeneca Canada, Eli Lilly and Company, F. Hoffmann-La Roche, Merck, Pfizer Canada Inc., Novartis. Javier Cortes: Consulting/advisory fees: AbbVie, AstraZeneca, Bioasis, Biocon, BioInvent, Biontech, Boehringer Ingelheim, BridgeBio, Circle Pharma, Clovis Oncology, Daiichi Sankyo, Ellipses, ExpreS2ion Biotechnologies, Gemoab, Gilead, Hibercell, Jazz Pharmaceuticals, Leuko, Lilly, Menarini, MSD, Reveal Genomics, Roche, Scorpion Therapeutics, Seattle Genetics, and Zymeworks. Honoraria: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, and Stemline Therapeutics. Research funding to the Institution: Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardant Health, IQVIA, MSD, Pfizer, Piqur Therapeutics, Queen Mary University of London, and Roche. Stock: Leuko (relative), MAJ3 Capital. Travel, accommodation, expenses: from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, MSD, Novartis, Pfizer, Roche, and Stemline Therapeutics. Patent for HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy (Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. Issued), and pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent (Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1. Licensed). Rebecca Dent: Consultant for Genentech. Travel from Genentech, MSD, and Pfizer. Other from AstraZeneca, Eisai, Eli Lilly and Company, Genentech, MSD, Novartis, and Pfizer. Joyce O’Shaughnessy: Honoraria for consulting and/or advisory boards from AbbVie Inc., Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, Lilly, Loxo Oncology, Merck, Mersana Therapeutics, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, and Veru. Lajos Pusztai: Clinical trial funding to my institution from Merck. Personal honorarium for consulting from Merck. Consulting fees and honoraria for advisory board participation from Pfizer, Astra Zeneca, Bristol-Myers Squibb, Stemline-Menarini, BeOne, Personalis, Natera, Agendia, Exact Sciences, Radionetics, and institutional research funding from Pfizer, AstraZeneca, Merck, Menarini-Stemline, Radionetics, Exact Sciences. Stock options in Ataraxis. Theodoros Foukakis: Invited speaker, payment to institution: Roche, Astra Zeneca, Gilead Sciences, Novartis, Daiichi Sankyo, Bristol Myers Squibb; royalties, personal: Wolters Kluwer (authorship of two chapters in UpToDate); clinical trial support to institution: AstraZeneca, Coordinating PI (research grant and study drug), Novartis; coordinating PI (research grant and study drug), Veracyte; coordinating PI (discount on the ProsignaPAM50 assay in ARIADNE clinical trial). Yeon Hee Park: Consultancy or advisory fees from AstraZeneca, Eisai, Eli Lilly Export S.A. Puerto Rico Branch, Novartis, Pfizer, and Roche. Research funding from AstraZeneca, MSD, Novartis, Pfizer, and Roche. Rina Hui: Consultant for Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly and Company, Janssen, Johnson & Johnson, Merck KGaA, MSD, Novartis, OncoSec Medical Incorporated, Pfizer Australia, Roche Products Pty Ltd, Seagen Inc, Takeda, and Zai Lab. Speaker honorarium from AstraZeneca, Daiichi Sankyo, Eli Lilly, Janssen, MSD, and Novartis. Research support to institution from AstraZeneca, Bristol-Myers Squibb, Corvus, Eisai, Eli Lilly, Janssen, MSD, Novartis, Oncosec, Olema, Roche, and Seagen. Fatima Cardoso: Payment or honoraria for advisory boards or educational events from Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, MSD, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung, Bioepis, Seagen, Teva, and Touchime. Carsten Denkert: Consultant for Daiichi Sankyo Company and MSD. Grant/contract from Myriad Genetic Laboratories, Inc. Other business ownership: Sividon diagnostics. Patent for therapy response (patent number: EP20150702464, WO2015114146A1, and WO2010076322A1) and diagnostic tests for cancer immunotherapy (patent number: EP18209672 and WO2020109570A1). Other from Amgen, F. Hoffmann-La Roche, Novartis, Pfizer, and Teva Pharmaceutical Industries. Liyi Jia, Wibur Pan, and Vassiliki Karantza: Employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Heather McArthur: Consulted for Bristol-Myers Squibb, Eli Lilly, Immunomedics, Merck, Pfizer, Daiichi-Sankyo, Seattle Genetics, AstraZeneca, Gilead, and Crown Bioscience; Research supported by Bristol-Myers Squibb; MedImmune, LLC/AstraZeneca; BTG; and Merck.
PMID 41739398 · 2026Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial.
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Simona F. Shaitelman reports equipment, drugs, or supplies was provided by Exact Sciences Corporation. Simona F. Shaitelman reports financial support and administrative support were provided by The University of Texas MD Anderson Cancer Center. Yu Shen and Heather Lin report data were generated in part through the use of the Biostatistics Resrouce Group (BRG), which receives partial support from the National Cancer Institute under grant P30CA016672 to UT MD Anderson Cancer Center. The research reported in this publicatin was not directly funded through grant P30CA016672 to UT MD Anderson Cancer Center and is not within the scope of said grant. Simona F. Shaitelman reports a relationship with ARTIDIS that includes: funding grants and travel reimbursement. Simona F. Shaitelman reports a relationship with Radionetics that includes: funding grants. Simona F. Shaitelman reports a relationship with Lumicell Inc that includes: funding grants, consulting or advisory. Benjamin D. Smith reports a relationship with ARTIDIS that includes: funding grants. Benjamin D. Smith reports a relationship with Oncora Medical Inc that includes: equity or stocks. Wendy A. Woodward reports a relationship with State of Texas Grant for Rare and Aggressive Breast Cancer that includes: funding grants. Wendy A. Woodward reports a relationship with National Institutes of Health that includes: funding grants. Savitri Krishnamurthy reports a relationship with Astra Zeneca that includes: board membership. Savitri Krishnamurthy reports a relationship with Daiichi Sankyo Inc that includes: board membership. Savitri Krishnamurthy reports a relationship with Hologic Inc that includes: funding grants. Savitri Krishnamurthy reports a relationship with Pathomiq that includes: funding grants. Savitri Krishnamurthy reports a relationship with AiraMatrix that includes: funding grants. Savitri Krishnamurthy reports a relationship with Artidis that includes: funding grants. Henry Kuerer reports a relationship with McGraw-Hill Professional Division that includes: consulting or advisory. Henry Kuerer reports a relationship with Elsevier that includes: consulting or advisory. Henry Kuerer reports a relationship with UptoDate Inc that includes: consulting or advisory. Henry Kuerer reports a relationship with Chartis Healthcare that includes: consulting or advisory. Chelain R. Goodman reports a relationship with Myriad Genetics Inc that includes: funding grants. Chelain R Goodman reports a relationship with Menarini Silicon Biosystems Inc that includes: funding grants. William F Symmans reports a relationship with AstraZeneca that includes: consulting or advisory. William F Symmans reports a relationship with Ionis Pharmaceuticals Inc that includes: equity or stocks. William F Symmans reports a relationship with Delphi Diagnostics that includes: equity or stocks. William F Symmans has patent #WO2024227177 issued to University of Texas MD Anderson Cancer Center. William F Symmans has patent #11,459,617 issued to University of Texas MD Anderson Cancer Center. Division of Radiation Oncology Biomarker Strategic Initiative Laboratory Group reports philanthropic funding support from the Donald J. Childress Family Foundation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PMID 42142534 · 2026Development and Preliminary Validation of a Tool to Assess Barriers and Facilitators to Participation in Adjuvant Endocrine Therapy Switch Trials.
The authors declare the following financial interests/personal relationships (all outside the submitted work): A.S.: Advisory Board: Bristol-Myers-Squibb (BMS), Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp and Dohme (MSD). Consultancy: Arqule, Sanofi, Incyte. Speaker’s Bureau: Takeda, BMS, Roche, Abb-Vie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD (all outside the submitted work). R.D.S.: honoraria for advisory board consultancy from Novartis, Istituto Clinico Gentili, Amgen, EISAI, Lilly, Gilead, and Ipsen (all outside the present work). A.Z.: honoraria and advisory board consultancy from Novartis, AstraZeneca, Lilly, Pfizer, Daiichi Sankyo, MSD, Roche, Seagen, Exact Sciences, Gilead, Istituto Gentili (all outside the present work). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
PMID 42346261 · 2026Italian guidelines for the use of digital breast tomosynthesis in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.
Declarations. Competing interests: Silvia Deandrea is President of the Italian Mammography Screening Group. Marco Rosselli Del Turco is a former medical consultant for senology to the FORA s.p.a. Paolo Giorgi Rossi and Livia Giordano are members of the panel that developed the European guidelines on breast cancer screening and diagnosis, which is the reference document for the ADOLOPMENT process. Vittorio Cannatà is a former Vice-President of the Italian Association of Medical Physics (AIFM). Isabella Castellano has been a professional consultant for the “Choosing the best therapy in ER + /HER2- breast cancer” symposium (token of attendance at the National Congress of Anatomic Pathology, October 2019), Myriad Genetics, s.r.l. Stefano Pacifici is President of the Italian Association of Senology Radiographers (AITeRS). Annalisa Trianni is member of the Italian Association of Medical Physics (AIFM). Paola Golinelli was reimbursed for participation in the European Federation of Organization for Medical Physics (EFOMP) Working Group on mammographic tomosynthesis equipment. The other authors have no relevant financial or non-financial interest to disclose. Gian Paolo Morgano is a contract staff member at the Joint Research Centre (JRC) of the European Commission, Ispra, VA (Italy). All panellists were required to disclose all financial, non-financial, personal, and institutional interests relevant to the scope of the guidelines by completing a standardized form, following the guidance from the guidance from the SNLG. The Scientific Committee assessed each individual interest, and ultimately, no panellist was excluded from the voting procedures. This policy was upheld throughout the entire process, including the selection of panel members, the generation and prioritization of research questions, and participation in the formulation of recommendations. The Scientific Committee consistently monitored the declaration of conflicts of interest. Francesco Sardanelli reports sponsored talks or ad hocadvisory board participation for Bayer Healthcare, Bracco Group, GE Healthcare, and Siemens Healthineers as well as research grants from Bayer Healthcare, Bracco Group, and GE Healthcare; in addition, he is the Scientific PI ofthe BreastSCan project (Pan-European Breast Image Platform for Advanced AI-based Breast Cancer Screening),funded by the European Commission under the EU4Health Programme.
PMID 41784888 · 202601
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
DEGRO practical guidelines: radiotherapy of breast cancer-regional nodal irradiation.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
PMID 42289007AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
PMID 42173036[Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain].
Atencion primaria · 2026
PMID 42296659Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026
PMID 42425164Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2).
Annals of internal medicine · 2026
PMID 41996183Italian guidelines for the use of digital breast tomosynthesis in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.
La Radiologia medica · 2026
PMID 41784888Robotic versus conventional nipple-sparing mastectomy in early breast cancer: a systematic review and meta-analysis.
BMC surgery · 2026
PMID 42067887Health Economic Evaluations of Breast Cancer Screening Strategies: A Systematic Review Focusing on Methodology and Quality Assessment.
Applied health economics and health policy · 2026
PMID 42213316Targeted axillary dissection in the primary surgery setting for node-positive breast cancer: A systematic review.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
PMID 42068696Breast Lesions in Women ≤ 40 Years: Diagnostic Accuracy and Risk of Malignancy of Fine Needle Aspiration Cytology Based on the World Health Organization Breast Cytology Reporting System-A Systematic Review and Meta Analysis.
Diagnostic cytopathology · 2026
PMID 42204730Economic Evaluation of Breast Cancer Screening in China: A Systematic Review of Costs and Cost-Effectiveness.
Value in health regional issues · 2026
PMID 41707447RGS Family Remodeling in Breast Cancer: A Meta-Analysis and Multi-Omics Profiling of Prognostic Biomarkers.
Cancer medicine · 2026
PMID 4252029102
Highest-Priority Research
DEGRO practical guidelines: radiotherapy of breast cancer-regional nodal irradiation.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
AIM: The aim of this work is to update the practical guidelines for adjuvant radiotherapy of the regional lymphatics in breast cancer, originally issued in 2014 by the Breast Cancer Expert Panel of the German Society of Radiation Oncology. METHODS: A comprehensive literature review concerning regional nodal irradiation (RNI) was performed using the search terms "breast cancer," "radiotherapy," and "regional node irradiation." Furthermore, data from recently published meta-analyses and international breast cancer society guidelines-providing new insights since 2014-served as the basis for defining evidence-based recommendations. This paper delineates the indications and dose-fractionation str…
PMID 42289007AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
The German Guideline Committee (AGO: Working Group on Gynecologic Cancers) updated its yearly recommendations on the diagnosis and treatment of breast cancer in March 2026. Chapters on oncological and oncoplastic-reconstructive surgery are coordinated with the Working Group for Plastic, Aesthetic, and Reconstructive Surgery in Gynecology (AWOgyn). The most important changes include the ommission of sentinel lymph node biopsy (SLNB) and preffered axillary staging in patients with node-positive breast cancer undergoing neoadjuvant chemotherapy (NACT). Targeted axillary dissection (TAD) is endorsed as the method of choice [AGO ++] in patients converting from cN + to ycN0 status, and other de-es…
PMID 42173036[Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain].
Atencion primaria · 2026
Metastatic breast cancer (mBC) has become a chronic disease for a growing number of women thanks to therapeutic advances, generating a new population of patients with prolonged response. This article, written by experts in oncology and primary care (PC) in Spain, offers practical recommendations for the comprehensive management of these patients. It addresses strategies to improve therapeutic compliance, the detection and management of toxicities, the early identification of signs of progression, and the management of comorbidities and drug interactions. In addition, it emphasizes the importance of psychosocial support, the promotion of healthy habits, and coordination between oncology and P…
PMID 42296659Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026
The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget's disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factor…
PMID 42425164Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2).
Annals of internal medicine · 2026
DESCRIPTION: The purpose of this updated guidance statement is to guide internal medicine physicians and other clinicians on screening for breast cancer in asymptomatic, average-risk adult females. METHODS: The American College of Physicians updated its guidance statement on screening for breast cancer using high-quality clinical guidelines from national guideline developers around the world. GUIDANCE STATEMENT 1: In asymptomatic, average-risk females aged 40 to 49 years, clinicians should discuss the female's risk of breast cancer, values and preferences, and uncertainty around benefits and harms of screening for breast cancer. Following shared decision making, if a female in this populatio…
PMID 41996183Italian guidelines for the use of digital breast tomosynthesis in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.
La Radiologia medica · 2026
To enhance the quality of organized mammographic screening in Italy, in accordance with national legislation, a multidisciplinary panel of experts applied the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)-ADOLOPMENT approach to adopt or adapt the European Commission Initiative on Breast Cancer (ECIBC) guidelines concerning the use of digital breast tomosynthesis (DBT). As prerequisite conditions for DBT adoption, the panel defines a full extension to women in the 45-74 age range, sufficient technical and professional resources, and an adequate monitoring system. The panel recommends the use of either DBT or digital mammography (DM) for asymptomatic women particip…
PMID 41784888Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.
International journal of cancer · 2026
At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial, NIH-AARP Diet and Health, we predicted BMI throughout adulthood. We landmarked to predefined ages of interest (AOI), ages 30 to 65 (5-yearly). Super-landmarking and a two-…
PMID 41952250The Impact of Metabolic Bariatric Surgery on the Incidence of Breast Cancer in Patients with Obesity: A Systematic Review and Meta-Analysis.
Obesity surgery · 2026
INTRODUCTION: Obesity is widely recognized as an important risk factor for breast cancer, largely due to its effects on hormonal regulation, chronic low-grade inflammation, and metabolic dysfunction. Metabolic bariatric surgery (MBS) produces long-term weight reduction and improves metabolic profiles, which may influence the development of obesity-related cancers. This systematic review and meta-analysis aimed to examine the relationship between bariatric surgery and breast cancer incidence in adult women with obesity. METHODS: This review followed the PRISMA reporting standards and was registered in PROSPERO. A comprehensive search of PubMed, Google Scholar, Cochrane Library, and Web of Sci…
PMID 42298137Adjuvant chemotherapy in elderly patients with HER2-negative early breast cancer: A systematic review and meta-analysis.
Tumori · 2025
Evidence from randomized trials regarding adjuvant chemotherapy and its impact on survival in older patients with resected breast cancer is limited. This study evaluates the current evidence on the use of adjuvant chemotherapy and its effects on overall mortality and breast cancer-specific mortality in older patients. A systematic review and meta-analysis were conducted on the impact of adjuvant chemotherapy in elderly patients with HER2-negative breast cancer. Searches in PubMed, Embase, and The Cochrane Library up to May 2024 included terms such as "breast cancer," "adjuvant," "chemotherapy," "elderly," and "HER2-negative." Eligible studies involved women aged 65 years or older with HER2-n…
PMID 39885632Progestin-only implant and breast cancer risk in adolescents and premenopausal women: A systematic review and meta-analysis.
Cancer epidemiology · 2026
Long-acting reversible contraception with progestin-only subdermal implants is widely adopted. However, the breast cancer (BC) risk signal attributable to implants remains under-characterized, limiting evidence-based counseling. We systematically searched PubMed/MEDLINE, Embase, and Scopus,and screened references for observational cohort and case-control studies evaluating progestin-only implant versus non-use hormonal contraception in adolescents and premenopausal women without prior BC. The primary endpoint was incident BC (invasive with/without in situ, per study definition). Maximally adjusted effect estimates were extracted; measures were harmonized to odds ratios (ORs). Risk of bias wa…
PMID 42190326Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks.
American journal of obstetrics and gynecology · 2025
OBJECTIVE: To assess the risk of breast cancer recurrence, breast cancer-specific mortality, and overall mortality for breast cancer survivors receiving vaginal estrogen therapy for genitourinary syndrome of menopause. DATA SOURCES: From the inception of each database to April 6th, 2024, a systematic literature search was conducted in Google Scholar, PubMed, EMBASE, CINAHL, NCBI, and Science Direct. A secondary search was conducted on September 26th, 2024 utilizing Google Scholar, PubMed, EMBASE, CINAHL, and Science Direct. STUDY ELIGIBILITY CRITERIA: We identified studies that reported on breast cancer recurrence defined per individual review criteria and considered both local and distant r…
PMID 39521301Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: Systematic review and meta-analysis.
Breast (Edinburgh, Scotland) · 2024
BACKGROUND: Biopsy-proven breast lesions such as atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS) and flat epithelial atypia (FEA) increase subsequent risk of breast cancer (BC), but long-term risk has not been synthesized. A systematic review was conducted to quantify future risk of breast cancer accounting for time since diagnosis of these high-risk lesions. METHODS: A systematic search of literature from 2000 was performed to identify studies reporting BC as an outcome following core-needle or excision biopsy histology diagnosis of ADH, ALH, LCIS, lobular neoplasia (LN) or FEA. Meta-analyses were conducted to estimate cumulative BC …
PMID 3927054303
Latest Research — Last 24 Months
2026
2026
Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer - A systematic review and meta-analysis.
Critical reviews in oncology/hematology · PMID 41722713
2026
2026
2026
2026
2026
2026
Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · PMID 42449201
2026
Managing diabetes while undergoing breast cancer treatment: a systematic review of women's experiences of self-care and clinical support.
Diabetes & metabolic syndrome · PMID 41895065
2026
2026
Responsible artificial intelligence in medical imaging: a systematic review.
Frontiers in digital health · PMID 42535035
2026
Self-Management Support for Cancer Survivors at Risk of Cardiotoxicity: A Scoping Review.
Heart, lung & circulation · PMID 42431760
2026
MRI radiomics for predicting pathological complete response in breast cancer: a systematic review of current evidence and limitations.
European journal of radiology · PMID 42541995
2026
2026
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
moderate-confidence evidence
Antineoplastic Agents
55 linked PMIDs6788 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, quality of life, mortality, overall survival, disease-free survival, pathological complete response, recurrence, progression-free survival
- Populations represented
- general population; triple-negative breast cancer; metastatic; HER2; triple-negative breast cancer; ER; ER
- Mechanism
- Such a characteristic structure not only induces potent antiproliferative activity against multiple human cancer cells (IC50 = 0.68-1.94 μM), but also leads to distinct cell-type-specific anticancer mechanisms: Suppression of proteasome activity in human colon cancer HCT-116 cells, but inhibition of protein tyrosine phosphatase 1B and T-cell protein tyrosine phosphatase in the human breast cancer MCF-7 cells However, their tendency to form lipid-bound structures in circulation limits their tumor-targeting therapeutic potential and raises the risk of off-target effects
limited evidence
Biomarkers, Tumor
34 linked PMIDs9458 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, pathological complete response, overall survival, recurrence, disease-free survival
- Populations represented
- general population; HER2; triple-negative breast cancer; metastatic breast cancer; metastatic; ER; ER; HER2; ER
- Mechanism
- Unraveling the spatial dynamics of gene expression can unveil key insights into tumor heterogeneity and aid in identifying potential therapeutic targets Current clinical analysis of the HER2 status primarily relies on solid tumour biopsies low-suitable for continuous real-time monitoring needed for possible adjustment of the treatment, while serum tests targeting blood-circulating HER-2/neu fragments often show conflicting tumour-serum relations
preliminary evidence
radiotherapy
25 linked PMIDs16809 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence, quality of life, adverse events
- Populations represented
- general population; triple-negative breast cancer; metastatic; early-stage; metastatic; ER; early-stage breast cancer; early-stage; advanced; previously treated
- Mechanism
- This paper delineates the indications and dose-fractionation strategies for radiotherapy targeting the regional lymphatic pathways following breast cancer surgery The combination of ionomycin and radiotherapy resulted in inhibition of the proliferation of breast cancer cells in vitro experiments, which was indicated by cell counting kit-8 and colony formation experiments
preliminary evidence
Erb-b2 Receptor Tyrosine Kinases
20 linked PMIDs392957 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, adverse events, overall survival, recurrence, progression-free survival, objective response rate, response rate, mortality
- Populations represented
- HER2; early-stage; HER2; triple-negative breast cancer; metastatic breast cancer; metastatic; HER2; ER; HER2; advanced; metastatic; first-line; second-line; HER2; metastatic; previously treated; HER2
- Mechanism
- Current clinical analysis of the HER2 status primarily relies on solid tumour biopsies low-suitable for continuous real-time monitoring needed for possible adjustment of the treatment, while serum tests targeting blood-circulating HER-2/neu fragments often show conflicting tumour-serum relations BACKGROUND: Apatinib is an oral small-molecule tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor-2
preliminary evidence
ERBB2 protein, human
15 linked PMIDs392674 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, recurrence, progression-free survival, objective response rate, response rate, adverse events, mortality
- Populations represented
- HER2; early-stage; HER2; triple-negative breast cancer; metastatic breast cancer; metastatic; HER2; ER; HER2; metastatic; previously treated; HER2; HER2-positive breast cancer; HER2
- Mechanism
- Current clinical analysis of the HER2 status primarily relies on solid tumour biopsies low-suitable for continuous real-time monitoring needed for possible adjustment of the treatment, while serum tests targeting blood-circulating HER-2/neu fragments often show conflicting tumour-serum relations BACKGROUND: Apatinib is an oral small-molecule tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor-2
preliminary evidence
Paclitaxel
15 linked PMIDs43570 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, adverse events, overall survival, disease-free survival, progression-free survival, response rate, objective response rate, event-free survival
- Populations represented
- general population; PD-L1; early-stage breast cancer; early-stage; metastatic breast cancer; metastatic; triple-negative breast cancer; advanced; metastatic; first-line; HER2; BRCA1; PD-L1; triple-negative breast cancer; early-stage
- Mechanism
- The GPER inverse agonist, a tetrapeptide (PLMI), was studied on pain-like symptoms, in murine models of chemotherapy-induced peripheral neuropathy We used the PLMI and the GPER antagonist G15 to study the role of GPER in mechanical allodynia in the model of paclitaxel-induced peripheral neuropathy
preliminary evidence
endocrine therapy
15 linked PMIDs9086 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, quality of life, recurrence, pathological complete response, disease-free survival
- Populations represented
- general population; ER; hormone receptor-positive breast cancer; advanced; metastatic; first-line; ER; early-stage; stage I; PR; HER2; hormone receptor-positive breast cancer; children
- Mechanism
- Neurokinin (NK) receptor antagonists represent a significant advancement in nonhormonal treatment of vasomotor symptoms (VMS) by targeting the underlying neuronal pathways driving thermoregulatory dysfunction Fezolinetant, a selective NK 3 receptor antagonist, and elinzanetant, a dual NK1/NK3 receptor antagonist, provide rapid and clinically meaningful reductions in VMS, with elinzanetant offering additional improvements in sleep
limited evidence
breast-conserving surgery
13 linked PMIDs4397 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, quality of life, recurrence, adverse events
- Populations represented
- general population; early-stage breast cancer; early-stage; hormone receptor-positive breast cancer; children
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Receptors, Estrogen
10 linked PMIDs12563 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, recurrence, progression-free survival, adverse events, disease-free survival
- Populations represented
- general population; metastatic breast cancer; metastatic; ER; ER; HER2; advanced; metastatic; first-line; ER; hormone receptor-positive breast cancer; children; metastatic breast cancer; metastatic; ER; HER2
- Mechanism
- The GPER inverse agonist, a tetrapeptide (PLMI), was studied on pain-like symptoms, in murine models of chemotherapy-induced peripheral neuropathy We used the PLMI and the GPER antagonist G15 to study the role of GPER in mechanical allodynia in the model of paclitaxel-induced peripheral neuropathy
limited evidence
Doxorubicin
10 linked PMIDs222 reported cumulative sample signal
- Research status
- mostly neutral
- Outcomes represented
- reported clinical outcomes
- Populations represented
- general population; PD-L1; triple-negative breast cancer; HER2-positive breast cancer; early-stage; locally advanced; advanced; HER2
- Mechanism
- The broad-spectrum chemotherapeutic agent doxorubicin (DOX) is incorporated into the hierarchical architecture, while hyaluronic acid functionalization enhances colloidal stability and tumor targeting Triple negative breast cancer (TNBC) remains a clinically challenging subtype because it lacks established molecular targets and often depends on cytotoxic chemotherapy
limited evidence
MicroRNAs
9 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- general population; triple-negative breast cancer
- Mechanism
- The assay reliably detected concentration differences across varying ratios using four breast cancer subtype-associated miRNAs in spiked human serum and successfully accessed endogenous miRNA targets in total RNA extracted from MCF-7 cells Therefore, multiple microRNA targets can be quantitatively detected within 45 min by two assay steps composed of (1) target capture/biotinylation and (2) fluorophore labeling via streptavidin-biotin interaction
preliminary evidence
Trastuzumab
8 linked PMIDs43609 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- objective response rate, response rate, mortality, overall survival, progression-free survival, quality of life, adverse events, reported clinical outcomes
- Populations represented
- metastatic; previously treated; HER2; HER2-positive breast cancer; HER2; triple-negative breast cancer; advanced; metastatic; first-line; HER2; BRCA1; PD-L1; general population; metastatic breast cancer; metastatic; ER; HER2; HER2-positive breast cancer; early-stage; locally advanced; advanced; HER2
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Tamoxifen
6 linked PMIDs7983 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, disease-free survival, recurrence
- Populations represented
- ER; general population; HER2
- Mechanism
- Using breast cancer as a proof-of-concept study, we measure the community cohesion score profiles of 950 case samples and predict the individualized therapeutic targets in 2-fold Then, we pinpoint more individualized therapeutic targets by discovering the genes which greatly contribute to the community cohesion looseness in each individualized gene network
preliminary evidence
Contrast Media
6 linked PMIDs3194 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, mortality
- Populations represented
- general population; early-stage breast cancer; early-stage
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Protein Kinase Inhibitors
6 linked PMIDs1060 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, progression-free survival, overall survival, adverse events
- Populations represented
- general population; metastatic breast cancer; metastatic; ER; HER2; metastatic breast cancer; metastatic; first-line; second-line; HER2; HER2-positive breast cancer; HER2
- Mechanism
- Herein, a novel series of pyrazole-based derivatives 5a-f, 6a-f, 7a,b, and 8a-f was rationally designed, synthesized, and evaluated as potential anticancer agents targeting tumor-associated carbonic anhydrase (hCA) isoforms IX and XII The concurrent inhibition of pH regulator-hCA IX and PRAK signaling by compound 8d disrupted hypoxia-driven survival pathways and promoted cell death in therapy-resistant tumor cells
limited evidence
Reactive Oxygen Species
6 linked PMIDs6 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, mortality
- Populations represented
- general population
- Mechanism
- However, their tendency to form lipid-bound structures in circulation limits their tumor-targeting therapeutic potential and raises the risk of off-target effects In contrast, the exposure to the tumor microenvironment, which is characterized by low pH and elevated ROS, could trigger a conformational transition to a structured α-helical state, thereby enhancing its membrane-disruptive and tumor-targeting capabilities
preliminary evidence
Cyclophosphamide
5 linked PMIDs100025 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, event-free survival, recurrence
- Populations represented
- general population; triple-negative breast cancer; early-stage
- Mechanism
- PURPOSE: The current candidate gene association study aims to investigate tag SNPs from the TACR1 gene as pharmacogenetic predictors of response to the antiemetic guidelines-recommended, NK-1 receptor antagonist-based, triple antiemetic regimens Data analysis for 121 ultimately enrolled patients was initiated by defining haplotype blocks using PHASE v.2.1
preliminary evidence
B7-H1 Antigen
5 linked PMIDs37817 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, progression-free survival
- Populations represented
- PD-L1; triple-negative breast cancer; PD-L1; metastatic; PD-L1; triple-negative breast cancer; advanced; metastatic; first-line; HER2; BRCA1; PD-L1
- Mechanism
- Tumor overexpression of programmed death-ligand one (PD-L1) inhibits immune recognition This research highlights a strategy to utilize ASOs without sequence modifications and with a reduced dosing frequency, enabling broadly applicable oncogene-targeting oligonucleotide delivery
05
Conflicting Research
higher-confidence evidence
43 studiesAntineoplastic Agents · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 41null: 1benefit: 1
higher-confidence evidence
29 studiesradiotherapy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 26mixed: 1null: 2
higher-confidence evidence
18 studiesbreast-conserving surgery · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 15null: 2harm: 1
limited evidence
12 studiesContrast Media · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 10benefit: 1harm: 1
06
Failed or Negative Trials
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
randomized controlled trial · 2026 · PMID 42508432
OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.
randomized controlled trial · 2026 · PMID 41833903
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).
randomized controlled trial · 2026 · PMID 41999978
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
randomized controlled trial · 2026 · PMID 41937088
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
randomized controlled trial · 2026 · PMID 41712503
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
randomized controlled trial · 2026 · PMID 42350643
Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.
randomized controlled trial · 2026 · PMID 42372743
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.
randomized controlled trial · 2026 · PMID 42275799
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.
randomized controlled trial · 2026 · PMID 42364416
Secondary Analysis of the CAN-Study, a Randomised Controlled Trial - Local Anaesthesia and Overall Survival.
randomized controlled trial · 2026 · PMID 42210709
07
Emerging and Experimental Research
Managing diabetes while undergoing breast cancer treatment: a systematic review of women's experiences of self-care and clinical support.
systematic review · 2026 · PMID 41895065
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
randomized controlled trial · 2026 · PMID 42150145
Self-Management Support for Cancer Survivors at Risk of Cardiotoxicity: A Scoping Review.
systematic review · 2026 · PMID 42431760
A complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trial.
randomized controlled trial · 2026 · PMID 41762807
Evaluation of patient experience from participation in the randomized INFLUENCE trial on fluorescence-guided sentinel node surgery.
randomized controlled trial · 2026 · PMID 42190367
Investigating the effect of web-based education on positive mental health of family caregivers of breast cancer patients: a quasi-experimental study.
randomized controlled trial · 2026 · PMID 42542461
Acute skin toxicity and cosmesis outcome in non-metastatic breast cancer patients treated with ultrahypofractionated radiotherapy: a randomized controlled phase II clinical trial comparing proton versus photon radiotherapy.
randomized controlled trial · 2026 · PMID 42183732
Differential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients.
randomized controlled trial · 2026 · PMID 42262213
Development and acceptability of gist-based decision aids for prostate and breast cancer screening: a two-phase qualitative interview study in an online setting.
phase 2 clinical trial · 2026 · PMID 42419884
Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.
unclassified · 2026 · PMID 41854411
08
Evidence Gaps
Detailed risk-of-bias assessment remains limited
PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care61 records
Rank112.0
DEGRO practical guidelines: radiotherapy of breast cancer-regional nodal irradiation.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026 · PMID 42289007
AIM: The aim of this work is to update the practical guidelines for adjuvant radiotherapy of the regional lymphatics in breast cancer, originally issued in 2014 by the Breast Cancer Expert Panel of the German Society of Radiation Oncology. METHODS: A comprehensive literature review concerning regional nodal irradiation (RNI) was performed using the search terms "breast cancer," "radiotherapy," and "regional node irradiation." Furthermore, data from recently published meta-analyses and international breast cancer so…
Rank110.0
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 42425164
The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget's disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV …
Rank110.0
[Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain].
Atencion primaria · 2026 · PMID 42296659
Metastatic breast cancer (mBC) has become a chronic disease for a growing number of women thanks to therapeutic advances, generating a new population of patients with prolonged response. This article, written by experts in oncology and primary care (PC) in Spain, offers practical recommendations for the comprehensive management of these patients. It addresses strategies to improve therapeutic compliance, the detection and management of toxicities, the early identification of signs of progression, and the management…
Rank110.0
AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42173036
The German Guideline Committee (AGO: Working Group on Gynecologic Cancers) updated its yearly recommendations on the diagnosis and treatment of breast cancer in March 2026. Chapters on oncological and oncoplastic-reconstructive surgery are coordinated with the Working Group for Plastic, Aesthetic, and Reconstructive Surgery in Gynecology (AWOgyn). The most important changes include the ommission of sentinel lymph node biopsy (SLNB) and preffered axillary staging in patients with node-positive breast cancer undergoi…
Rank110.0
Italian guidelines for the use of digital breast tomosynthesis in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.
La Radiologia medica · 2026 · PMID 41784888
To enhance the quality of organized mammographic screening in Italy, in accordance with national legislation, a multidisciplinary panel of experts applied the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)-ADOLOPMENT approach to adopt or adapt the European Commission Initiative on Breast Cancer (ECIBC) guidelines concerning the use of digital breast tomosynthesis (DBT). As prerequisite conditions for DBT adoption, the panel defines a full extension to women in the 45-74 age range, suffic…
Rank110.0
Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2).
Annals of internal medicine · 2026 · PMID 41996183
DESCRIPTION: The purpose of this updated guidance statement is to guide internal medicine physicians and other clinicians on screening for breast cancer in asymptomatic, average-risk adult females. METHODS: The American College of Physicians updated its guidance statement on screening for breast cancer using high-quality clinical guidelines from national guideline developers around the world. GUIDANCE STATEMENT 1: In asymptomatic, average-risk females aged 40 to 49 years, clinicians should discuss the female's risk…
Rank106.7
Robotic versus conventional nipple-sparing mastectomy in early breast cancer: a systematic review and meta-analysis.
BMC surgery · 2026 · PMID 42067887
OBJECTIVE: This study aimed to systematically compare robot-assisted nipple-sparing mastectomy (R-NSM) with conventional nipple-sparing mastectomy (C-NSM) in terms of perioperative safety and oncological outcomes through a meta-analysis. METHODS: A comprehensive literature search was conducted in PubMed/MEDLINE, Web of Science Core Collection, Embase, and the Cochrane Central Register of Controlled Trials from database inception to February 27, 2026. Controlled studies comparing robotic nipple-sparing mastectomy (R…
Rank104.2
Health Economic Evaluations of Breast Cancer Screening Strategies: A Systematic Review Focusing on Methodology and Quality Assessment.
Applied health economics and health policy · 2026 · PMID 42213316
BACKGROUND: Breast cancer screening is vital for early detection and improved health outcomes but requires robust health economic evaluations to guide implementation. This systematic review examines the methodology, quality, and results of health economic evaluations of screening strategies to support decision making and future research. METHODS: A literature search was performed in PubMed, Embase, Web of Science, EconLit, and the HTA database. Health economic evaluations of breast cancer screening strategies using…
Rank103.6
Targeted axillary dissection in the primary surgery setting for node-positive breast cancer: A systematic review.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42068696
INTRODUCTION: Targeted axillary dissection (TAD) improves the accuracy of axillary staging in patients undergoing neoadjuvant chemotherapy but its role in patients with low volume nodal disease undergoing primary surgery is unclear. This study aimed to summarise the evidence of upfront TAD in the primary surgical setting in patients with node-positive breast cancer. METHODS: Searches were performed in PubMed, Embase, and Scopus to identify studies reporting the outcomes of upfront TAD in patients with node-positive…
Rank102.6
Breast Lesions in Women ≤ 40 Years: Diagnostic Accuracy and Risk of Malignancy of Fine Needle Aspiration Cytology Based on the World Health Organization Breast Cytology Reporting System-A Systematic Review and Meta Analysis.
Diagnostic cytopathology · 2026 · PMID 42204730
INTRODUCTION: Breast cancer is the most common malignancy and the leading cause of cancer deaths among women worldwide. Diagnostic vigilance is vital as malignant cases in young women show higher proliferation and lower hormone-regulated gene expression, indicating more aggressive cases. The proposed IAC-IARC-WHO reporting system will adopt and update the current IAC Yokohama System for reporting breast cytology, which has five categories. This review evaluates the diagnostic accuracy of FNAC in women aged ≤ 40 usi…
Rank100.0
Economic Evaluation of Breast Cancer Screening in China: A Systematic Review of Costs and Cost-Effectiveness.
Value in health regional issues · 2026 · PMID 41707447
OBJECTIVES: This study systematically reviewed evidence on the cost and cost-effectiveness of breast cancer screening programs in China to support the development of structured, population-based screening initiatives and guide future economic evaluations. METHODS: A comprehensive search was conducted across Web of Science, CINAHL, PubMed, Embase, Medline, Google Scholar, PsycINFO, Cochrane, Scopus, and China National Knowledge Infrastructure for studies published up to June 2025. Eligible studies reported costs or …
Rank100.0
RGS Family Remodeling in Breast Cancer: A Meta-Analysis and Multi-Omics Profiling of Prognostic Biomarkers.
Cancer medicine · 2026 · PMID 42520291
BACKGROUND: Breast cancer (BC) is a heterogeneous malignancy with diverse molecular subtypes and variable clinical outcomes. Despite diagnostic and therapeutic advances, recurrence and metastasis contribute to poor prognosis in subsets of patients. Regulators of G protein signaling (RGS) proteins, negative modulators of G protein-coupled receptor (GPCR) pathways, influence tumor progression, but their expression profiles, genomic alterations, immune associations, and prognostic roles in BC remain incompletely under…
Rank98.0
Postmastectomy Radiotherapy With Immediate Implant Reconstruction: Treatment Fractionation, Implant Plane, and Clinical Outcomes.
Clinical breast cancer · 2026 · PMID 42173060
Immediate implant-based breast reconstruction (IBR) after mastectomy raises concerns when postmastectomy radiotherapy (PMRT) is required. While conventional PMRT has traditionally used 50 Gy in 25 fractions, hypofractionated schedules are increasingly adopted. This narrative review aims at summarizing current evidence and guideline recommendations regarding hypofractionated PMRT in patients undergoing implant-based reconstruction and evaluates whether implant placement (prepectoral vs. subpectoral) influences outco…
Rank90.1
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110).
Japanese journal of clinical oncology · 2026 · PMID 41615067
Oligometastasis is a concept that refers to the condition between localized cancer and widespread distant metastases; however, a consensus on the definition has yet to be reached. Metastasis-directed therapy (MDT) has recently been established to incorporate local therapy, such as radiotherapy and surgery, for distant metastases. Previous trials have proposed the possibility of long-term survival with the administration of MDT for patients with oligometastases. However, the efficacy and safety of MDT have not been …
Rank70.0
AI software as a third reader in breast cancer screening-a prospective diagnostic observational study.
European radiology · 2026 · PMID 41642301
OBJECTIVE: Despite advances in mammography screening, some cancers remain undetected, prompting the evaluation of artificial intelligence (AI) as an independent third reader to reduce missed cancers. MATERIALS AND METHODS: In this prospective study, women eligible for the German Mammography Screening were enrolled at six sites belonging to one screening unit between August 2023 and February 2024. Each mammogram underwent double reading and was independently analyzed using Transpara, an AI-based detection software. …
Rank55.0
How much radiologist time can be saved by implementing AI in screen-reading mammograms?
European radiology · 2026 · PMID 41498825
OBJECTIVE: There is a lack of breast radiologists in Norway and in Europe. Artificial intelligence (AI) offers an alternative to solely human readers and has demonstrated promising results in cancer detection in mammographic screening. We aimed to estimate the potential reduction in radiologists' workload by replacing one of the two radiologists with AI in screen-reading mammograms in BreastScreen Norway. MATERIALS AND METHODS: BreastScreen Norway targets about 680,000 women aged 50-69 who are invited biennially. T…
Rank55.0
Relationship Between the Incidence of Metabolic Syndrome and Breast Cancer.
Cardiovascular drugs and therapy · 2026 · PMID 41055859
PURPOSE: Breast cancer affects females from puberty onward, with incidence rates increasing with age. Although metabolic syndrome (MetS) has reportedly increased the incidence of almost all cancers, no clear consensus on the role of MetS in breast cancer development exists. We aimed to clarify the effects of MetS on breast cancer incidence. METHODS: To investigate this relationship, we analyzed Japanese healthcare data of females from 2005 to 2020 and examined the incidence of breast cancer. MetS was evaluated base…
Rank51.9
Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42134665
BACKGROUND AND PURPOSE: Adjuvant loco-regional radiotherapy reduces recurrence risk and enhances survival in early-stage breast cancer. The ESTRO consensus guideline on target volume delineation for elective radiotherapy of early-stage breast cancer, published in 2015, sought to standardise contouring practices. In the DBCG Skagen Trial 1, all clinical target volume (CTV) delineations followed the ESTRO guideline, allowing pre-planned prospective validation. This study aimed to characterise the loco-regional recurr…
Rank51.4
A systematic comparison of abbreviated and unenhanced breast MRI protocols in women with mammographically dense breasts compared to full multiparametric breast MR imaging.
European journal of radiology · 2026 · PMID 41967277
OBJECTIVE: While the feasibility of MRI as a supplemental screening tool for breast cancer has been established, there is no consensus regarding the optimal examination protocol. This reader study aims to provide a systematic comparison of abbreviated contrast-enhanced MRI, IV-contrast-free, and a full multiparametric protocol, to diagnose breast cancer in a population of women with mammographically dense breasts. MATERIALS AND METHODS: This IRB-approved retrospective reader study was performed in 166 patients with…
Rank49.9
Benchmarking large language models in breast cancer care: agreement with radiology-led multidisciplinary tumor board decisions.
BMC medical informatics and decision making · 2026 · PMID 42121209
BACKGROUND: Multidisciplinary tumor boards (MDTBs) play a central role in breast cancer management by integrating imaging findings with clinical and pathological information to guide treatment decisions. The increasing integration of artificial intelligence into clinical workflows has raised interest in the potential role of large language models (LLMs) as supportive tools in oncologic decision-making. The aim of this study was to evaluate the concordance between treatment recommendations generated by LLMs and deci…
Rank49.6
Contrast-enhanced mammography versus breast MRI in the preoperative evaluation of the nipple-areola complex: data from a real-world setting.
European radiology · 2026 · PMID 41735676
OBJECTIVES: Accurate preoperative assessment of nipple-areolar complex (NAC) involvement is critical for surgical planning in breast cancer patients. While magnetic resonance imaging (MRI) is the established modality for NAC evaluation, contrast-enhanced mammography (CEM) has emerged as a potential alternative. This study aims to compare the diagnostic performance of CEM and MRI in predicting NAC involvement in a real-world setting, using histopathology as the reference standard. MATERIALS AND METHODS: A retrospect…
Rank49.4
Beyond the Trade-Off: Achieving High Spatial and Temporal Resolution in Breast DCE-MRI Using a Novel 4D Stack-of-Stars Sequence.
Academic radiology · 2026 · PMID 41708385
RATIONALE AND OBJECTIVES: To clinically implement and evaluate a 4D diamond-shaped pseudo-golden angle stack-of-stars acquisition with k-space weighted image contrast reconstruction for breast dynamic contrast-enhanced MRI (4D-DCE), assessing image quality, diagnostic confidence, and Breast Imaging Reporting and Data System (BI-RADS) agreement across conventional and ultrafast protocols. MATERIAL AND METHODS: This retrospective study included female patients who underwent breast MRI at 3 T using the 4D-DCE sequence…
Rank47.8
Adenoid cystic carcinoma of the breast: a case series of 26 patients.
Breast cancer research and treatment · 2026 · PMID 42283891
BACKGROUND: Although triple-negative, adenoid cystic carcinoma of the breast (ACCB) is an uncommon, slow-growing malignancy with a favorable prognosis. There are no treatment standards or therapeutic consensus because of its scarcity. METHODS: Data on 26 patients with ACCB from two distinct French cancer centers were presented in this study. Clinical, histological and molecular features of these carcinomas were described. Therapeutic management and patient follow-up was also reported. RESULTS: The median age of thi…
Rank47.7
Identifying priority areas to support primary care engagement in breast cancer survivorship care: A Delphi study.
Cancer medicine · 2024 · PMID 38686635
INTRODUCTION: Existing approaches in cancer survivorship care delivery have proven to be insufficient to engage primary care. This study aimed to identify stakeholder-informed priorities to improve primary care engagement in breast cancer survivorship care. METHODS: Experts in U.S. cancer survivorship care delivery were invited to participate in a 4-round online Delphi panel to identify and evaluate priorities for defining and fostering primary care's engagement in breast cancer survivorship. Panelists were asked t…
Rank47.6
Delphi technique for design and content validation by experts of a mobile app for self-care of breast cancer-related lymphedema.
Journal of cancer survivorship : research and practice · 2026 · PMID 39688627
INTRODUCTION: Breast cancer-related lymphedema (BCRL) is a complication that requires lifelong control, with patients taking responsibility for self-care. Mobile applications (apps) can be an effective health education strategy to help manage BCRL by promoting collaborative learning environments in physical therapy. The objective of this study was to design and validate the content for the development of a mobile application for self-care in the health of the BCRL. METHODS: The Delphi technique was used through two…
Diagnosis And Screening206 records
Rank110.0
The Impact of Metabolic Bariatric Surgery on the Incidence of Breast Cancer in Patients with Obesity: A Systematic Review and Meta-Analysis.
Obesity surgery · 2026 · PMID 42298137
INTRODUCTION: Obesity is widely recognized as an important risk factor for breast cancer, largely due to its effects on hormonal regulation, chronic low-grade inflammation, and metabolic dysfunction. Metabolic bariatric surgery (MBS) produces long-term weight reduction and improves metabolic profiles, which may influence the development of obesity-related cancers. This systematic review and meta-analysis aimed to examine the relationship between bariatric surgery and breast cancer incidence in adult women with obes…
Rank106.7
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors.
Journal of cancer survivorship : research and practice · 2025 · PMID 37906420
PURPOSE: Breast cancer survivors are more likely to report psychological distress and unmet need for support compared to healthy controls. Psychological mobile health interventions might be used in follow-up care of breast cancer patients to improve their mental health. METHODS: We searched MEDLINE, PsychINFO, Cochrane and PROSPERO for articles on controlled trials examining the effectiveness of psychological mobile health interventions compared to routine care regarding mental health outcomes of adult breast cance…
Rank105.8
Diagnostic performance of contrast-enhanced mammography for suspicious findings in dense breasts: A systematic review and meta-analysis.
Cancer medicine · 2024 · PMID 38659408
PURPOSE: Contrast-enhanced spectral imaging (CEM) is a new mammography technique, but its diagnostic value in dense breasts is still inconclusive. We did a systematic review and meta-analysis of studies evaluating the diagnostic performance of CEM for suspicious findings in dense breasts. MATERIALS AND METHODS: The PubMed, Embase, and Cochrane Library databases were searched systematically until August 6, 2023. Prospective and retrospective studies were included to evaluate the diagnostic performance of CEM for sus…
Rank102.0
Effectiveness of self-management interventions in reducing cancer treatment-related cardiotoxicity in breast cancer survivors: A systematic review.
Asia-Pacific journal of oncology nursing · 2026 · PMID 41953236
OBJECTIVE: To evaluate the effectiveness of self-management interventions in reducing cancer therapy-induced cardiotoxicity among breast cancer survivors. METHODS: Six English-language databases were searched for studies from January 2004 to November 2024. JBI appraisal tools and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework were applied to assess the methodological quality and certainty of the evidence. Meta-analysis and descriptive qualitative synthesis were applied. RES…
Rank100.5
The effect of different combinations of open invitations and timed appointments on breast screening attendance: service evaluation of invitation strategies in the NHS Breast Screening Programme.
British journal of cancer · 2026 · PMID 42129338
BACKGROUND: The NHS Breast Screening Programme invites eligible women using either a timed appointment letter (option to change), or an open invitation to make an appointment. Non-attenders receive a 'Timed' or 'Open' second invitation. NHS England commissioned a service evaluation to determine the effect of different combinations of timed and open invitations. METHODS: Seven services, selected to ensure adequate representation of diverse socio-economic, ethnic, urban/rural, and current uptake groups, participated.…
Rank100.0
Responsible artificial intelligence in medical imaging: a systematic review.
Frontiers in digital health · 2026 · PMID 42535035
INTRODUCTION: Responsible artificial intelligence (AI) in medical imaging requires more than high diagnostic accuracy; it also requires transparent reasoning, equitable performance across patient subgroups, privacy protection, calibrated uncertainty, and clinical trustworthiness. METHODS: This PRISMA-informed systematic review synthesized 24 studies published between 2020 and 2025 that used AI or deep learning for disease detection or diagnostic support in X-ray, CT, MRI, mammography, ultrasound, dermoscopy, retina…
Rank100.0
The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.
Annals of medicine · 2026 · PMID 41503829
BACKGROUND: Breast cancer (BC) remains a major global health concern, accounting for 11.7% of all cancer cases and ranking as the second leading cause of female cancer-related deaths worldwide. Increasing evidence highlights the interplay between gut microbiota (GM) dysbiosis and obesity-associated metabolic dysfunction in BC progression. This review aims to elucidate the role of GM in obese patients with BC. METHODS: A systematic literature search was conducted in PubMed and Web of Science databases for publicatio…
Rank99.2
Self-Management Support for Cancer Survivors at Risk of Cardiotoxicity: A Scoping Review.
Heart, lung & circulation · 2026 · PMID 42431760
BACKGROUND: Cancer survivorship has significantly increased globally. This success has brought new challenges, including the rise in cardiovascular complications due to cardiotoxic effects of cancer treatments. Self-management (SM) support is increasingly recognised as an important component in overcoming these challenges; however, its implementation into practice remains inconsistent. AIM: This scoping review aims to map the current landscape of SM for cancer survivors at risk of or experiencing cardiotoxicity, wi…
Rank98.0
Mapping the evolution and impact of microfluidic technology research on cancer diagnosis: A comprehensive bibliometric analysis from 2015 to 2024.
Medicine · 2026 · PMID 42536556
BACKGROUND: To explore the research trends of microfluidic technology for cancer diagnosis from 2015 to 2024 using bibliometric and visualization methods (not a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review), and provide references for subsequent scientific research. METHODS: Relevant literatures were retrieved from the Web of Science Core Collection, and analyzed using tools such as Origin 2018, R software, VOSviewer, and CiteSpace. The cooperation network, co - cit…
Rank96.0
Positive affect and inflammation in women with breast cancer: A systematic review.
Brain, behavior, & immunity - health · 2026 · PMID 42502425
BACKGROUND: Positive affect has been implicated in psychobiological processes relevant to cancer adaptation and survivorship. However, evidence linking positive affect to objective inflammatory and immune-related biomarkers in women with breast cancer remains limited, fragmented, and methodologically heterogeneous. This systematic review was conducted to provide a focused and transparent synthesis of studies examining associations between positive affect and inflammatory or immune-related outcomes in this populatio…
Rank96.0
Plasma proteome-genome integration reveals novel protein biomarkers and therapeutic targets linked to breast cancer survival.
Archives of medical science : AMS · 2026 · PMID 42540540
INTRODUCTION: Identifying new drug targets is essential for improving breast cancer survival. The proteome provides a rich source for potential therapeutic targets. This study aimed to identify protein markers and therapeutic targets for breast cancer by using proteome-wide Mendelian randomization (MR). MATERIAL AND METHODS: Protein quantitative trait loci (pQTL) data were obtained from four large-scale proteomic studies, including 17,267 circulating protein markers. Genetic associations with breast cancer survival…
Rank92.0
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.
Cancer chemotherapy and pharmacology · 2024 · PMID 38814343
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a treatment-limiting and debilitating neurotoxicity of many commonly used anti-cancer agents, including paclitaxel. The objective of this study was to confirm the previously found inverse association between pre-treatment blood concentrations of histidine and CIPN occurrence and examine relationships of other amino acids with CIPN severity. METHODS: Pre-treatment serum concentrations of 20 amino acids were measured in the SWOG S0221 (NCT00070564) tria…
Rank90.1
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
JAMA oncology · 2026 · PMID 42530945
IMPORTANCE: Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. OBJECTIVE: To evaluate the combination of anti-programmed cell death 1 protein (PD-1) cemiplimab and anti-lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2-negative early-stage, high-risk breast cancer. DESIGN, SETTING, …
Rank85.0
Antioxidant Activity and Dose-Dependent Toxicity of a Traditionally Consumed Ipomoea pes-caprae Infusion Evaluated in a Triple-Negative Breast Cancer Xenograft Model.
Nutrients · 2026 · PMID 42514317
Background/Objectives: Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes and remains associated with limited therapeutic options and high systemic toxicity from conventional chemotherapy. Ipomoea pes-caprae is a coastal medicinal plant traditionally consumed in Mexico for inflammatory and renal disorders and contains bioactive metabolites with reported antioxidant and pharmacological properties. However, its antitumoral activity and systemic safety profile remain poorly under…
Rank80.0
Differences in Ambulatory Care Outcomes Between Trainees and Faculty: A Multi-center Study.
Journal of general internal medicine · 2025 · PMID 40461739
BACKGROUND: Academic medical centers (AMCs) provide the nation's most complex care, with no differences in performance between trainees and faculty for inpatient outcomes. Single-center analyses demonstrated low performance on ambulatory outcomes among residents vs. faculty. OBJECTIVE: Determine whether resident-faculty ambulatory care performance disparities are a national problem, understand contributing factors present in AMCs. DESIGN: Retrospective cohort study, survey-based study PARTICIPANTS: A total of 146,9…
Rank77.6
Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512912
Background and Objectives: Neoadjuvant dual HER2 blockade combined with chemotherapy is the standard treatment approach for patients with high-risk early-stage or locally advanced HER2-positive breast cancer. However, the optimal chemotherapy backbone and the predictive value of systemic inflammatory biomarkers remain subjects of ongoing investigation. This study aimed to compare pathologic complete response (pCR) rates between neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel plus trastuzu…
Rank73.0
Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.
Future oncology (London, England) · 2026 · PMID 42376794
BACKGROUND: The androgen receptor (AR) is a potential biomarker in breast cancer (BC), but its predictive and prognostic value-especially regarding neoadjuvant chemotherapy (NAC) response-remains unclear. This study evaluates the relationship between pre-treatment AR expression and both therapeutic response and survival outcomes. METHODS: A retrospective multicenter cohort of 194 BC patients treated with NAC was analyzed. AR expression was assessed by immunohistochemistry on pretreatment core biopsy samples. Associ…
Rank64.4
Outcomes of a joint paediatric breast clinic: an observational case series.
Archives of disease in childhood · 2026 · PMID 41871920
OBJECTIVE: Female paediatric patients with breast symptoms may see a range of specialists with varying expertise and experience in managing their condition. There is a paucity of evidence to guide diagnosis and treatment. We report our joint paediatric breast clinic experience to describe the spectrum of symptoms and outcomes, with follow-up, in female paediatric patients presenting with breast-related symptoms. METHOD: A retrospective review of clinical records of all females (<18 years) seen between December 2017…
Rank63.6
Analysis of Lesion Shrinkage and Factors Influencing Shrinkage Following Radiofrequency Ablation of Breast Nodules: An Observational Study.
Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2026 · PMID 42454750
PURPOSE: To evaluate the reduction in ablated lesion volume after ultrasound-guided percutaneous radiofrequency ablation (RFA) for benign breast tumors and identify factors associated with shrinkage. METHODS: This retrospective study included 64 patients (244 benign breast tumors) treated with RFA from December 2014 to February 2021. All tumors were biopsy confirmed before ablation. Follow-up at 1, 3, 6, and 12 months measured nodule volume changes and recorded complications, with analyses at the individual nodule …
Rank62.0
SIGNIFIED: whole-body MRI screening in Li-Fraumeni syndrome in the UK.
ESMO open · 2026 · PMID 41740205
BACKGROUND: Li-Fraumeni syndrome (LFS), caused by a pathogenic germline variant of the TP53 tumour suppressor gene, is an autosomal dominant condition that predisposes affected individuals to multiple cancers at a young age. International guidelines recommend yearly screening to identify cancers: in addition to annual breast magnetic resonance imaging (MRI) in female patients and full dermatological skin check, patients should undergo whole-body imaging. Whole-body MRI (WB-MRI) can image from vertex to toes in a si…
Rank53.8
[The effectiveness of the Hungarian mammography screening program].
Orvosi hetilap · 2025 · PMID 41139334
Introduction: Mammography screening enabling early detection of breast cancer among women aged 45–65 has been available in Hungary since 2002. Objective: Our aim was to assess the effectiveness of the Hungarian mammography screening program based on the frequency of appearance and health outcomes of breast cancer patients. Method: Data on women aged 45–64 undergoing mammography screening between 2010 and 2021 was acquired from the National Health Insurance Fund. Frequency and regularity of screening was analyzed by…
Rank53.6
Machine learning prediction of axillary lymph node metastasis using multimodal ultrasound in breast cancer.
Future oncology (London, England) · 2026 · PMID 42359462
OBJECTIVES: Accurate prediction of axillary lymph node metastasis (ALNM) is crucial for tailoring breast cancer treatments, this study aimed to develop a machine-learning model for predicting ALNM in patients with breast cancer based on multimodal ultrasound (MU) features. MATERIALS AND METHODS: A total of 696 breast cancer patients were included From January 2016 to December 2022. Data and MU images were collected and incorporated using 9 machine learning models to predict ALNM. Model performance was evaluated by …
Rank53.3
Nomograms for the prognosis prediction model of early-stage triple-negative breast cancer - based on SEER database.
Future science OA · 2026 · PMID 41964897
AIMS: Triple-negative breast cancer (TNBC) is aggressive and unresponsive to hormone therapy, drawing widespread attention to its treatment and prognosis. This study aimed to summarize the prognosis of early-stage TNBC and construct nomograms to accurately predict survival and improve treatment strategies. PATIENTS & METHODS: The modeling group comprised early-stage TNBC patients from the SEER database. Prognostic factors were identified via Cox regression, and nomograms were developed using R software. A validatin…
Rank52.5
Social Media Discourse on Breast Cancer Screening Barriers in Japanese and English: Cross-Sectional Infodemiology Study.
Journal of medical Internet research · 2026 · PMID 42537013
BACKGROUND: Despite clinical advances, breast cancer screening adherence remains stagnant in Japan (<50%) compared with the United States (>70%). Understanding distinct cross-cultural barriers is essential; however, traditional methodologies often fail to capture visceral, real-world individual experiences and hidden deterrents to screening. OBJECTIVE: This study aims to characterize and compare cross-cultural informatics profiles of barriers to breast cancer screening across Japanese-language and English-language …
Rank52.2
Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer.
Clinical breast cancer · 2026 · PMID 42537448
HER2-low breast cancer has emerged as a distinct biological subtype with implications for treatment response. However, its impact on response to neoadjuvant endocrine therapy (NET) in hormone receptor-positive (HR+) breast cancer remains unclear. The objective of this study is to evaluate whether HER2-low status is associated with improved clinical response to NET among patients with early-stage HR+ breast cancer. A retrospective cohort study was conducted using data from the NCDB from 2010 to 2017, identifying wom…
Evidence Syntheses69 records
Rank110.0
Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.
International journal of cancer · 2026 · PMID 41952250
At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screenin…
Rank110.0
The Impact of Metabolic Bariatric Surgery on the Incidence of Breast Cancer in Patients with Obesity: A Systematic Review and Meta-Analysis.
Obesity surgery · 2026 · PMID 42298137
INTRODUCTION: Obesity is widely recognized as an important risk factor for breast cancer, largely due to its effects on hormonal regulation, chronic low-grade inflammation, and metabolic dysfunction. Metabolic bariatric surgery (MBS) produces long-term weight reduction and improves metabolic profiles, which may influence the development of obesity-related cancers. This systematic review and meta-analysis aimed to examine the relationship between bariatric surgery and breast cancer incidence in adult women with obes…
Rank109.7
Progestin-only implant and breast cancer risk in adolescents and premenopausal women: A systematic review and meta-analysis.
Cancer epidemiology · 2026 · PMID 42190326
Long-acting reversible contraception with progestin-only subdermal implants is widely adopted. However, the breast cancer (BC) risk signal attributable to implants remains under-characterized, limiting evidence-based counseling. We systematically searched PubMed/MEDLINE, Embase, and Scopus,and screened references for observational cohort and case-control studies evaluating progestin-only implant versus non-use hormonal contraception in adolescents and premenopausal women without prior BC. The primary endpoint was i…
Rank108.5
Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer - A systematic review and meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 41722713
BACKGROUND: The benefit of adjuvant chemotherapy for patients with small, early-stage (T1a-bN0) triple-negative breast cancer (TNBC) is unclear because these patients have largely been excluded from randomized trials. We performed a systematic review and meta-analysis to analyze the effect of adjuvant chemotherapy in this population. METHODS: We included interventional and observational studies comparing adjuvant chemotherapy with no chemotherapy in patients with T1a-bN0 TNBC. Studies were identified through system…
Rank108.1
Effects of different mind-body exercises on quality of life and cancer-related fatigue in breast cancer survivors: a systematic review and network meta-analysis.
Journal of cancer survivorship : research and practice · 2026 · PMID 40178706
PURPOSE: To compare the efficacy of the different mind-body exercises (MBEs) for quality of life (QOL) and cancer-related fatigue (CRF) in women breast cancer (BC) survivors. METHODS: This review searched published randomized controlled trials (RCTs) in eight electronic databases: PubMed, Web of Science, Embase, Cochrane CENTRAL, EBSCO, CNKI, VIP, and WanFang from inception to October 30, 2023. NMA and comparative effects ranking were performed using STATA 17.0 software. RESULTS: This study included 121 studies wit…
Rank107.7
Diagnostic accuracy of circulating microRNAs and lipidomic biomarkers for early breast cancer detection: A systematic review and meta-analysis.
PloS one · 2026 · PMID 42497233
BACKGROUND: Breast cancer outcomes improve substantially with earlier detection, yet mammography performance can be limited in dense breasts and may lead to false-positive investigations. Circulating microRNAs (miRNAs) and lipidomic/metabolomic signatures have emerged as promising minimally invasive biomarkers that could complement imaging for early-stage detection. The aim of this systematic review and meta-analysis is to evaluate the diagnostic accuracy of circulating microRNAs and lipidomic/metabolomic biomarker…
Rank107.4
Clinical outcomes of magnetic seed and wire-guided localisation for non-palpable breast lesions: a systematic review and meta-analysis.
Surgical oncology · 2026 · PMID 42320423
BACKGROUND: Wire-guided localisation (WGL) has been historically widely used as the standard method of pre-operative localisation of non-palpable breast lesions. Magnetic seeds (Magseed) were developed to overcome the logistical and technical limitations associated with wires. The aim of this systematic review was to compare the clinical outcomes associated with Magseed and WGL techniques. METHODS: A systematic literature search of relevant databases was performed. A meta-analysis using the Mantel-Haenszel method w…
Rank107.2
Robot-assisted versus conventional mastectomy and immediate breast reconstruction: A systematic review and comparative and single-arm meta-analysis.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2026 · PMID 42308843
BACKGROUND: Robot-assisted mastectomy (RAM) is increasingly adopted in breast and plastic surgery with proposed benefits including improved cosmetic outcomes, surgical precision, and surgeon ergonomics. However, concerns remain regarding longer operative times. This systematic review and meta-analysis aimed to evaluate outcomes of RAM with immediate breast reconstruction (IBR) of any type compared with conventional mastectomy (CM). METHODS: The study was conducted according to PRISMA guidelines. Database searches w…
Rank107.2
Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis.
Breast (Edinburgh, Scotland) · 2026 · PMID 42372581
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have demonstrated clinical benefit in early-stage breast cancer (eBC), enhancing antitumor immune responses. However, their incorporation into perioperative polychemotherapy has introduced new concerns regarding safety and immune-related toxicities (irAEs). We conducted a systematic review and meta-analysis to comprehensively evaluate the safety profile and tolerability of ICIs in patients with eBC. METHODS: A systematic review was conduc…
Rank107.2
Comparative efficacy of mind-body exercises on quality of life, anxiety, and depression in patients with breast cancer: a systematic review with pairwise and network meta-analysis of randomized controlled trials.
Frontiers in public health · 2026 · PMID 42534521
BACKGROUND: Comparative evidence on the effects of different mind-body exercises (MBEs) for psychological outcomes in breast cancer patients remains limited. This study aimed to compare the effects of Yoga, Tai Chi, Qigong, Pilates, and Dance on quality of life, anxiety, and depression in breast cancer patients. METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 31, 2026. Pairwise meta-analyses were performed using random-effects models with Hedges' g. Bayesian…
Rank106.7
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors.
Journal of cancer survivorship : research and practice · 2025 · PMID 37906420
PURPOSE: Breast cancer survivors are more likely to report psychological distress and unmet need for support compared to healthy controls. Psychological mobile health interventions might be used in follow-up care of breast cancer patients to improve their mental health. METHODS: We searched MEDLINE, PsychINFO, Cochrane and PROSPERO for articles on controlled trials examining the effectiveness of psychological mobile health interventions compared to routine care regarding mental health outcomes of adult breast cance…
Rank106.7
Estimating overall survival for breast cancer in Ghana: A time-to-event meta-analysis.
Cancer epidemiology · 2026 · PMID 42217387
OBJECTIVE: To estimate overall survival among patients with breast cancer in Ghana by synthesizing time-to-event data from published studies using reconstructed individual patient data. METHODS: We conducted a search of PubMed, SCOPUS and Embase for studies published from inception to November 28, 2025. Eligible studies directly provided Kaplan-Meier survival curves for overall survival (OS) for patients with breast cancer. Pseudo-individual patient data were digitized from published survival curves using WebPlotDi…
Rank106.4
Global prevalence of anxiety, depression and stress in women with breast cancer: A systematic review and meta-analysis.
Journal of affective disorders · 2026 · PMID 41802573
BACKGROUND: A consistent correlation has been highlighted between screening-based mental health indicators and women suffering from breast cancer (BC), which significantly reduced their related quality of life perceptions. This systematic review and meta-analysis aimed to comprehensively evaluate the prevalence rates of Anxiety, Depression and Stress in women with BC over the last decade. METHODS: This systematic review was conducted in accordance with Cochrane Collaboration guidelines and reported following the Pr…
Rank106.3
Comparative efficacy of various exercise modalities on sleep quality in breast cancer survivors after primary treatment: A systematic review and dose-response network meta-analysis.
Medicine · 2026 · PMID 42536584
BACKGROUND: This study aims to assess the dose-response relationship between different exercise modalities and sleep quality in breast cancer survivors who have completed their primary treatment, and to propose evidence-based exercise prescriptions for clinical practice. METHODS: Bayesian network and dose-response meta-analyses using a random-effects model were conducted to evaluate the impact of exercise on sleep quality in breast cancer survivors. Exercise dose was calculated as the product of duration, frequency…
Rank106.3
Comparative Histological Features of Phyllodes Tumor and Fibroadenoma in Breast Core Needle Biopsies.
International journal of surgical pathology · 2026 · PMID 41979873
BackgroundPhyllodes tumors (PT) are fibroepithelial breast lesions with variable clinical behavior and histological features that frequently overlap with those of fibroadenomas. Accurate differentiation is critical, as PT may exhibit aggressive behavior. However, their distinction is particularly challenging in core needle biopsy, especially for benign and borderline PT, due to the limited amount of tissue provided by this technique. This meta-analysis investigates histological features that improve the distinction…
Rank106.2
Beyond the first dose: Systematic review on external beam radiotherapy for locoregional breast cancer recurrence.
Breast (Edinburgh, Scotland) · 2026 · PMID 42372580
BACKGROUND: The optimal management of locoregional breast cancer recurrence after prior radiotherapy remains challenging. Reirradiation (ReRT) may allow repeat breast-conserving surgery as an alternative to mastectomy; however, prospective evidence is scarce, and existing data are largely retrospective, with the strongest support for brachytherapy. Despite this, external beam reirradiation (EBreRT) is widely used because of its availability. This systematic review evaluated the feasibility, oncologic outcomes, toxi…
Rank106.0
Contrast-Enhanced Mammography for Breast Cancer Screening: A Systematic Review and Meta-Analysis.
Journal of breast imaging · 2026 · PMID 42479629
OBJECTIVE: To evaluate pathway-specific cancer detection and summarise screening outcomes (recall/biopsy/PPV3) for contrast-enhanced mammography when reported, and to compare them with those for low-energy mammography and breast MRI. METHODS: This systematic review and meta-analysis followed PRISMA guidelines. PubMed (MEDLINE), Embase, Scopus, and Web of Science were searched from January 1, 2011, through August 31, 2025, for studies evaluating contrast-enhanced mammography in screening or surveillance populations …
Rank105.9
Factors influencing women's preferences and decision making regarding the extent of axillary surgery in breast cancer: A systematic review.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42330708
Axillary surgery in early-stage breast cancer is increasingly de-escalated. However, variation in practice persists, and the patient level factors influencing treatment decisions remain unclear. This systematic review synthesised evidence on the psychological, clinical, and contextual factors shaping women's preferences and decision making regarding the extent of axillary surgery they receive. A PRISMA-guided search of Ovid MEDLINE, Embase and Cochrane databases was conducted in December 2025. Ten studies involving…
Rank105.8
Total Breast Reconstruction with Autologous Fat Grafting after Mastectomy: A Systematic Review.
Plastic and reconstructive surgery · 2026 · PMID 41329566
BACKGROUND: Total breast reconstruction with autologous fat grafting after mastectomy has emerged as an alternative for patients who are not candidates for flap surgery or prefer to avoid implants. This review evaluates technical considerations, the role of assistive methods, the complication profile, oncologic safety, and patient satisfaction. METHODS: A systematic search of PubMed and Web of Science identified 16 eligible studies from a total of 4316 publications. Only studies that performed total breast reconstr…
Rank105.8
Diagnostic performance of contrast-enhanced mammography for suspicious findings in dense breasts: A systematic review and meta-analysis.
Cancer medicine · 2024 · PMID 38659408
PURPOSE: Contrast-enhanced spectral imaging (CEM) is a new mammography technique, but its diagnostic value in dense breasts is still inconclusive. We did a systematic review and meta-analysis of studies evaluating the diagnostic performance of CEM for suspicious findings in dense breasts. MATERIALS AND METHODS: The PubMed, Embase, and Cochrane Library databases were searched systematically until August 6, 2023. Prospective and retrospective studies were included to evaluate the diagnostic performance of CEM for sus…
Rank105.4
Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026 · PMID 42140114
BACKGROUND: Leptomeningeal disease (LMD) is an increasingly recognised late-stage complication of solid tumours (primarily melanoma, lung and breast cancers). It involves dissemination to the leptomeninges surrounding the brain and spinal cord and carries a poor prognosis ranging from 2-6 months. Recent advances in emerging therapies such as CNS-active targeted therapy, intrathecal agents, and early-phase immunotherapy necessitate an updated appraisal of prospective data. METHODS: A systematic search of MEDLINE, Em…
Rank105.0
Extended applications of chest wall perforator flaps in breast surgery: case series and systematic literature review.
Breast cancer research and treatment · 2026 · PMID 42455196
PURPOSE: Chest wall perforator flaps (CWPFs) are integral to modern oncoplastic breast surgery, offering volume replacement without muscle sacrifice. While their role in partial breast reconstruction is established, data on extended and non-conventional applications remain limited. This study aims to synthesize current clinical experience and delineate the extended applications of chest wall perforator flaps beyond conventional oncoplastic contexts. METHODS: This study combined a prospective institutional case seri…
Rank104.5
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Annals of medicine · 2026 · PMID 41949990
BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…
Rank102.6
Breast Lesions in Women ≤ 40 Years: Diagnostic Accuracy and Risk of Malignancy of Fine Needle Aspiration Cytology Based on the World Health Organization Breast Cytology Reporting System-A Systematic Review and Meta Analysis.
Diagnostic cytopathology · 2026 · PMID 42204730
INTRODUCTION: Breast cancer is the most common malignancy and the leading cause of cancer deaths among women worldwide. Diagnostic vigilance is vital as malignant cases in young women show higher proliferation and lower hormone-regulated gene expression, indicating more aggressive cases. The proposed IAC-IARC-WHO reporting system will adopt and update the current IAC Yokohama System for reporting breast cytology, which has five categories. This review evaluates the diagnostic accuracy of FNAC in women aged ≤ 40 usi…
Rank101.2
Risk factors associated with breast cancer in Ethiopia: A systematic review and meta-analysis (2000-2025).
Cancer epidemiology · 2026 · PMID 42341632
INTRODUCTION: Breast cancer is the leading malignancy among women in Ethiopia and represents a growing public health concern. Although several studies have examined potential determinants, findings remain fragmented and inconsistent. This study aimed to systematically synthesize evidence on risk factors associated with breast cancer among women in Ethiopia. METHODS: A systematic review and meta-analysis were conducted following PRISMA guidelines. Electronic databases were searched for observational studies publishe…
Landmark Evidence72 records
Rank110.0
Adjuvant chemotherapy in elderly patients with HER2-negative early breast cancer: A systematic review and meta-analysis.
Tumori · 2025 · PMID 39885632
Evidence from randomized trials regarding adjuvant chemotherapy and its impact on survival in older patients with resected breast cancer is limited. This study evaluates the current evidence on the use of adjuvant chemotherapy and its effects on overall mortality and breast cancer-specific mortality in older patients. A systematic review and meta-analysis were conducted on the impact of adjuvant chemotherapy in elderly patients with HER2-negative breast cancer. Searches in PubMed, Embase, and The Cochrane Library u…
Rank110.0
The Impact of Metabolic Bariatric Surgery on the Incidence of Breast Cancer in Patients with Obesity: A Systematic Review and Meta-Analysis.
Obesity surgery · 2026 · PMID 42298137
INTRODUCTION: Obesity is widely recognized as an important risk factor for breast cancer, largely due to its effects on hormonal regulation, chronic low-grade inflammation, and metabolic dysfunction. Metabolic bariatric surgery (MBS) produces long-term weight reduction and improves metabolic profiles, which may influence the development of obesity-related cancers. This systematic review and meta-analysis aimed to examine the relationship between bariatric surgery and breast cancer incidence in adult women with obes…
Rank109.6
Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks.
American journal of obstetrics and gynecology · 2025 · PMID 39521301
OBJECTIVE: To assess the risk of breast cancer recurrence, breast cancer-specific mortality, and overall mortality for breast cancer survivors receiving vaginal estrogen therapy for genitourinary syndrome of menopause. DATA SOURCES: From the inception of each database to April 6th, 2024, a systematic literature search was conducted in Google Scholar, PubMed, EMBASE, CINAHL, NCBI, and Science Direct. A secondary search was conducted on September 26th, 2024 utilizing Google Scholar, PubMed, EMBASE, CINAHL, and Scienc…
Rank109.4
Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: Systematic review and meta-analysis.
Breast (Edinburgh, Scotland) · 2024 · PMID 39270543
BACKGROUND: Biopsy-proven breast lesions such as atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS) and flat epithelial atypia (FEA) increase subsequent risk of breast cancer (BC), but long-term risk has not been synthesized. A systematic review was conducted to quantify future risk of breast cancer accounting for time since diagnosis of these high-risk lesions. METHODS: A systematic search of literature from 2000 was performed to identify studies reporting BC …
Rank108.5
Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer - A systematic review and meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 41722713
BACKGROUND: The benefit of adjuvant chemotherapy for patients with small, early-stage (T1a-bN0) triple-negative breast cancer (TNBC) is unclear because these patients have largely been excluded from randomized trials. We performed a systematic review and meta-analysis to analyze the effect of adjuvant chemotherapy in this population. METHODS: We included interventional and observational studies comparing adjuvant chemotherapy with no chemotherapy in patients with T1a-bN0 TNBC. Studies were identified through system…
Rank107.7
CADONOT: Comparing axillary dissection or not in breast cancer surgery.
Breast (Edinburgh, Scotland) · 2025 · PMID 40220731
INTRODUCTION: Sentinel lymph node biopsy (SLNB) is the gold standard for the axillary evaluation of clinically node-negative early breast cancer. The ACOSOG Z0011 study demonstrated the safety of omitting axillary dissection for limited SLNB disease, with other trials confirming SLNB alone or with axillary radiotherapy (AR) as non-inferior. METHODS: We followed PRISMA guidelines and registered at PROSPERO. Using Medline, Embase, and Cochrane, we reviewed randomized controlled trials (2010-2024). Outcomes, including…
Rank107.2
Comparative efficacy of mind-body exercises on quality of life, anxiety, and depression in patients with breast cancer: a systematic review with pairwise and network meta-analysis of randomized controlled trials.
Frontiers in public health · 2026 · PMID 42534521
BACKGROUND: Comparative evidence on the effects of different mind-body exercises (MBEs) for psychological outcomes in breast cancer patients remains limited. This study aimed to compare the effects of Yoga, Tai Chi, Qigong, Pilates, and Dance on quality of life, anxiety, and depression in breast cancer patients. METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 31, 2026. Pairwise meta-analyses were performed using random-effects models with Hedges' g. Bayesian…
Rank107.0
Migraine and Risk of Breast Cancer: A Systematic Review and Meta-analysis.
Clinical breast cancer · 2023 · PMID 36624014
Migraine and breast cancer are 2 prevalent diseases with high morbidity and mortality rates world-wide. There have been inconsistent reports regarding the association between migraine and risk of breast cancer. This systematic review and meta-analysis aimed to assess the risk of breast cancer in patients with migraine. By December, 1, 2022, we searched PubMed, Web of Science, Scopus, and Cochrane Library databases. Odds ratio (OR), hazard ratio (HR), and 95% confidence intervals (CIs) were extracted or assessed to …
Rank106.7
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors.
Journal of cancer survivorship : research and practice · 2025 · PMID 37906420
PURPOSE: Breast cancer survivors are more likely to report psychological distress and unmet need for support compared to healthy controls. Psychological mobile health interventions might be used in follow-up care of breast cancer patients to improve their mental health. METHODS: We searched MEDLINE, PsychINFO, Cochrane and PROSPERO for articles on controlled trials examining the effectiveness of psychological mobile health interventions compared to routine care regarding mental health outcomes of adult breast cance…
Rank106.5
Gut microbiota and breast cancer: systematic review and meta-analysis.
Breast cancer (Tokyo, Japan) · 2025 · PMID 39652259
BACKGROUND: The gastrointestinal microbiota can modulate systemic estrogens, potentially influencing estrogen-induced breast neoplasia development. This study aimed to assess alterations in the gut microbiota in breast cancer patients. METHODS: A search strategy was developed using the terms: "Microbiota," "Gastrointestinal Microbiome," "Breast Cancer," and synonyms. Ten observational studies were included. RESULTS: The total sample was 1730 women (929 cases and 801 controls). The meta-analysis of alpha diversity, …
Rank106.3
Comparative efficacy of various exercise modalities on sleep quality in breast cancer survivors after primary treatment: A systematic review and dose-response network meta-analysis.
Medicine · 2026 · PMID 42536584
BACKGROUND: This study aims to assess the dose-response relationship between different exercise modalities and sleep quality in breast cancer survivors who have completed their primary treatment, and to propose evidence-based exercise prescriptions for clinical practice. METHODS: Bayesian network and dose-response meta-analyses using a random-effects model were conducted to evaluate the impact of exercise on sleep quality in breast cancer survivors. Exercise dose was calculated as the product of duration, frequency…
Rank106.3
Chatbots for breast cancer education: a systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39730943
BACKGROUND: Effective education and awareness regarding breast cancer are critical. Traditional educational methods often fail to meet the diverse information needs of patients. Patients should be provided with tailored, accessible information to improve their retention and understanding of disease-related information. PURPOSE: This systematic review and meta-analysis evaluated the effectiveness of chatbots for providing breast cancer education. By examining patient satisfaction with and the usability and efficacy …
Rank106.2
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Cancer treatment reviews · 2022 · PMID 36202026
Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. We performed a systematic review and multiple Bayesian network meta-analyses according to treatment line to establish an optimal therapeutic sequencing strategy for this lethal disease. We included 125 first-line trials (37,812 patients) and 33 s/further-lines trials (11,321 patients). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overal…
Rank105.8
Diagnostic performance of contrast-enhanced mammography for suspicious findings in dense breasts: A systematic review and meta-analysis.
Cancer medicine · 2024 · PMID 38659408
PURPOSE: Contrast-enhanced spectral imaging (CEM) is a new mammography technique, but its diagnostic value in dense breasts is still inconclusive. We did a systematic review and meta-analysis of studies evaluating the diagnostic performance of CEM for suspicious findings in dense breasts. MATERIALS AND METHODS: The PubMed, Embase, and Cochrane Library databases were searched systematically until August 6, 2023. Prospective and retrospective studies were included to evaluate the diagnostic performance of CEM for sus…
Rank104.8
Psychoeducation for breast cancer: A systematic review and meta-analysis.
Breast (Edinburgh, Scotland) · 2022 · PMID 35121502
BACKGROUND: Psychoeducation has emerged as an intervention for women with breast cancer (BC). This meta-analysis evaluated the effectiveness of psychoeducation on adherence to diagnostic procedures and medical treatment, anxiety, depression, quality of life (QoL), and BC knowledge among patients with BC symptoms or diagnosis and BC survivors. METHODS: A systematic literature search (in PubMed, Embase, PsycINFO and Cochrane) for randomised controlled trials (RCTs) comparing the effects of psychoeducation to control …
Rank103.7
The Association Between Meningioma and Breast Cancer: A Systematic Review and Meta-analysis.
JAMA network open · 2023 · PMID 37326990
IMPORTANCE: A potential relationship between meningioma and breast cancer was suggested 70 years ago. However, to date, no conclusive evidence is available on this topic. OBJECTIVE: To provide a comprehensive review of the literature on the association of meningioma with breast cancer, supported by a meta-analysis. DATA SOURCES: A systematic PubMed search was performed up to April 2023 to identify articles on the association of meningioma with breast cancer. The following key words were used strategically: meningio…
Rank103.5
Impact on fatigue of different types of physical exercise during adjuvant chemotherapy and radiotherapy in breast cancer: systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 35064331
BACKGROUND: Physical exercise in women with breast cancer has shown benefits in reducing fatigue levels during adjuvant radiotherapy and chemotherapy. However, it is not well understood which type of exercise is more effective. OBJECTIVE: Assess the impact of different types of physical exercises on fatigue and which is the most effective in reducing this adverse effect during adjuvant treatment in breast cancer. METHODS: The inclusion criteria were randomized clinical trials of physical exercise in women diagnosed…
Rank103.5
Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Journal of cancer research and therapeutics · 2023 · PMID 38376268
Tumor budding is gaining importance as a prognostic factor in various carcinomas due to its association with epithelial-mesenchymal transition (EMT) and hence clinical outcome. Reporting tumor budding in breast cancer lacks homogeneity. We aim to systematically review the existing literature and conduct a meta-analysis to assess the prognostic implication of tumor budding in breast carcinoma. A systematic search was performed to identify studies that compared different prognostic variables between high- and low-gra…
Rank103.4
Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: A systematic review with network meta-analysis.
Critical reviews in oncology/hematology · 2023 · PMID 36535489
Aromatase inhibitor-induced arthralgia (AIA) contributes to poor adherence of aromatase inhibitor therapies in patients with breast cancer. A systematic review using network meta-analysis (NMA) was conducted to examine the clinical effectiveness of multiple therapies and rank probabilities for the management of AIA. Randomized controlled trials (RCTs) assessing treatments for AIA in postmenopausal women with stage 0-III hormone receptor-positive breast cancer were searched from inception to October 2021. The main N…
Rank103.4
Manual Lymphatic Drainage for Breast Cancer-related Lymphedema: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Clinical breast cancer · 2022 · PMID 35370085
BACKGROUND: The purpose of this systematic review was to meta-analyze the effectiveness of manual lymphatic drainage (MLD) in breast cancer-related lymphedema (BCRL) patients. METHODS: The following databases: the Cochrane Library, the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Web of Science, ClinicalTrials.gov were systematically searched. All English publications before April 2021 have been retrieved without any restrictions of countries, time, or article type. We included randomized control…
Rank102.6
Platinum chemotherapy for early triple-negative breast cancer.
Breast (Edinburgh, Scotland) · 2024 · PMID 38492276
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with shorter survival and a higher likelihood of recurrence. In early TNBC, platinum chemotherapy has been shown to improve pathological complete response (pCR); however, its effect on long-term survival outcomes has not been fully elucidated. METHODS: Randomised controlled trials examining neoadjuvant or adjuvant platinum chemotherapy for early TNBC were included. Primary outcomes were disease-free survival (DFS) …
Rank102.5
Exposure to per- and polyfluoroalkyl substances and breast cancer risk: a systematic review and meta-analysis of epidemiologic studies.
American journal of epidemiology · 2024 · PMID 38400646
We synthesized the epidemiologic evidence on the associations between per- and polyfluoroalkyl substances (PFAS) exposure and breast cancer risk. Our systematic review and meta-analysis included 18 and 11 articles, respectively, covering studies up to February 2023. The summary relative risks (RRs) estimated by random-effects meta-analyses did not support an association between PFAS and overall breast cancer risk (eg, a natural log (ln)-unit increase in serum/plasma concentrations [ng/mL] for perfluorooctanoate [PF…
Rank101.8
Breast Cancer Screening in Women With Schizophrenia: A Systematic Review and Meta-Analysis.
Psychiatric services (Washington, D.C.) · 2020 · PMID 31722645
OBJECTIVE: Women with schizophrenia appear to receive breast cancer diagnoses at later stages of the disease compared with the general population. To study this disparity, this report reviewed and quantified the differences in rates of mammography screening for women with schizophrenia and other psychotic disorders compared with the general population. METHODS: A systematic literature search was conducted in PubMed, Embase, Web of Science, and PsycINFO databases. Each database was searched from inception to Septemb…
Rank101.8
Folate Intake and Breast Cancer Risk: A Systematic Review and Meta-Analysis.
Molecular nutrition & food research · 2026 · PMID 41437765
This study aimed to evaluate the relationship between folate intake and breast cancer risk in adult women. A blinded paired-matched search was conducted in Embase, PubMed/Medline, and Web of Science. Cohort and case-control studies assessing folate intake or supplementation and breast cancer risk were included. The search yielded 377 studies. After exclusion of duplicates and reading of the titles and abstracts, 13 were selected for full-text reading, and 11 met the eligibility criteria. Most studies (n = 8) found …
Rank100.9
Worldwide review with meta-analysis of women's awareness about breast cancer.
Patient education and counseling · 2022 · PMID 34952749
OBJECTIVE: To summarize the awareness levels of breast cancer (BC) worldwide and investigate factors associated with BC awareness to determine differences in awareness between China and other countries. METHODS: This systematic review followed the PRISMA guidelines and included 92 articles up to July, 2021. We calculated percentages for BC awareness levels and conducted subgroup analysis and cumulative meta-analysis. RESULTS: A total 84% (95% confidence interval [95%CI]: 78-90%) of women knew about BC; however, onl…
Most Effective Evidence Supported Treatments84 records
Rank110.0
The Impact of Metabolic Bariatric Surgery on the Incidence of Breast Cancer in Patients with Obesity: A Systematic Review and Meta-Analysis.
Obesity surgery · 2026 · PMID 42298137
INTRODUCTION: Obesity is widely recognized as an important risk factor for breast cancer, largely due to its effects on hormonal regulation, chronic low-grade inflammation, and metabolic dysfunction. Metabolic bariatric surgery (MBS) produces long-term weight reduction and improves metabolic profiles, which may influence the development of obesity-related cancers. This systematic review and meta-analysis aimed to examine the relationship between bariatric surgery and breast cancer incidence in adult women with obes…
Rank108.5
Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer - A systematic review and meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 41722713
BACKGROUND: The benefit of adjuvant chemotherapy for patients with small, early-stage (T1a-bN0) triple-negative breast cancer (TNBC) is unclear because these patients have largely been excluded from randomized trials. We performed a systematic review and meta-analysis to analyze the effect of adjuvant chemotherapy in this population. METHODS: We included interventional and observational studies comparing adjuvant chemotherapy with no chemotherapy in patients with T1a-bN0 TNBC. Studies were identified through system…
Rank108.1
Effects of different mind-body exercises on quality of life and cancer-related fatigue in breast cancer survivors: a systematic review and network meta-analysis.
Journal of cancer survivorship : research and practice · 2026 · PMID 40178706
PURPOSE: To compare the efficacy of the different mind-body exercises (MBEs) for quality of life (QOL) and cancer-related fatigue (CRF) in women breast cancer (BC) survivors. METHODS: This review searched published randomized controlled trials (RCTs) in eight electronic databases: PubMed, Web of Science, Embase, Cochrane CENTRAL, EBSCO, CNKI, VIP, and WanFang from inception to October 30, 2023. NMA and comparative effects ranking were performed using STATA 17.0 software. RESULTS: This study included 121 studies wit…
Rank107.4
Clinical outcomes of magnetic seed and wire-guided localisation for non-palpable breast lesions: a systematic review and meta-analysis.
Surgical oncology · 2026 · PMID 42320423
BACKGROUND: Wire-guided localisation (WGL) has been historically widely used as the standard method of pre-operative localisation of non-palpable breast lesions. Magnetic seeds (Magseed) were developed to overcome the logistical and technical limitations associated with wires. The aim of this systematic review was to compare the clinical outcomes associated with Magseed and WGL techniques. METHODS: A systematic literature search of relevant databases was performed. A meta-analysis using the Mantel-Haenszel method w…
Rank107.2
Robot-assisted versus conventional mastectomy and immediate breast reconstruction: A systematic review and comparative and single-arm meta-analysis.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2026 · PMID 42308843
BACKGROUND: Robot-assisted mastectomy (RAM) is increasingly adopted in breast and plastic surgery with proposed benefits including improved cosmetic outcomes, surgical precision, and surgeon ergonomics. However, concerns remain regarding longer operative times. This systematic review and meta-analysis aimed to evaluate outcomes of RAM with immediate breast reconstruction (IBR) of any type compared with conventional mastectomy (CM). METHODS: The study was conducted according to PRISMA guidelines. Database searches w…
Rank107.2
Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis.
Breast (Edinburgh, Scotland) · 2026 · PMID 42372581
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have demonstrated clinical benefit in early-stage breast cancer (eBC), enhancing antitumor immune responses. However, their incorporation into perioperative polychemotherapy has introduced new concerns regarding safety and immune-related toxicities (irAEs). We conducted a systematic review and meta-analysis to comprehensively evaluate the safety profile and tolerability of ICIs in patients with eBC. METHODS: A systematic review was conduc…
Rank107.2
Comparative efficacy of mind-body exercises on quality of life, anxiety, and depression in patients with breast cancer: a systematic review with pairwise and network meta-analysis of randomized controlled trials.
Frontiers in public health · 2026 · PMID 42534521
BACKGROUND: Comparative evidence on the effects of different mind-body exercises (MBEs) for psychological outcomes in breast cancer patients remains limited. This study aimed to compare the effects of Yoga, Tai Chi, Qigong, Pilates, and Dance on quality of life, anxiety, and depression in breast cancer patients. METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 31, 2026. Pairwise meta-analyses were performed using random-effects models with Hedges' g. Bayesian…
Rank106.7
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors.
Journal of cancer survivorship : research and practice · 2025 · PMID 37906420
PURPOSE: Breast cancer survivors are more likely to report psychological distress and unmet need for support compared to healthy controls. Psychological mobile health interventions might be used in follow-up care of breast cancer patients to improve their mental health. METHODS: We searched MEDLINE, PsychINFO, Cochrane and PROSPERO for articles on controlled trials examining the effectiveness of psychological mobile health interventions compared to routine care regarding mental health outcomes of adult breast cance…
Rank106.3
Comparative Histological Features of Phyllodes Tumor and Fibroadenoma in Breast Core Needle Biopsies.
International journal of surgical pathology · 2026 · PMID 41979873
BackgroundPhyllodes tumors (PT) are fibroepithelial breast lesions with variable clinical behavior and histological features that frequently overlap with those of fibroadenomas. Accurate differentiation is critical, as PT may exhibit aggressive behavior. However, their distinction is particularly challenging in core needle biopsy, especially for benign and borderline PT, due to the limited amount of tissue provided by this technique. This meta-analysis investigates histological features that improve the distinction…
Rank106.3
Comparative efficacy of various exercise modalities on sleep quality in breast cancer survivors after primary treatment: A systematic review and dose-response network meta-analysis.
Medicine · 2026 · PMID 42536584
BACKGROUND: This study aims to assess the dose-response relationship between different exercise modalities and sleep quality in breast cancer survivors who have completed their primary treatment, and to propose evidence-based exercise prescriptions for clinical practice. METHODS: Bayesian network and dose-response meta-analyses using a random-effects model were conducted to evaluate the impact of exercise on sleep quality in breast cancer survivors. Exercise dose was calculated as the product of duration, frequency…
Rank106.2
Beyond the first dose: Systematic review on external beam radiotherapy for locoregional breast cancer recurrence.
Breast (Edinburgh, Scotland) · 2026 · PMID 42372580
BACKGROUND: The optimal management of locoregional breast cancer recurrence after prior radiotherapy remains challenging. Reirradiation (ReRT) may allow repeat breast-conserving surgery as an alternative to mastectomy; however, prospective evidence is scarce, and existing data are largely retrospective, with the strongest support for brachytherapy. Despite this, external beam reirradiation (EBreRT) is widely used because of its availability. This systematic review evaluated the feasibility, oncologic outcomes, toxi…
Rank105.9
Factors influencing women's preferences and decision making regarding the extent of axillary surgery in breast cancer: A systematic review.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42330708
Axillary surgery in early-stage breast cancer is increasingly de-escalated. However, variation in practice persists, and the patient level factors influencing treatment decisions remain unclear. This systematic review synthesised evidence on the psychological, clinical, and contextual factors shaping women's preferences and decision making regarding the extent of axillary surgery they receive. A PRISMA-guided search of Ovid MEDLINE, Embase and Cochrane databases was conducted in December 2025. Ten studies involving…
Rank105.8
Total Breast Reconstruction with Autologous Fat Grafting after Mastectomy: A Systematic Review.
Plastic and reconstructive surgery · 2026 · PMID 41329566
BACKGROUND: Total breast reconstruction with autologous fat grafting after mastectomy has emerged as an alternative for patients who are not candidates for flap surgery or prefer to avoid implants. This review evaluates technical considerations, the role of assistive methods, the complication profile, oncologic safety, and patient satisfaction. METHODS: A systematic search of PubMed and Web of Science identified 16 eligible studies from a total of 4316 publications. Only studies that performed total breast reconstr…
Rank105.4
Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026 · PMID 42140114
BACKGROUND: Leptomeningeal disease (LMD) is an increasingly recognised late-stage complication of solid tumours (primarily melanoma, lung and breast cancers). It involves dissemination to the leptomeninges surrounding the brain and spinal cord and carries a poor prognosis ranging from 2-6 months. Recent advances in emerging therapies such as CNS-active targeted therapy, intrathecal agents, and early-phase immunotherapy necessitate an updated appraisal of prospective data. METHODS: A systematic search of MEDLINE, Em…
Rank104.5
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Annals of medicine · 2026 · PMID 41949990
BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…
Rank100.5
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42508432
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. M…
Rank100.4
Association of mobile application information on multidisciplinary therapy and treatment compliance in early-stage breast cancer: A prospective multicenter randomized phase III study.
Breast (Edinburgh, Scotland) · 2026 · PMID 42150214
BACKGROUND: Multidisciplinary therapy (MDT) can improve early breast cancer outcome, while its treatment completion rate is critical. This study aimed to evaluate the association of a mobile health application (RJBC-APP) information on MDT and its treatment adherence, compared with standard clinical management. METHODS: The RJBC-APP study is a prospective, multicenter, randomized, phase 3 clinical trial that enrolled patients with early-stage breast cancer after MDT for adjuvant treatment. Eligible patients were ra…
Rank100.0
Integrating Shared Decision-Making Into Breast Cancer Postmastectomy Reconstruction: A Systematic Review of Evidence, Barriers, and Real-World Implementation.
International journal of cancer · 2026 · PMID 42098969
This systematic review synthesizes empirical evidence on the development, effectiveness, patient experience, and implementation of decision aids (DAs) for postmastectomy breast reconstruction (PMBR) and to evaluate the role of pre-consultation educational interventions in supporting shared decision-making (SDM). Following PRISMA guidelines and a preregistered protocol (OSF: https://osf.io/mu9hv), six electronic databases and gray literature sources were searched for studies on PMBR DAs through November 2025. Eligib…
Rank100.0
Thermal ablation for early-stage breast cancer: cryoablation, microwave ablation, radiofrequency ablation, high-intensity focused ultrasound ablation, and laser ablation - a systematic review.
Breast (Edinburgh, Scotland) · 2026 · PMID 42322704
BACKGROUND: Thermal ablation techniques have been proposed as minimally invasive alternatives to surgery for early-stage breast cancer (BC), with the potential to reduce treatment burden while preserving oncological outcomes. The aim of this review was to evaluate the available evidence on the effectiveness and safety of thermal ablation techniques in patients with early-stage BC. METHODS: We conducted a systematic review and narrative synthesis in accordance with PRISMA guidelines. MEDLINE, Embase, the Cochrane Li…
Rank100.0
Managing diabetes while undergoing breast cancer treatment: a systematic review of women's experiences of self-care and clinical support.
Diabetes & metabolic syndrome · 2026 · PMID 41895065
BACKGROUND: Women with diabetes face a higher risk of developing breast cancer than those without, and when both conditions coexist, the risk of adverse health outcomes is higher. Little is known about the impact of adjuvant breast cancer treatment on diabetes management. This systematic literature review aimed to understand the experiences of women living with diabetes in their diabetes care when undergoing adjuvant breast cancer treatment. METHOD: This PROSPERO-registered (CRD420251046300) systematic review follo…
Rank100.0
Radiation therapy in adolescents and young adults (AYA): contemporary evidence on utilization, outcomes, late toxicities, and second malignant neoplasms - A comprehensive systematic review and synthesis.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42251999
Adolescent and young adult (AYA; 15-39 years) cancer survivors face decades of potential life-years, making radiotherapy (RT) modality and technique selection central determinants of long-term health. A PRISMA 2020-reported systematic review was performed using PubMed, Web of Science, and the Cochrane Library (January 2026). Data were synthesised qualitatively using a Synthesis Without Meta-analysis (SWiM) approach. The primary synthesis focused on RT utilization and late outcomes including late toxicity, survivors…
Rank100.0
Deep inspiration breath hold versus free breathing in postoperative radiotherapy strategy for patients with left-sided breast cancer treated with volumetric modulated arc therapy: A meta-analysis and systematic review.
PloS one · 2026 · PMID 41911243
This meta-analysis aimed to determine the effect of deep inspiration breath hold (DIBH) compared with free breathing (FB) on dose to the organs at risk (OARs), such as the heart, left anterior descending (LAD) coronary artery, lungs, and contralateral breast, in patients with left-sided breast cancer treated with volumetric modulated arc therapy (VMAT). PubMed, EMBASE, and Cochrane Library electronic databases were searched for studies until March 21, 2024. Cochrane RevMan version 5.4 statistical software was used …
Rank100.0
Digital behavioural weight loss interventions for weight management in breast cancer survivors: A meta-analysis.
European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2026 · PMID 42385539
OBJECTIVE: This study aims to systematically evaluate the effectiveness of digital behavioural weight-loss interventions on body weight, BMI, waist circumference, physical activity, and quality of life in breast cancer survivors. METHODS: A comprehensive search was conducted across six databases, including PubMed, Scopus, Embase, Web of Science, CINAHL, and Cochrane Library, to identify eligible randomised controlled trials that investigated the effectiveness of digital behavioural weight loss interventions in weig…
Rank100.0
The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.
Annals of medicine · 2026 · PMID 41503829
BACKGROUND: Breast cancer (BC) remains a major global health concern, accounting for 11.7% of all cancer cases and ranking as the second leading cause of female cancer-related deaths worldwide. Increasing evidence highlights the interplay between gut microbiota (GM) dysbiosis and obesity-associated metabolic dysfunction in BC progression. This review aims to elucidate the role of GM in obese patients with BC. METHODS: A systematic literature search was conducted in PubMed and Web of Science databases for publicatio…
Rank100.0
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.
Breast (Edinburgh, Scotland) · 2026 · PMID 42372579
BACKGROUND: Recent years have seen rapid advances in human epidermal growth factor receptor 2 (HER2)-directed therapies for breast cancer. The shifting therapeutic landscape has presented patients and clinicians with a plethora of effective treatment options, but optimal treatment sequencing can be challenging. Tucatinib is a HER2-selective tyrosine kinase inhibitor that, when given in combination with trastuzumab and capecitabine, has demonstrated survival benefits for patients with HER2-positive (HER2+) metastati…
New Research Last 24 Months366 records
Rank110.0
The Impact of Metabolic Bariatric Surgery on the Incidence of Breast Cancer in Patients with Obesity: A Systematic Review and Meta-Analysis.
Obesity surgery · 2026 · PMID 42298137
INTRODUCTION: Obesity is widely recognized as an important risk factor for breast cancer, largely due to its effects on hormonal regulation, chronic low-grade inflammation, and metabolic dysfunction. Metabolic bariatric surgery (MBS) produces long-term weight reduction and improves metabolic profiles, which may influence the development of obesity-related cancers. This systematic review and meta-analysis aimed to examine the relationship between bariatric surgery and breast cancer incidence in adult women with obes…
Rank108.5
Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer - A systematic review and meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 41722713
BACKGROUND: The benefit of adjuvant chemotherapy for patients with small, early-stage (T1a-bN0) triple-negative breast cancer (TNBC) is unclear because these patients have largely been excluded from randomized trials. We performed a systematic review and meta-analysis to analyze the effect of adjuvant chemotherapy in this population. METHODS: We included interventional and observational studies comparing adjuvant chemotherapy with no chemotherapy in patients with T1a-bN0 TNBC. Studies were identified through system…
Rank107.2
Comparative efficacy of mind-body exercises on quality of life, anxiety, and depression in patients with breast cancer: a systematic review with pairwise and network meta-analysis of randomized controlled trials.
Frontiers in public health · 2026 · PMID 42534521
BACKGROUND: Comparative evidence on the effects of different mind-body exercises (MBEs) for psychological outcomes in breast cancer patients remains limited. This study aimed to compare the effects of Yoga, Tai Chi, Qigong, Pilates, and Dance on quality of life, anxiety, and depression in breast cancer patients. METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 31, 2026. Pairwise meta-analyses were performed using random-effects models with Hedges' g. Bayesian…
Rank106.3
Comparative efficacy of various exercise modalities on sleep quality in breast cancer survivors after primary treatment: A systematic review and dose-response network meta-analysis.
Medicine · 2026 · PMID 42536584
BACKGROUND: This study aims to assess the dose-response relationship between different exercise modalities and sleep quality in breast cancer survivors who have completed their primary treatment, and to propose evidence-based exercise prescriptions for clinical practice. METHODS: Bayesian network and dose-response meta-analyses using a random-effects model were conducted to evaluate the impact of exercise on sleep quality in breast cancer survivors. Exercise dose was calculated as the product of duration, frequency…
Rank106.0
Thyroid Hormone Treatment and Breast Cancer Risk in Women: A Systematic Review and Meta-Analysis of Observational Studies.
Metabolites · 2026 · PMID 42506418
OBJECTIVE: Thyroid hormone treatment is the standard therapy for hypothyroidism, particularly in women. Concerns have been raised that exogenous thyroid hormone use may increase breast cancer risk, but evidence remains inconclusive. This study aimed to systematically review and synthesize observational evidence on the association between thyroid hormone treatment and breast cancer risk in women. DESIGN: We conducted a systematic review and meta-analysis of observational studies. METHODS: MEDLINE, EMBASE, and Web of…
Rank102.6
Meta-analysis of the effect of sexual health nursing interventions on improving post-treatment sexual dysfunction and partner relationship satisfaction in breast cancer patients.
Sexual medicine · 2026 · PMID 42540624
INTRODUCTION: Breast cancer survivors frequently experience sexual dysfunction and impaired partner relationships after treatment, but the effectiveness of nursing interventions in improving these post-treatment outcomes remains uncertain. To evaluate the efficacy of sexual health, nursing interventions on sexual dysfunction and quality of life in breast cancer survivors through a systematic review and meta-analysis of randomized controlled trials. METHODS: We searched PubMed, Embase, and Web of Science for randomi…
Rank100.5
The effect of different combinations of open invitations and timed appointments on breast screening attendance: service evaluation of invitation strategies in the NHS Breast Screening Programme.
British journal of cancer · 2026 · PMID 42129338
BACKGROUND: The NHS Breast Screening Programme invites eligible women using either a timed appointment letter (option to change), or an open invitation to make an appointment. Non-attenders receive a 'Timed' or 'Open' second invitation. NHS England commissioned a service evaluation to determine the effect of different combinations of timed and open invitations. METHODS: Seven services, selected to ensure adequate representation of diverse socio-economic, ethnic, urban/rural, and current uptake groups, participated.…
Rank100.0
Managing diabetes while undergoing breast cancer treatment: a systematic review of women's experiences of self-care and clinical support.
Diabetes & metabolic syndrome · 2026 · PMID 41895065
BACKGROUND: Women with diabetes face a higher risk of developing breast cancer than those without, and when both conditions coexist, the risk of adverse health outcomes is higher. Little is known about the impact of adjuvant breast cancer treatment on diabetes management. This systematic literature review aimed to understand the experiences of women living with diabetes in their diabetes care when undergoing adjuvant breast cancer treatment. METHOD: This PROSPERO-registered (CRD420251046300) systematic review follo…
Rank100.0
Deep inspiration breath hold versus free breathing in postoperative radiotherapy strategy for patients with left-sided breast cancer treated with volumetric modulated arc therapy: A meta-analysis and systematic review.
PloS one · 2026 · PMID 41911243
This meta-analysis aimed to determine the effect of deep inspiration breath hold (DIBH) compared with free breathing (FB) on dose to the organs at risk (OARs), such as the heart, left anterior descending (LAD) coronary artery, lungs, and contralateral breast, in patients with left-sided breast cancer treated with volumetric modulated arc therapy (VMAT). PubMed, EMBASE, and Cochrane Library electronic databases were searched for studies until March 21, 2024. Cochrane RevMan version 5.4 statistical software was used …
Rank100.0
Responsible artificial intelligence in medical imaging: a systematic review.
Frontiers in digital health · 2026 · PMID 42535035
INTRODUCTION: Responsible artificial intelligence (AI) in medical imaging requires more than high diagnostic accuracy; it also requires transparent reasoning, equitable performance across patient subgroups, privacy protection, calibrated uncertainty, and clinical trustworthiness. METHODS: This PRISMA-informed systematic review synthesized 24 studies published between 2020 and 2025 that used AI or deep learning for disease detection or diagnostic support in X-ray, CT, MRI, mammography, ultrasound, dermoscopy, retina…
Rank100.0
Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42449201
OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in…
Rank100.0
Dairy consumption is associated with breast cancer risk: a comprehensive meta-analysis stratified by hormone receptor and menopausal status, and age.
Nutrition research (New York, N.Y.) · 2025 · PMID 40311535
Breast cancer (BC) is a prevalent global health concern, with various risk factors contributing to its heterogeneity. This comprehensive meta-analysis aims to explore the association between dairy consumption and BC risk, stratified by hormone receptor, menopausal status, and age. To assess the association between dairy consumption and BC risk, a systematic literature review based on studies published until December 2024 retrieved from PubMed, SCOPUS, Web of Science, and Cochrane Library. Summary relative risks (RR…
Rank99.2
Self-Management Support for Cancer Survivors at Risk of Cardiotoxicity: A Scoping Review.
Heart, lung & circulation · 2026 · PMID 42431760
BACKGROUND: Cancer survivorship has significantly increased globally. This success has brought new challenges, including the rise in cardiovascular complications due to cardiotoxic effects of cancer treatments. Self-management (SM) support is increasingly recognised as an important component in overcoming these challenges; however, its implementation into practice remains inconsistent. AIM: This scoping review aims to map the current landscape of SM for cancer survivors at risk of or experiencing cardiotoxicity, wi…
Rank99.0
MRI radiomics for predicting pathological complete response in breast cancer: a systematic review of current evidence and limitations.
European journal of radiology · 2026 · PMID 42541995
BACKGROUND: Machine learning models based on MRI radiomics show promise for predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer, with increasing interest in clinical translation. However, uncertainties remain regarding methodological quality, generalizability, and performance across patient subgroups. This systematic review provides a comprehensive evaluation of MRI radiomics models for pCR prediction, focusing on methodological robustness, validation practices, and factors affec…
Rank98.0
Mapping the evolution and impact of microfluidic technology research on cancer diagnosis: A comprehensive bibliometric analysis from 2015 to 2024.
Medicine · 2026 · PMID 42536556
BACKGROUND: To explore the research trends of microfluidic technology for cancer diagnosis from 2015 to 2024 using bibliometric and visualization methods (not a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review), and provide references for subsequent scientific research. METHODS: Relevant literatures were retrieved from the Web of Science Core Collection, and analyzed using tools such as Origin 2018, R software, VOSviewer, and CiteSpace. The cooperation network, co - cit…
Rank97.8
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Annals of surgical oncology · 2026 · PMID 41739398
PURPOSE: We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study (NCT03036488). METHODS: Participants with previously untreated, early-stage TNBC (AJCC stage T1c N1-2 or T2-4 N0-2) were randomized 2:1 to neoadjuvant pembrolizumab/placebo plus paclitaxel-carboplatin for 4 cycles, followed by pembrolizumab/placebo plus doxorubicin/epirubicin an…
Rank97.0
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 40632989
PURPOSE: We investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor-positive (HR+) BC who had a live birth in the POSITIVE trial. PATIENTS AND METHODS: POSITIVE is a prospective trial that demonstrated no increased short-term risk of BC events in women with early HR+ BC who interrupted endocrine therapy (ET) to attempt pregnancy. We describe the frequency, duration, and laterality of breastfeeding and estimate the cumulative incidence of …
Rank96.6
A complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 41762807
PURPOSE: Those living beyond a cancer diagnosis experience unmet supportive care needs due to fragmented post-treatment pathways and limited integration of digital health tools. The Linking You to Support and Advice (LYSA) trial assessed the feasibility of a complex-intervention which incorporated a nurse- and dietitian-led multidisciplinary clinic and a digital platform for capturing and responding to electronic Patient-Reported Outcome (ePRO) data for women with early-stage breast and gynecologic cancer less than…
Rank96.5
Randomized Controlled Trial of Group-Blended and Individual-Unguided Online Mindfulness-Based Cognitive Therapy to Reduce Psychological Distress in People With Cancer.
Psycho-oncology · 2025 · PMID 40968786
OBJECTIVE: Online mindfulness-based cognitive therapy (eMBCT) can reduce psychological distress in people with cancer, but adherence and scalability could be improved. Through co-creation, we developed two eMBCT formats: group-blended and individual-unguided. This trial compared the effects of the two eMBCT to care as usual (CAU) on psychological distress and other mental health outcomes in people with cancer. METHODS: In this parallel, three-armed randomized controlled trial, people with cancer were randomly alloc…
Rank96.3
Brief Post-Surgical Stress Management Intervention Effects on Positive Psychological Well-Being and Self-Efficacy in Women Being Treated With Adjuvant Endocrine Therapy for Hormone-Receptor Positive Breast Cancer.
Psycho-oncology · 2025 · PMID 40846861
BACKGROUND: Women prescribed adjuvant endocrine therapy (AET) for nonmetastatic breast cancer may experience a decline in positive psychological well-being (PPWB) and self-efficacy. Brief cognitive behavioral therapy (CBT) and relaxation training (RT) interventions have shown short-term efficacy in reducing distress, but their impact on PPWB and self-efficacy over longer periods among women prescribed AET is unknown. AIMS: We aimed to investigate longitudinal effects of CBT and RT on PPWB and self-efficacy among wo…
Rank96.0
Evaluation of vaginitis and its treatment.
Current opinion in obstetrics & gynecology · 2026 · PMID 42456118
PURPOSE OF REVIEW: Vaginitis is one of the most common reasons a patient will present for care in both the ambulatory and urgent care settings. The objective of this review is to summarize traditional methods of evaluation and treatment for the most commonly seen vaginitis and vaginosis, but also to present updated literature and future management directions for this common and sometimes resilient medical problem. RECENT FINDINGS: A randomized controlled trial of partners in monogamous heterosexual relationships an…
Rank96.0
Sexual Quality of Life among Women with Female Cancers in Arab Countries: A Mixed Systematic Review.
Annals of African medicine · 2026 · PMID 42459036
The sexual health of women with gynecological or breast cancer is a major determinant of their quality of life, yet it is largely ignored in oncological care pathways. This systematic review, based on 25 studies conducted in Arab countries among patients aged 18 years and over (undergoing treatment or in remission), reveals a profound alteration in their intimate lives: Decreased desire, lubrication difficulties, orgasmic disorders, sexual dissatisfaction, and infrequent intercourse. These dysfunctions are not sole…
Rank96.0
Sense of coherence and health-related outcomes among patients with breast cancer: a systematic review.
Korean journal of family medicine · 2026 · PMID 42533683
Patients with breast cancer frequently experience substantial psychological burden and persistent symptoms. Sense of coherence (SOC), a central construct of the salutogenic framework, has emerged as a key psychosocial resource for chronic illnesses. However, its association with diverse health-related outcomes in patients with breast cancer has not yet been systematically investigated. This systematic review examined the association between SOC and health-related outcomes in patients with breast cancer. The review …
Rank96.0
Association between adolescent alcohol consumption and cigarette smoking with adult risk of breast cancer: A systematic review and meta-analysis.
Preventive medicine · 2026 · PMID 42501871
OBJECTIVE: Alcohol and smoking are established carcinogens; however, evidence on adolescent exposure during mammary development on breast cancer risk remains inconsistent. This study assessed the associations between adolescent alcohol intake, smoking, and adult breast cancer risk. METHODS: A systematic search of PubMed/MEDLINE (1966), Web of Science (1900), and Scopus (1970) from inception to September 2025 identified 31 eligible studies (eleven on alcohol, twenty on smoking). Pooled relative risks (RRs) with 95% …
Rank96.0
Pathology or New Norm? Reframing Social Constraints in Breast Cancer Survivors: A Scoping Review.
Holistic nursing practice · 2026 · PMID 42302728
While medical advancements have significantly increased breast cancer survival rates, current survivorship often remains trapped within a biomedical framework that views physical alterations merely as deficits to be fixed. Consequently, the lived experience of survivors involves persistent body surveillance and cultural stigma that conflict with societal norms. Guided by Georges Canguilhem's philosophy of normativity, this scoping review maps social constraints in breast cancer survivors using the Arksey and O'Mall…
Preclinical Research125 records
Rank100.0
Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42449201
OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in…
Rank100.0
The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.
Annals of medicine · 2026 · PMID 41503829
BACKGROUND: Breast cancer (BC) remains a major global health concern, accounting for 11.7% of all cancer cases and ranking as the second leading cause of female cancer-related deaths worldwide. Increasing evidence highlights the interplay between gut microbiota (GM) dysbiosis and obesity-associated metabolic dysfunction in BC progression. This review aims to elucidate the role of GM in obese patients with BC. METHODS: A systematic literature search was conducted in PubMed and Web of Science databases for publicatio…
Rank85.0
Antioxidant Activity and Dose-Dependent Toxicity of a Traditionally Consumed Ipomoea pes-caprae Infusion Evaluated in a Triple-Negative Breast Cancer Xenograft Model.
Nutrients · 2026 · PMID 42514317
Background/Objectives: Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes and remains associated with limited therapeutic options and high systemic toxicity from conventional chemotherapy. Ipomoea pes-caprae is a coastal medicinal plant traditionally consumed in Mexico for inflammatory and renal disorders and contains bioactive metabolites with reported antioxidant and pharmacological properties. However, its antitumoral activity and systemic safety profile remain poorly under…
Rank47.3
Improved Nondestructive Ultrasound Molecular Imaging With Lightweight Convolutional Neural Network.
IEEE transactions on medical imaging · 2026 · PMID 42043989
Ultrasound molecular imaging (USMI) is an imaging approach that utilizes targeted microbubbles (MBs) to highlight biomarkers of disease. While differential targeted enhancement (DTE) is the current state-of-the-art for USMI, its reliance on destructive pulses hinders real-time clinical application. We have developed a neural network-based nondestructive USMI, validated in vivo using a transgenic mouse model of spontaneous breast cancer. To enhance training efficacy despite a limited animal number (N=14), we utilize…
Rank47.3
Belt electrode-skeletal muscle electrical stimulation-induced attenuation of aromatase inhibitor-induced bone loss in ovariectomized rats.
Bone · 2026 · PMID 42259425
Cancer treatment-induced bone loss (CTIBL) is a clinically significant adverse effect of endocrine therapy in hormone-related cancers, including breast cancer. Pharmacological interventions, including antiresorptive agents, are widely used; however, few nonpharmacological interventions ensure preservation of bone health without imposing excessive physical burden. We investigated the preventive effects of belt electrode-skeletal muscle electrical stimulation (B-SES) on aromatase inhibitor (AI)-induced bone loss in a…
Rank46.8
Diets Rich in n-6 or n-3 Polyunsaturated Fatty Acids Combined with Exercise Influences Tumour Development in a Her-2 Breast Cancer Model.
Nutrients · 2026 · PMID 42514331
Background/Objectives: Dietary changes or increased physical activity to promote health accompanies breast cancer treatment to improve outcomes and prevent cancer recurrence. However, primary breast cancer prevention studies are limited and while there is a growing benefit to diet and exercise, the combinatory benefits of diet and exercise are limited. Therefore, the objective of this exploratory study was to determine the effects of exposure to diets high in n-3 or n-6 polyunsaturated fatty acids (PUFA) combined w…
Rank46.4
Different effects of moderate tibial loading and Yoda1 on breast cancer-induced osteolysis in aged mice.
Bone · 2025 · PMID 40345567
Elderly breast cancer patients and survivors are at high risk of bone loss but experience obstacles to harness the known benefits of exercise due to aging, cancer, and cancer treatment. Previously, we and others showed that moderate mechanical loading suppressed breast cancer-induced osteolysis in young adult mice. To overcome the mechano-transduction deficits in aged skeletons, we recently tested a dual therapy combining mechanical and Yoda1 activation of mechanosensitive Piezo1 channels. We found that the dual th…
Rank45.0
Environmental-dose chlorpyrifos disrupts gut microbiota and microbial metabolite profiles: An indirect mechanism promoting breast tumor growth.
Journal of environmental sciences (China) · 2026 · PMID 42498388
Chlorpyrifos (CPF), a persistent organic pollutant prevalent in the environment, has been associated with an increased risk of breast cancer through mechanisms that remain incompletely elucidated. Since microorganisms are more susceptible to CPF than animals, this study employed a 24-week exposure mouse model to investigate the impacts of environmental-dose CPF (2 and 20 μg/kg) on gut microbiota (GM), microbial metabolites, and breast tumor growth. Our findings revealed that chronic CPF exposure reduced bacterial α…
Rank45.0
Application of a Modified In Situ Perfusion Model to Quantify Intestinal Drug Excretion and Transporter-Mediated Interactions after Intravenous Administration.
The AAPS journal · 2026 · PMID 41813996
Intestinal excretion (IE), one of the under-investigated mechanisms of drug elimination, has been identified as the loci of drug-drug interactions (DDIs) within the intestinal tract. Here, we employed a modified rat in situ intestinal perfusion model to examine of the drug clearance of apixaban, talinolol, and irinotecan in the short time drug recovery study. The influence of specific efflux transporter inhibitors, including P-glycoprotein (P-gp) inhibitor elacridar, multidrug resistance-associated protein 2 (Mrp2)…
Rank45.0
Dose-dependent neurotoxic effects of anastrozole via disrupting NLRP3 inflammasome and α-synuclein pathways.
Tissue & cell · 2026 · PMID 42139902
Anastrozole (ANZ) is a commonly used aromatase inhibitor in the treatment of hormone-dependent breast cancer. Despite its toxicity profile reported in different studies, the neurotoxic effects against this drug have not been explored yet. The present study was aimed at investigating the neurotoxic effects of ANZ in Sprague Dawley rats using comprehensive biochemical, molecular and histopathological analysis. Rats were divided into control and ANZ treated (0.1, 0.2 and 0.5 mg/ kg) doses. It was found that ANZ intoxi…
Rank45.0
An exploratory pre-clinical study of the combination of hyperthermia and checkpoint inhibitors.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42517178
BACKGROUND AND PURPOSE: This was a pre-clinical study designed to investigate the potential of combining hyperthermia with checkpoint inhibitors. MATERIAL AND METHODS: C3H mammary carcinomas, grown in the right rear foot of CDF1 mice, were treated when tumors reached 200 mm3. Hyperthermia (39.5-42.5 °C for 30-120 min) was applied following immersion of the tumor bearing leg into a circulating water bath. The checkpoint inhibitors were anti-CTLA-4/PD-1/PD-L1 antibodies injected intraperitoneally (4 x 10 mg/kg). Tumo…
Rank45.0
Brain-Selective Estrogen Therapy in Male and Female Marmosets Partially Counteracts the Adverse Effects of Aromatase Inhibition on the Brain and Behavior.
The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026 · PMID 42259621
Blocking estrogen synthesis via aromatase inhibition helps prevent the recurrence of estrogen receptor-positive breast cancer but also results in cognitive, sleep, and thermoregulatory disturbances. These side effects diminish quality of life and contribute to treatment nonadherence in a large proportion of patients. 10β,17β-Dihydroxyestra-1,4-dien-3-one (DHED) is a brain-selective prodrug that, in rodent models, converts to 17β-estradiol (E 2) selectively in the brain without affecting the periphery. We investigat…
Rank45.0
Detection of malignancies in mice using TXRF analysis and reaction-based optical fingerprinting of blood plasma.
Analytica chimica acta · 2026 · PMID 42508915
This study explores the potential of reaction-based optical fingerprinting and total X-ray fluorescence (TXRF) elemental analysis, both separately and in combination, as a rapid and inexpensive approach to preliminary cancer diagnostics. Plasma samples from BALB/c mice with transplanted mammary carcinoma (EMT-6) and BDF1 mice with Lewis lung carcinoma (LLC) or B16 melanoma were analyzed. The optical fingerprinting method relies on differences in the oxidation rate of a carbocyanine dye in the presence of blood plas…
Rank45.0
Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026 · PMID 42378880
HER2-positive tumors persist as a formidable therapeutic challenge despite advances in targeted agents, chemotherapy, and immunotherapy. Recently, messenger RNA (mRNA) vaccines have emerged as promising avenues for the treatment of advanced tumors and their recurrence, although their clinical application remains challenging. Herein, we developed lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccines encoding the modified extracellular domain (ECD) sequence from rat HER2 (rHER2 ECD mRNA-LNP) and hum…
Rank45.0
Characterization of microvascular remodeling in metastatic sentinel lymph nodes via skeletonization framework generated by ultrasound localization microscopy.
Ultrasonics · 2026 · PMID 42090859
Lymphatic spread to the sentinel lymph node (SLN) represents the primary pathway for early-stage breast cancer metastasis. Given that metastatic progression is fundamentally driven by pathological angiogenesis, high-resolution imaging and quantification of SLN microvasculature are critical for assessing tumor spread. In this study, we applied ultrasound localization microscopy (ULM) to a rabbit VX2 breast tumor model and developed a skeletonization-based analytical framework to quantify lymphatic microvascular morp…
Rank33.6
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
Cancer chemotherapy and pharmacology · 2024 · PMID 38305868
PURPOSE: Giredestrant is a potent, orally bioavailable, small-molecule selective estrogen receptor antagonist and degrader (SERD) that is being developed for the treatment of patients with estrogen receptor (ER)-positive breast cancer. In vitro, giredestrant was primarily metabolized by UGT1A4. The goal of this study was to investigate if UGT1A4 polymorphism had a clinically relevant impact on giredestrant exposure. METHODS: Genotyping and pharmacokinetic data were obtained from 118 and 61 patients in two clinical …
Rank33.0
An integrated machine learning and computational framework with experimental validation for the identification of novel CXCR4 inhibitors.
European journal of medicinal chemistry · 2026 · PMID 42068640
Chemokine receptor 4 (CXCR4) is a clinically significant G protein-coupled receptor implicated in HIV-1 entry, cancer progression, immune regulation, and metastatic dissemination, making it an attractive therapeutic target. This study employed an integrated computational and experimental framework to identify novel small-molecule CXCR4 inhibitors. A curated dataset of 608 compounds from peer-reviewed literature and patents was used to train machine-learning classification models. Decision Tree, Logistic Regression,…
Rank32.9
Early local immune activation following intra-operative radiotherapy in human breast tissue.
Oncoimmunology · 2026 · PMID 41943280
The local immune effects of cancer radiotherapy remain poorly characterized in humans due to limited access to irradiated tissue. Mechanistic insights largely derive from preclinical models employing tumor-intact, neoadjuvant-like settings. Here, we present real-world immunoprofiling data from breast cancer patients undergoing breast-conserving surgery with (n = 20) or without (n = 29) intraoperative radiotherapy (IORT). Postoperative wound fluid samples were analyzed by flow cytometry, multiplex cytokine profiling…
Rank31.4
Precise sequential combination of cisplatin and cyclophosphamide induces higher anti-tumor and immunomodulatory effects against experimental Ehrlich ascites.
Immunology letters · 2026 · PMID 42251904
BACKGROUND: Cisplatin (CIS) and cyclophosphamide (CTX) are commonly used in clinical oncology, often in combination to improve therapeutic outcomes. However, most preclinical studies have examined these agents individually, overlooking the potential synergistic and immunomodulatory effects of combined treatment. This study aimed to compare the antitumor and immune-modulating effects of single versus combined CTX and CIS chemotherapy, and to determine the treatment sequence that achieves maximum efficacy with minima…
Rank31.4
A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model.
Journal of translational medicine · 2025 · PMID 41053808
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited therapeutic options. Immune checkpoint inhibitors targeting the programmed death-ligand 1 (PD-L1) pathway show restricted efficacy in TNBC, with response rates of only 5-10% as monotherapy. Interleukin-8 (IL-8/CXCL8) signaling promotes immunosuppression and mediates resistance to anti-PD-L1 therapy, necessitating combination approaches to overcome these limitations. However, the underlying mechanisms of enhanced efficacy from …
Rank30.0
Breast Cancer-Derived AZU1 Educates Neutrophils to Promote Tumor Progression and Metastasis Through PAD4-Dependent Extracellular Trap Formation.
Molecular carcinogenesis · 2026 · PMID 42541493
Neutrophil extracellular traps (NETs) play crucial roles in cancer progression, but their regulatory mechanisms in breast cancer remain poorly understood. We developed a NETs-related prognostic risk model using TCGA breast cancer data and identified key biomarkers through bioinformatics analysis. AZU1 expression was validated in clinical samples using qRT-PCR and immunohistochemistry. In vitro experiments investigated AZU1's effects on neutrophil activation and NET formation using recombinant protein treatment, co-…
Rank30.0
Artesunate-loaded bovine serum albumin nanoplatform with metal-polyphenol network coating for ferroptosis-driven breast cancer therapy.
International journal of pharmaceutics: X · 2026 · PMID 42540475
Ferroptosis, an iron-dependent programmed cell death process driven by reactive oxygen species (ROS) accumulation, represents a promising therapeutic strategy for breast cancer. However, the efficacy of ferroptosis therapy in breast cancer is often compromised by insufficient intracellular levels of hydrogen peroxide (H2O2) and iron ions. To address these problems, we developed pH-responsive nanoparticles comprising a metal-phenolic network (MPN) shell and a bovine serum albumin (BSA) core for the delivery of artes…
Rank30.0
Terephthaloyl-based amide-linked derivatives and polymeric networks with selective cytotoxicity: In vitro evaluation, Molecular docking, Molecular dynamics, and DFT insights.
Bioorganic chemistry · 2026 · PMID 42398391
Cancer remains a major global health challenge, emphasizing the need for new therapeutic candidates with improved selectivity toward malignant cells and reduced toxicity toward normal cells. In this study, four terephthaloyl-based amide-linked derivatives and polymeric materials, designated as compounds (1-4), were synthesized through the reaction of terephthaloyl dichloride with hydrazine, diamine, and mono-amino aromatic precursors. Based on the synthetic routes, compounds (3) and (4) are assigned as discrete N,N…
Rank30.0
Self-assembled paclitaxel-loaded spermidine-geranic acid ionic liquid nanoaggregates: preparation, enhanced cellular uptake, and antitumor efficacy.
International journal of pharmaceutics · 2026 · PMID 42542261
Paclitaxel (PTX) is a potent anticancer drug whose efficacy is limited by poor solubility and severe side effects. This study developed a self-assembled nanoaggregate system based on a novel spermidine-geranic acid ionic liquid ([Spd][Ger] IL) for PTX delivery. The synthesized [Spd][Ger] IL exhibited a low apparent critical aggregation concentration (0.33 mg/mL), and molecular dynamics simulation confirmed its spontaneous self-assembly in water. PTX was efficiently incorporated into [Spd][Ger] nanoaggregates, affor…
Rank30.0
Exploration of mechanism of anticancer potential of fisetin nanoformulations: nanotized fisetin/fisetin loaded polymannose nanoparticles in the treatment of triple negative breast carcinoma.
3 Biotech · 2025 · PMID 40726567
UNLABELLED: Triple-negative breast cancer (TNBC) remains one of the most aggressive and difficult-to-treat subtypes of breast cancer due to the lack of targeted therapies. This study investigates the anti-proliferative and anti-metastatic potential of fisetin (FIS) and its nanoformulations, nanotized fisetin (Nano-FIS) and FIS-loaded polymannose nanoparticles (FIS-PM NPs) in TNBC cells. Both Nano-FIS and FIS-PM NPs demonstrated significant, time- and dose-dependent cytotoxicity, with FIS-PM NPs showing the greatest…
Promising Experimental Therapies71 records
Rank100.0
Managing diabetes while undergoing breast cancer treatment: a systematic review of women's experiences of self-care and clinical support.
Diabetes & metabolic syndrome · 2026 · PMID 41895065
BACKGROUND: Women with diabetes face a higher risk of developing breast cancer than those without, and when both conditions coexist, the risk of adverse health outcomes is higher. Little is known about the impact of adjuvant breast cancer treatment on diabetes management. This systematic literature review aimed to understand the experiences of women living with diabetes in their diabetes care when undergoing adjuvant breast cancer treatment. METHOD: This PROSPERO-registered (CRD420251046300) systematic review follo…
Rank99.6
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42150145
PURPOSE: The WSG TP-II trial (ClinicalTrials.gov identifier: NCT03272477) was designed to compare the impact of 12 weeks of neoadjuvant trastuzumab + pertuzumab combined with endocrine therapy (ET) versus chemotherapy (once per week paclitaxel) on the pathologic complete response (pCR) rate and survival in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC). Analysis of the primary end point revealed that the pCR rate in the paclitaxel + trastuzumab + pertuzu…
Rank99.2
Self-Management Support for Cancer Survivors at Risk of Cardiotoxicity: A Scoping Review.
Heart, lung & circulation · 2026 · PMID 42431760
BACKGROUND: Cancer survivorship has significantly increased globally. This success has brought new challenges, including the rise in cardiovascular complications due to cardiotoxic effects of cancer treatments. Self-management (SM) support is increasingly recognised as an important component in overcoming these challenges; however, its implementation into practice remains inconsistent. AIM: This scoping review aims to map the current landscape of SM for cancer survivors at risk of or experiencing cardiotoxicity, wi…
Rank96.6
A complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 41762807
PURPOSE: Those living beyond a cancer diagnosis experience unmet supportive care needs due to fragmented post-treatment pathways and limited integration of digital health tools. The Linking You to Support and Advice (LYSA) trial assessed the feasibility of a complex-intervention which incorporated a nurse- and dietitian-led multidisciplinary clinic and a digital platform for capturing and responding to electronic Patient-Reported Outcome (ePRO) data for women with early-stage breast and gynecologic cancer less than…
Rank96.0
Evaluation of patient experience from participation in the randomized INFLUENCE trial on fluorescence-guided sentinel node surgery.
Surgery · 2026 · PMID 42190367
BACKGROUND: Recruitment to surgical trials is limited by strong patient and surgeon preferences, lack of equipoise, and anxiety surrounding randomization. There is minimal research exploring patient perspectives on randomization within surgical oncology, especially involving novel technologies like fluorescence-guided surgery. This study assessed patient experience following participation in the INFLUENCE trial, which compared indocyanine green fluorescence with standard tracer methods for sentinel lymph node local…
Rank95.9
The Effect of Life Coaching on Post-Traumatic Growth and Well-Being in Breast Cancer Survivors: A Randomized Controlled Trial.
Psycho-oncology · 2025 · PMID 41068064
BACKGROUND: Breast cancer survivors often experience psychosocial challenges, including fear of cancer recurrence, diminished quality of life, and are less aware of the potential for post-traumatic growth. Life coaching is a strengths-based, goal-directed approach that may promote adjustment and recovery after cancer. AIM: This randomized controlled trial evaluated the effects of a life coaching intervention on post-traumatic growth (PTG), fear of cancer recurrence (FCR), and quality of life (QoL) in breast cancer …
Rank95.7
Investigating the effect of web-based education on positive mental health of family caregivers of breast cancer patients: a quasi-experimental study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42542461
BACKGROUND AND AIM: The increasing incidence of cancer and the fact that the family is an important factor in cancer care; attention to the positive mental health of cancer patients should be sought to provide solutions to improve the mental health of these caregivers. The present study aimed to investigate the effect of web-based education on positive mental health of family caregivers of breast cancer patients undergoing chemotherapy in educational and treatment centers of Zahedan University of Medical Sciences. …
Rank95.1
Acute skin toxicity and cosmesis outcome in non-metastatic breast cancer patients treated with ultrahypofractionated radiotherapy: a randomized controlled phase II clinical trial comparing proton versus photon radiotherapy.
Journal of radiation research · 2026 · PMID 42183732
The 1-week photon radiotherapy schedule of 26 Gy in 5 fractions is as safe and effective as the standard 3-week schedule of 40 Gy in 15 fractions for adjuvant local radiotherapy in early stage breast cancer. Proton radiotherapy offers dosimetric advantages by reducing heart and lung dose but may be associated with increased acute skin toxicity, and the acute toxicity of ultra-hypofractionated proton therapy remains unknown. In this randomized trial, non-metastatic breast cancer patients were assigned to receive eit…
Rank94.6
Differential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients.
Pakistan journal of pharmaceutical sciences · 2026 · PMID 42262213
BACKGROUND: Evidence from experimental and clinical studies suggests that anesthetic drugs may modulate tumor biology by influencing immune regulation, inflammation and intracellular calcium signaling. However, the extent to which sevoflurane or propofol alters calcium-related molecular expression in human breast cancer tissue remains unclear. OBJECTIVES: This study aimed to compare the effects of sevoflurane- versus propofol-based anesthesia on calcium signaling pathway-related gene and protein expression in breas…
Rank88.3
Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41854411
PURPOSE: For older patients with competing comorbidities, optimizing oncologic therapies is of paramount importance. Circulating tumor DNA (ctDNA) is a validated prognostic factor across solid tumors and may provide a strategy to identify patients for whom safe de-escalation of certain therapies is possible. EXPERIMENTAL DESIGN: In this prospective, hybrid-decentralized trial (n = 43 patients; NCT05914792) that integrated clinical outcomes, patient- and caregiver-reported outcomes, and correlative tissue analysis, …
Rank84.7
Early Safety of Ultra-Hypofractionated Whole Breast Irradiation and Sequential Tumor Bed Boost for Early Breast Cancer (SHIFT): A Multicenter, Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41759682
PURPOSE: The multicenter, single-arm, phase 2 SHIFT trial evaluated an ultra-hypofractionated radiation therapy regimen that completes both whole breast irradiation and a sequential tumor bed boost within 1.5 weeks, with the primary endpoint of acute toxicity. METHODS AND MATERIALS: Patients at 4 tertiary hospitals in China aged 18 years or above with invasive breast carcinoma (pT1-3, N0-1mic, M0) or ductal carcinoma in situ after BCS were eligible. All enrolled patients underwent whole breast irradiation of 26 Gy …
Rank83.6
Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).
Breast cancer research and treatment · 2026 · PMID 42474572
PURPOSE: In the postMONARCH trial, abemaciclib plus fulvestrant (FUL) yielded a progression-free survival (PFS) of 6.0 months in hormone receptor (HR)-positive HER2-negative metastatic breast cancer patients who progressed after receiving CDK4/6 inhibitor plus endocrine therapy (ET). However, only 8% of these patients had previously received abemaciclib. METHODS: This multicenter, single-arm, phase II study enrolled patients who developed disease progression after abemaciclib plus ET. Patients were switched from ar…
Rank83.3
A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer.
Frontiers in immunology · 2026 · PMID 42495649
BACKGROUND: The modest neoadjuvant response in early-stage HR+/HER2- breast cancer necessitates novel treatment intensification strategies. While radiotherapy can enhance systemic efficacy via immune modulation, the optimal fractionation for integration with immunochemotherapy remains unknown. This multicenter phase II study aims to evaluate the feasibility, safety, and preliminary efficacy of Toripalimab combined with chemotherapy and tumor-directed radiotherapy, specifically investigating three distinct fractiona…
Rank80.2
Tumor flare-like response: A novel imaging phenomenon with predictive significance in triple negative breast cancer patients undergoing neoadjuvant immuno-chemotherapy.
Breast (Edinburgh, Scotland) · 2026 · PMID 42214154
BACKGROUND: Preoperative immuno-chemotherapy improves outcomes in triple-negative breast cancer, but associated imaging response patterns remain poorly characterized. This study aimed to describe a novel MRI phenomenon, tumor flare-like response (TFLR), and evaluate its association with pathological complete response (pCR). METHODS: Ad hoc imaging analysis of a prospective phase II trial (NCT04213898; n = 39). Breast MRI was performed at baseline and after every two cycles. TFLR was defined a priori as new enhancin…
Rank80.0
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42167437
BACKGROUND: BEGONIA (NCT03742102) is a phase Ib/II, Simon's 2-stage, open-label, platform study evaluating the safety and efficacy of durvalumab, an anti-programmed death ligand-1 (PD-L1) antibody, combined with novel therapies, as first-line treatment for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Arms 7 and 8 of BEGONIA assessed the combination of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, with durvalumab. PATIENTS AND METHODS:…
Rank79.8
A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer.
Cancer medicine · 2026 · PMID 42504645
Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) whose disease had progressed on ado-trastuzumab emtansine therapy. In Phase I, cohorts of three patients received ibrutinib 560 mg or 420 mg by mouth once daily combined with standard dosing of trastuzumab. Phase II enrolled additional p…
Rank76.6
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.
Breast cancer research and treatment · 2026 · PMID 42429895
PURPOSE: There is limited evidence supporting the addition of everolimus to endocrine therapy in women with ER-positive/HER2-negative advanced breast cancer disease progression on CDK4/6 inhibitors. We aimed to assess the effectiveness and safety of everolimus in this setting. METHODS: EVERGREEN is a multicentre, international, retrospective quasi-experimental study of women with ER-positive/HER2-negative advanced breast cancer who started an immediate next line of endocrine therapy after progression on CDK4/6 inhi…
Rank65.0
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41894563
PURPOSE: Significant correlations exist between the presence of intratumoral macrophages, tumor progression, and poor outcomes in triple-negative breast cancer (TNBC) with limited therapeutic options available for advanced-stage disease. Preclinical studies revealed that inhibition of myelomonocytic colony-stimulating factor 1 (CSF1) or its receptor (CSF1R) plus cytotoxic chemotherapy decreased primary tumor growth kinetics and pulmonary metastases by CD8+ T cell-dependent mechanisms. This translational study evalu…
Rank48.8
Dense Breast Legislation and Supplemental Breast Imaging Among Women Undergoing Mammography.
JAMA network open · 2026 · PMID 42525414
IMPORTANCE: State-level dense breast legislation aims to increase awareness of breast density and promote supplemental imaging, yet the association of specific legislation type with imaging use remains unclear. OBJECTIVES: To evaluate the differential association of dense breast notification and insurance coverage laws with supplemental imaging use and to assess how specific legislative features are associated with imaging use. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, quasi-experimental cohort study u…
Rank48.7
Augmented Reality-Based Breast Self-Examination Education and Its Effects on Knowledge and Perceived Behavioral Control Among Indonesian Adolescent Girls: A Quasi-Experimental Study.
Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 42522827
BACKGROUND: Breast cancer is the most common malignancy among women, with an increasing burden among adolescents and young adults. Breast self-examination (BSE) is a simple and low-cost method for early detection; yet, its practice remains suboptimal in this age group. Augmented Reality (AR) is a promising approach to enhancing cancer education. OBJECTIVE: This study aims to rigorously compare the effects of AR-based education and traditional learning on breast self-examination (BSE) knowledge and perceived behavio…
Rank48.1
Histopathological evaluation of RPL5 expression in triple-negative breast cancer: an integrated immunohistochemical and transcriptomic study.
European journal of histochemistry : EJH · 2026 · PMID 42489642
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high invasiveness, limited therapeutic options, and unfavorable clinical outcomes. Ribosomal protein L5 (RPL5), a component of the large ribosomal subunit, has been implicated in ribosome biogenesis, translational regulation, and p53-associated cellular processes. This study investigated the immunohistochemical expression pattern of RPL5 in TNBC tissues and explored its potential biological significance through integrate…
Rank47.6
A mixed prebiotic/probiotic intervention (MBR-01) for the management of diarrhea during abemaciclib treatment of early breast cancer in postmenopausal patients: A single-center prospective case-control pilot study.
Breast (Edinburgh, Scotland) · 2026 · PMID 42235180
BACKGROUND: Adjuvant abemaciclib + endocrine therapy (ET) improves long-term outcomes in high-risk, hormone receptor-positive (HR+)/HER2-negative early breast cancer (eBC). However, treatment is frequently complicated by diarrhea, affecting adherence and quality-of-life (QoL). Increasing evidence suggests that abemaciclib-induced gastrointestinal toxicity may involve gut microbiota alterations. We conducted a prospective case-control pilot study evaluating the efficacy of MBR-01, a standardized prebiotic/probiotic …
Rank46.4
Different effects of moderate tibial loading and Yoda1 on breast cancer-induced osteolysis in aged mice.
Bone · 2025 · PMID 40345567
Elderly breast cancer patients and survivors are at high risk of bone loss but experience obstacles to harness the known benefits of exercise due to aging, cancer, and cancer treatment. Previously, we and others showed that moderate mechanical loading suppressed breast cancer-induced osteolysis in young adult mice. To overcome the mechano-transduction deficits in aged skeletons, we recently tested a dual therapy combining mechanical and Yoda1 activation of mechanosensitive Piezo1 channels. We found that the dual th…
Rank45.0
Modeling macrophage-T cell interactions in the breast cancer immune microenvironment: from spatial omics to functional validation.
Frontiers in immunology · 2026 · PMID 42523839
Breast cancer immunity depends on more than the number of immune cells in a tumor. It is also shaped by where those cells sit, which neighbors they contact, and what functional states they adopt locally. Tumor-associated macrophages (TAMs) and T cells are a key pairing in this setting. Depending on tissue context, their crosstalk may support cytotoxic immunity, reinforce immune exclusion, promote T-cell exhaustion, or weaken therapeutic response. Spatial technologies now allow these states to be examined in intact …
Rank45.0
Chemometrics-Assisted Enhancement of Electrochemical Biosensor Performance toward miRNA Detection.
Analytical chemistry · 2025 · PMID 40217571
Chemometrics represents a potent tool for optimizing the experimental setup and subsequently boosting the performance of analytical methods. In particular, design of experiments (DoE) allows the experimental conditions to be optimized with high accuracy and a lower number of experiments when compared with the classical univariate approach, also known as one variable at a time (OVAT), which provides only a partial understanding on how factors affect the response. In this work, DoE was exploited, specifically a D-opt…
Prospective Cohort Studies66 records
Rank110.0
Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.
International journal of cancer · 2026 · PMID 41952250
At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screenin…
Rank100.4
Association of mobile application information on multidisciplinary therapy and treatment compliance in early-stage breast cancer: A prospective multicenter randomized phase III study.
Breast (Edinburgh, Scotland) · 2026 · PMID 42150214
BACKGROUND: Multidisciplinary therapy (MDT) can improve early breast cancer outcome, while its treatment completion rate is critical. This study aimed to evaluate the association of a mobile health application (RJBC-APP) information on MDT and its treatment adherence, compared with standard clinical management. METHODS: The RJBC-APP study is a prospective, multicenter, randomized, phase 3 clinical trial that enrolled patients with early-stage breast cancer after MDT for adjuvant treatment. Eligible patients were ra…
Rank100.0
Efficacy evaluation of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis based on multiple sets of clinical data.
The Journal of international medical research · 2026 · PMID 42447291
ObjectiveTo evaluate the efficacy and safety of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer and their impact on clinical outcomes, including overall survival and progression-free survival.MethodsThis systematic review was registered with PROSPERO (CRD420261383276). A systematic search of PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov was conducted for randomized controlled trials and prospective cohort studies published between Janu…
Rank99.4
24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 42070391
BACKGROUND: Aromatase inhibitor (AI) induced arthralgia/myalgia (AIA) is a frequent side-effect of adjuvant breast cancer (BC) endocrine therapy. We investigated the effect of a user-friendly activity tracker to accompany a 24-week walking program, from the start of adjuvant AI-therapy, on patient AIA symptom burden and medication adherence. METHODS: 320 early-stage BC patients were included and randomly allocated to the intervention (arm A, n = 158) or control arm (arm B, n = 162). The intervention in arm A was ai…
Rank97.8
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Annals of surgical oncology · 2026 · PMID 41739398
PURPOSE: We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study (NCT03036488). METHODS: Participants with previously untreated, early-stage TNBC (AJCC stage T1c N1-2 or T2-4 N0-2) were randomized 2:1 to neoadjuvant pembrolizumab/placebo plus paclitaxel-carboplatin for 4 cycles, followed by pembrolizumab/placebo plus doxorubicin/epirubicin an…
Rank97.1
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42372741
BACKGROUND: Patients with stage III, human epidermal-growth-factor-receptor 2 (HER2; also known as ERBB2)-negative breast cancer with homologous recombination deficiency (HRD) had a 4-year overall survival of 35% after anthracycline-based chemotherapy versus 78% after intensified alkylating chemotherapy with autologous stem cell rescue (IACT) in a post-hoc analysis of an earlier randomised controlled trial. In this study, we aimed to prospectively assess 4-year overall survival with IACT and establish whether this …
Rank97.0
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 40632989
PURPOSE: We investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor-positive (HR+) BC who had a live birth in the POSITIVE trial. PATIENTS AND METHODS: POSITIVE is a prospective trial that demonstrated no increased short-term risk of BC events in women with early HR+ BC who interrupted endocrine therapy (ET) to attempt pregnancy. We describe the frequency, duration, and laterality of breastfeeding and estimate the cumulative incidence of …
Rank95.9
Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life.
Cancer chemotherapy and pharmacology · 2026 · PMID 42439956
OBJECTIVE: Dexamethasone is routinely used as premedication during weekly paclitaxel to prevent hypersensitivity reactions; however, prolonged corticosteroid exposure may induce clinically relevant metabolic, endocrine, and patient-reported adverse effects. This study evaluated whether selective omission of dexamethasone after the second paclitaxel infusion is safe and explored its effects on quality of life, metabolic/endocrine parameters, and short-term oncologic outcomes, including recurrence and disease-related…
Rank95.7
Clinical Hypothyroidism After Proton Versus Photon Regional Nodal Irradiation: A Prospective Correlative Study Within the RADCOMP Randomized Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41692352
PURPOSE: Thyroid dysfunction is a common complication of breast regional nodal irradiation (RNI). Proton therapy has been proposed as a means to spare normal tissue. We prospectively evaluated the incidence of hypothyroidism in a cohort of patients receiving RNI on a randomized trial comparing proton with photon modalities. A secondary objective was to evaluate the associations between thyroid dose-volume metrics and the risk of subsequent hypothyroidism. METHODS AND MATERIALS: We conducted a single-institution pro…
Rank94.8
Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.
Cancer chemotherapy and pharmacology · 2024 · PMID 38324036
PURPOSE: Myelosuppressive chemotherapy-induced neutropenia (CIN) remains a major limitation of cancer treatment efficacy, necessitating very expensive supportive care. Lithium carbonate, an inexpensive drug, can increase the number of neutrophils, possibly providing an efficacious and cost-effective alternative for treating CIN. The aim of this study was to determine whether lithium therapy can attenuate chemotherapy-induced neutropenia and leukopenia in breast cancer patients. METHODS: A total of 50 breast cancer …
Rank94.6
Differential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients.
Pakistan journal of pharmaceutical sciences · 2026 · PMID 42262213
BACKGROUND: Evidence from experimental and clinical studies suggests that anesthetic drugs may modulate tumor biology by influencing immune regulation, inflammation and intracellular calcium signaling. However, the extent to which sevoflurane or propofol alters calcium-related molecular expression in human breast cancer tissue remains unclear. OBJECTIVES: This study aimed to compare the effects of sevoflurane- versus propofol-based anesthesia on calcium signaling pathway-related gene and protein expression in breas…
Rank90.9
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.
Breast (Edinburgh, Scotland) · 2026 · PMID 42330688
BACKGROUND: IMpassion130 trial results led to approval of first-line atezolizumab plus nab-paclitaxel for PD-L1-positive advanced triple-negative breast cancer (aTNBC). The global single-arm EL1SSAR study (NCT04148911) enrolled a broader patient population to elucidate outcomes in routine practice. METHODS: Patients with measurable PD-L1-positive aTNBC and no prior systemic therapy for advanced disease received atezolizumab (840 mg, days 1&15) plus nab-paclitaxel (100 mg/m2, days 1,8,15) every 28 days until disease…
Rank88.3
Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41854411
PURPOSE: For older patients with competing comorbidities, optimizing oncologic therapies is of paramount importance. Circulating tumor DNA (ctDNA) is a validated prognostic factor across solid tumors and may provide a strategy to identify patients for whom safe de-escalation of certain therapies is possible. EXPERIMENTAL DESIGN: In this prospective, hybrid-decentralized trial (n = 43 patients; NCT05914792) that integrated clinical outcomes, patient- and caregiver-reported outcomes, and correlative tissue analysis, …
Rank83.3
A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer.
Frontiers in immunology · 2026 · PMID 42495649
BACKGROUND: The modest neoadjuvant response in early-stage HR+/HER2- breast cancer necessitates novel treatment intensification strategies. While radiotherapy can enhance systemic efficacy via immune modulation, the optimal fractionation for integration with immunochemotherapy remains unknown. This multicenter phase II study aims to evaluate the feasibility, safety, and preliminary efficacy of Toripalimab combined with chemotherapy and tumor-directed radiotherapy, specifically investigating three distinct fractiona…
Rank80.7
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.
ESMO open · 2026 · PMID 42407196
BACKGROUND: Adjuvant abemaciclib decreases recurrence rates and improves overall survival for patients with high-risk early-stage hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, toxicity, particularly diarrhea, may lead to dose reductions and early discontinuation. Primary results of the TRADE trial demonstrated that early dose escalation of abemaciclib can help patients reach and maintain the target dose of 150 mg twice daily (b.i.d.) by 12 weeks on t…
Rank80.2
Tumor flare-like response: A novel imaging phenomenon with predictive significance in triple negative breast cancer patients undergoing neoadjuvant immuno-chemotherapy.
Breast (Edinburgh, Scotland) · 2026 · PMID 42214154
BACKGROUND: Preoperative immuno-chemotherapy improves outcomes in triple-negative breast cancer, but associated imaging response patterns remain poorly characterized. This study aimed to describe a novel MRI phenomenon, tumor flare-like response (TFLR), and evaluate its association with pathological complete response (pCR). METHODS: Ad hoc imaging analysis of a prospective phase II trial (NCT04213898; n = 39). Breast MRI was performed at baseline and after every two cycles. TFLR was defined a priori as new enhancin…
Rank79.8
Integration of longitudinal MRI and biopsy whole slide images for early prediction of neoadjuvant therapy response and personalized management in breast cancer: A multicenter retrospective and prospective study.
Cancer letters · 2026 · PMID 41985873
PURPOSE: Early prediction of treatment response during neoadjuvant therapy (NAT) is crucial for timely therapeutic adjustments in breast cancer. Jointly capturing dynamic tumor evolution from longitudinal imaging and tumor microenvironmental cues from biopsy enables improved predictive performance and fosters the development of a personalized tool to assist clinicians in managing NAT. METHODS: We proposed a multimodal framework, RePALM, which integrated clinical information, pre-NAT MRI, biopsy pathology, and post-…
Rank77.0
Indocyanine green use, detection and safety in patients with breast cancer undergoing sentinel lymph node biopsy: A French prospective observational study.
Surgical oncology · 2026 · PMID 42296697
BACKGROUND: Sentinel lymph node (SLN) biopsy is the standard procedure for staging patients with early-stage breast cancer. Indocyanine green (ICG), a near-infrared fluorescent dye, has emerged as an alternative to other colorimetric and radioactive tracers for SLN mapping that has high sensitivity and is rarely allergenic. METHODS: The Observational Assess SLN Infracyanine® (ICG) Surgery (OASIS) study was a prospective, multicenter, observational, single-arm study that enrolled 101 female patients with breast canc…
Rank76.6
Optimizing breast conservative surgery for ductal carcinoma in situ: Comparative outcomes of intraoperative ultrasound and wire localization in achieving negative margins.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42247964
BACKGROUND: Intraoperative ultrasound-guided surgery (IOUS) is an effective technique for invasive breast cancer, offering advantages over wire localization (WL), such as smaller resection volumes, lower rates of involved margins, and better patient satisfaction. However, evidence for ductal carcinoma in situ (DCIS) is limited. This study aimed to compare specimen margins and excision volume in DCIS treated with IOUS versus WL. MATERIAL AND METHODS: From February 2018 to December 2023, women diagnosed with DCIS and…
Rank75.8
Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.
The Lancet. Oncology · 2026 · PMID 42372742
BACKGROUND: Indications for postoperative locoregional radiotherapy in cT1-2N1 breast cancer after primary systemic therapy are disputed. The previously published 5-year outcomes of the RAPCHEM study showed excellent locoregional control when radiotherapy was tailored to the nodal response after primary chemotherapy. Here, we present 10-year results. METHODS: In this prospective registry study (RAPCHEM, BOOG 2010-03), patients referred to one of 17 participating Dutch radiation oncology centres between Jan 1, 2011,…
Rank74.5
Financial distress among women with advanced or metastatic breast cancer in Germany: secondary analysis of prospective ePROCOM data of a two-center cohort.
Archives of gynecology and obstetrics · 2026 · PMID 42455164
KEY MESSAGE: In this study, half of all female patients with advanced and metastatic breast cancer reported experiencing financial difficulties. This highlights the need for gynecology and oncology specialists to also address patients' socio-medical needs. Electronic patient-reported outcomes (ePRO) must be used to identify such areas of concern. PURPOSE: The aim was to investigate whether and to what extent female patients with advanced or metastatic breast cancer who are undergoing chemotherapy report financial d…
Rank73.0
Incidence of lymphomas in a nationwide prospective cohort study of breast-implanted women.
Breast (Edinburgh, Scotland) · 2026 · PMID 42090861
BACKGROUND: The true incidence of Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare cancer associated with textured breast implants, remains uncertain due to limitations of implant exposure data and long-term follow-up. Concerns regarding other implant-associated malignancies are growing. This study aimed to determine the incidence of BIA-ALCL, non-BIA-ALCL lymphoma, and Breast Implant Associated-Squamous Cell Carcinoma (BIA-SCC). METHODS: 10,339 women with a first-time breast implantation…
Rank73.0
Risk factors and complication predictors in prepectoral breast reconstruction using ADM and smooth round implants: An observational cohort study.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2026 · PMID 42302701
BACKGROUND: Prepectoral implant-based reconstruction using acellular dermal matrices (ADMs) has emerged as a viable option for immediate breast reconstruction (IBR) following mastectomy. This multicenter, prospective observational cohort study evaluated the outcomes of prepectoral reconstruction using Braxon® ADMs and smooth round implants across two specialized Italian cancer centers. METHODS: From April 2019 to December 2024, 140 female patients (221 breasts) underwent skin- or nipple-sparing mastectomy followed …
Rank71.4
Beyond surgical risk: Multidimensional predictors of postoperative arm morbidity after breast cancer treatment.
Breast (Edinburgh, Scotland) · 2026 · PMID 42330687
BACKGROUND: Postoperative upper-limb morbidity following breast cancer treatment is common and clinically significant, encompassing pain, functional impairment, range-of-motion limitation, and lymphedema. While traditional risk models have focused primarily on surgical and treatment-related factors, less is known about the relative contribution of psychosocial and behavioral determinants. The Arm Morbidity following Breast Cancer Treatment (ARM-BCT) tool was developed as a clinically practical risk stratification i…
Rank70.5
Air Pollution and Cardiac Remodeling and Function in Patients With Breast Cancer.
JAMA network open · 2026 · PMID 41538185
IMPORTANCE: The relationship between air pollution and cardiac remodeling in patients with cancer treated with cardiotoxic therapy is undefined. OBJECTIVE: To assess the associations between air pollutants and changes in cardiac function, structure, and remodeling in patients with breast cancer treated with anthracyclines and/or trastuzumab therapy. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal prospective cohort study included patients with breast cancer enrolled at multiple sites of a quaternary health car…
Quality Of Life87 records
Rank108.1
Effects of different mind-body exercises on quality of life and cancer-related fatigue in breast cancer survivors: a systematic review and network meta-analysis.
Journal of cancer survivorship : research and practice · 2026 · PMID 40178706
PURPOSE: To compare the efficacy of the different mind-body exercises (MBEs) for quality of life (QOL) and cancer-related fatigue (CRF) in women breast cancer (BC) survivors. METHODS: This review searched published randomized controlled trials (RCTs) in eight electronic databases: PubMed, Web of Science, Embase, Cochrane CENTRAL, EBSCO, CNKI, VIP, and WanFang from inception to October 30, 2023. NMA and comparative effects ranking were performed using STATA 17.0 software. RESULTS: This study included 121 studies wit…
Rank107.2
Comparative efficacy of mind-body exercises on quality of life, anxiety, and depression in patients with breast cancer: a systematic review with pairwise and network meta-analysis of randomized controlled trials.
Frontiers in public health · 2026 · PMID 42534521
BACKGROUND: Comparative evidence on the effects of different mind-body exercises (MBEs) for psychological outcomes in breast cancer patients remains limited. This study aimed to compare the effects of Yoga, Tai Chi, Qigong, Pilates, and Dance on quality of life, anxiety, and depression in breast cancer patients. METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 31, 2026. Pairwise meta-analyses were performed using random-effects models with Hedges' g. Bayesian…
Rank106.2
Beyond the first dose: Systematic review on external beam radiotherapy for locoregional breast cancer recurrence.
Breast (Edinburgh, Scotland) · 2026 · PMID 42372580
BACKGROUND: The optimal management of locoregional breast cancer recurrence after prior radiotherapy remains challenging. Reirradiation (ReRT) may allow repeat breast-conserving surgery as an alternative to mastectomy; however, prospective evidence is scarce, and existing data are largely retrospective, with the strongest support for brachytherapy. Despite this, external beam reirradiation (EBreRT) is widely used because of its availability. This systematic review evaluated the feasibility, oncologic outcomes, toxi…
Rank105.4
Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026 · PMID 42140114
BACKGROUND: Leptomeningeal disease (LMD) is an increasingly recognised late-stage complication of solid tumours (primarily melanoma, lung and breast cancers). It involves dissemination to the leptomeninges surrounding the brain and spinal cord and carries a poor prognosis ranging from 2-6 months. Recent advances in emerging therapies such as CNS-active targeted therapy, intrathecal agents, and early-phase immunotherapy necessitate an updated appraisal of prospective data. METHODS: A systematic search of MEDLINE, Em…
Rank104.9
Postoperative survival in patients undergoing surgery for long bone metastases: a systematic review and Meta-analysis of outcomes across primary tumor types.
Journal of bone oncology · 2026 · PMID 42388270
BACKGROUND: Surgery for long bone metastases is performed to alleviate pain, restore function, and improve quality of life. Accurate postoperative survival estimates are essential for surgical planning and shared decision-making, yet no comprehensive synthesis exists across primary tumor types. This systematic review aimed to characterize postoperative survival and its temporal trend in patients undergoing surgery for long bone metastases. METHODS: A systematic literature search was performed in PubMed, EMBASE, and…
Rank102.6
Meta-analysis of the effect of sexual health nursing interventions on improving post-treatment sexual dysfunction and partner relationship satisfaction in breast cancer patients.
Sexual medicine · 2026 · PMID 42540624
INTRODUCTION: Breast cancer survivors frequently experience sexual dysfunction and impaired partner relationships after treatment, but the effectiveness of nursing interventions in improving these post-treatment outcomes remains uncertain. To evaluate the efficacy of sexual health, nursing interventions on sexual dysfunction and quality of life in breast cancer survivors through a systematic review and meta-analysis of randomized controlled trials. METHODS: We searched PubMed, Embase, and Web of Science for randomi…
Rank101.8
Chronic Diseases and Health Related Quality of Life in South and Southeast Asia: A Systematic Review of Burden, Interventions, and Measurement Tools.
Health science reports · 2026 · PMID 42504231
BACKGROUND: In South and Southeast Asia, chronic diseases (CD) are a major public health concern and have a considerable impact on people's quality of life (QoL). CD and their ailments place a dual burden of sickness and socioeconomic difficulties on afflicted people and healthcare systems. AIM: This review aims to provide a comprehensive synthesis of evidence on the relationship between chronic diseases and HRQoL in the region, focusing on study populations, disease types, methodologies, sample sizes, and assessme…
Rank101.4
Effectiveness of Telerehabilitation for Upper-Limb Pain After Breast Cancer: Systematic Review.
Pain management nursing : official journal of the American Society of Pain Management Nurses · 2026 · PMID 42532693
CONTEXT: Upper-limb pain is a frequent and disabling sequela following breast cancer treatment, often persisting beyond the acute postoperative period and substantially impairing function, self-management, and quality of life. Telerehabilitation has emerged as a strategy to expand access to physiotherapy-based care; however, its effectiveness for pain management in this population remains unclear. OBJECTIVES: To systematically evaluate the effectiveness of telerehabilitation interventions in reducing upper-limb pai…
Rank100.5
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42508432
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. M…
Rank100.0
Radiation therapy in adolescents and young adults (AYA): contemporary evidence on utilization, outcomes, late toxicities, and second malignant neoplasms - A comprehensive systematic review and synthesis.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42251999
Adolescent and young adult (AYA; 15-39 years) cancer survivors face decades of potential life-years, making radiotherapy (RT) modality and technique selection central determinants of long-term health. A PRISMA 2020-reported systematic review was performed using PubMed, Web of Science, and the Cochrane Library (January 2026). Data were synthesised qualitatively using a Synthesis Without Meta-analysis (SWiM) approach. The primary synthesis focused on RT utilization and late outcomes including late toxicity, survivors…
Rank100.0
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.
Breast (Edinburgh, Scotland) · 2026 · PMID 42372579
BACKGROUND: Recent years have seen rapid advances in human epidermal growth factor receptor 2 (HER2)-directed therapies for breast cancer. The shifting therapeutic landscape has presented patients and clinicians with a plethora of effective treatment options, but optimal treatment sequencing can be challenging. Tucatinib is a HER2-selective tyrosine kinase inhibitor that, when given in combination with trastuzumab and capecitabine, has demonstrated survival benefits for patients with HER2-positive (HER2+) metastati…
Rank100.0
Digital behavioural weight loss interventions for weight management in breast cancer survivors: A meta-analysis.
European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2026 · PMID 42385539
OBJECTIVE: This study aims to systematically evaluate the effectiveness of digital behavioural weight-loss interventions on body weight, BMI, waist circumference, physical activity, and quality of life in breast cancer survivors. METHODS: A comprehensive search was conducted across six databases, including PubMed, Scopus, Embase, Web of Science, CINAHL, and Cochrane Library, to identify eligible randomised controlled trials that investigated the effectiveness of digital behavioural weight loss interventions in weig…
Rank99.2
Self-Management Support for Cancer Survivors at Risk of Cardiotoxicity: A Scoping Review.
Heart, lung & circulation · 2026 · PMID 42431760
BACKGROUND: Cancer survivorship has significantly increased globally. This success has brought new challenges, including the rise in cardiovascular complications due to cardiotoxic effects of cancer treatments. Self-management (SM) support is increasingly recognised as an important component in overcoming these challenges; however, its implementation into practice remains inconsistent. AIM: This scoping review aims to map the current landscape of SM for cancer survivors at risk of or experiencing cardiotoxicity, wi…
Rank98.1
The Effect of Yoga on Cancer-Related Fatigue and Quality of Life Among Racially and Ethnically Diverse Cancer Survivors: A Secondary Data Analysis.
Journal of integrative and complementary medicine · 2025 · PMID 40467527
Introduction: Survivors from racially and ethnically diverse backgrounds tend to experience cancer-related fatigue (CRF) at higher rates than non-Hispanic Whites (NHWs), often leading to a decline in quality of life (QOL). It is crucial to consider the impact their marginalized identities have on cancer outcomes. Although yoga has shown promise as a supportive intervention for CRF and QOL, existing research has largely centered on NHW populations. This study seeks to evaluate the impact of yoga on CRF and QOL among…
Rank96.6
A complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 41762807
PURPOSE: Those living beyond a cancer diagnosis experience unmet supportive care needs due to fragmented post-treatment pathways and limited integration of digital health tools. The Linking You to Support and Advice (LYSA) trial assessed the feasibility of a complex-intervention which incorporated a nurse- and dietitian-led multidisciplinary clinic and a digital platform for capturing and responding to electronic Patient-Reported Outcome (ePRO) data for women with early-stage breast and gynecologic cancer less than…
Rank96.3
Brief Post-Surgical Stress Management Intervention Effects on Positive Psychological Well-Being and Self-Efficacy in Women Being Treated With Adjuvant Endocrine Therapy for Hormone-Receptor Positive Breast Cancer.
Psycho-oncology · 2025 · PMID 40846861
BACKGROUND: Women prescribed adjuvant endocrine therapy (AET) for nonmetastatic breast cancer may experience a decline in positive psychological well-being (PPWB) and self-efficacy. Brief cognitive behavioral therapy (CBT) and relaxation training (RT) interventions have shown short-term efficacy in reducing distress, but their impact on PPWB and self-efficacy over longer periods among women prescribed AET is unknown. AIMS: We aimed to investigate longitudinal effects of CBT and RT on PPWB and self-efficacy among wo…
Rank96.0
Sexual Quality of Life among Women with Female Cancers in Arab Countries: A Mixed Systematic Review.
Annals of African medicine · 2026 · PMID 42459036
The sexual health of women with gynecological or breast cancer is a major determinant of their quality of life, yet it is largely ignored in oncological care pathways. This systematic review, based on 25 studies conducted in Arab countries among patients aged 18 years and over (undergoing treatment or in remission), reveals a profound alteration in their intimate lives: Decreased desire, lubrication difficulties, orgasmic disorders, sexual dissatisfaction, and infrequent intercourse. These dysfunctions are not sole…
Rank96.0
Managing psychological distress in women with breast cancer: A systematic review of intervention trends in the past decade.
Asia-Pacific journal of oncology nursing · 2026 · PMID 41541190
OBJECTIVE: The rising incidence and survival rates of breast cancer have increased the number of breast cancer survivors (BCSs) experiencing psychological distress that often overlaps with anxiety, depression, and fear of recurrence. Many existing interventions neglect the unique psychosocial contexts of BCSs, and unclear definitions of distress hinder consistent assessment and management. This systematic review evaluated recent interventions targeting psychological distress in BCSs and offers evidence-based insigh…
Rank96.0
Impact of breast reconstruction on sexual function and body image in breast cancer survivors: A systematic review.
JPRAS open · 2026 · PMID 42376013
BACKGROUND: Breast cancer remains the most prevalent malignancy among women globally. As survival rates improve, the clinical focus has shifted toward the quality of life (QoL) and psychosexual survivorship. This systematic review evaluates the impact of breast reconstruction (BR) on sexual function and body image in breast cancer survivors compared to mastectomy alone. METHODS: A systematic literature search was conducted in PubMed following PRISMA guidelines (January 2016-January 2026). Methodological quality was…
Rank96.0
Sense of coherence and health-related outcomes among patients with breast cancer: a systematic review.
Korean journal of family medicine · 2026 · PMID 42533683
Patients with breast cancer frequently experience substantial psychological burden and persistent symptoms. Sense of coherence (SOC), a central construct of the salutogenic framework, has emerged as a key psychosocial resource for chronic illnesses. However, its association with diverse health-related outcomes in patients with breast cancer has not yet been systematically investigated. This systematic review examined the association between SOC and health-related outcomes in patients with breast cancer. The review …
Rank95.9
The Effect of Life Coaching on Post-Traumatic Growth and Well-Being in Breast Cancer Survivors: A Randomized Controlled Trial.
Psycho-oncology · 2025 · PMID 41068064
BACKGROUND: Breast cancer survivors often experience psychosocial challenges, including fear of cancer recurrence, diminished quality of life, and are less aware of the potential for post-traumatic growth. Life coaching is a strengths-based, goal-directed approach that may promote adjustment and recovery after cancer. AIM: This randomized controlled trial evaluated the effects of a life coaching intervention on post-traumatic growth (PTG), fear of cancer recurrence (FCR), and quality of life (QoL) in breast cancer …
Rank95.8
Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery.
Cancer biotherapy & radiopharmaceuticals · 2026 · PMID 41645929
OBJECTIVE: To assess the clinical impact of docetaxel and capecitabine administered under ultrasound-mediated enhancement in patients with advanced triple-negative breast cancer (TNBC), with an emphasis on safety, quality of life, immunological modulation, and therapeutic efficacy. METHODS: A total of 80 patients with advanced TNBC who received treatment at this institution between October 2021 and October 2022 were chosen at random and placed in either the control group (CG, n = 40) or the observation group (OG, n…
Rank95.0
External vacuum expansion in autologous fat transfer as total breast reconstruction: Is it worth it? The interim analysis of the multicentre randomised controlled EVE trial.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2026 · PMID 42314328
BACKGROUND: Autologous fat transfer (AFT) is an emerging option for total breast reconstruction. To improve graft survival, perioperative external vacuum expansion (EVE) is used to optimise recipient-site environment. However, the efficacy of EVE and its treatment burden on women needs consideration. This interim analysis of a multicentre randomised controlled trial (RCT) evaluates the effect of EVE on volumetric outcomes and safety. METHODS: Women undergoing total breast reconstruction with AFT were randomised 2:1…
Rank92.5
Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial.
Contemporary clinical trials · 2026 · PMID 42501860
BACKGROUND: For patients with hormone receptor (HR) positive early breast cancer (BC), adjuvant endocrine therapy (ET) represents the cornerstone of treatment. However, 75% of patients experience ET-related symptoms that negatively affect their quality of life (QOL). Despite their high prevalence, these symptoms are often underestimated and under-addressed during consultations. As a result, non-adherence to ET is common and remains a major barrier for optimal disease and survival outcomes. METHODS: National, prospe…
Rank92.0
The effect of vaginal tamoxifen on symptoms of anxiety, depression, and health-related quality of life in postmenopausal women with and without breast cancer.
Maturitas · 2026 · PMID 42235095
OBJECTIVES: Genitourinary syndrome of menopause is a common condition among postmenopausal women. Although estrogen therapy is considered an effective treatment, some women are hesitant to use it; others are advised against it medically. We previously showed that vaginal tamoxifen effectively treats genitourinary syndrome of menopause. However, because vaginal tamoxifen may have systemic effects and its impact on mental health and health-related quality of life has not been previously evaluated, we focused on anxie…
Randomized Controlled Trials76 records
Rank108.5
Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer - A systematic review and meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 41722713
BACKGROUND: The benefit of adjuvant chemotherapy for patients with small, early-stage (T1a-bN0) triple-negative breast cancer (TNBC) is unclear because these patients have largely been excluded from randomized trials. We performed a systematic review and meta-analysis to analyze the effect of adjuvant chemotherapy in this population. METHODS: We included interventional and observational studies comparing adjuvant chemotherapy with no chemotherapy in patients with T1a-bN0 TNBC. Studies were identified through system…
Rank108.1
Effects of different mind-body exercises on quality of life and cancer-related fatigue in breast cancer survivors: a systematic review and network meta-analysis.
Journal of cancer survivorship : research and practice · 2026 · PMID 40178706
PURPOSE: To compare the efficacy of the different mind-body exercises (MBEs) for quality of life (QOL) and cancer-related fatigue (CRF) in women breast cancer (BC) survivors. METHODS: This review searched published randomized controlled trials (RCTs) in eight electronic databases: PubMed, Web of Science, Embase, Cochrane CENTRAL, EBSCO, CNKI, VIP, and WanFang from inception to October 30, 2023. NMA and comparative effects ranking were performed using STATA 17.0 software. RESULTS: This study included 121 studies wit…
Rank107.2
Comparative efficacy of mind-body exercises on quality of life, anxiety, and depression in patients with breast cancer: a systematic review with pairwise and network meta-analysis of randomized controlled trials.
Frontiers in public health · 2026 · PMID 42534521
BACKGROUND: Comparative evidence on the effects of different mind-body exercises (MBEs) for psychological outcomes in breast cancer patients remains limited. This study aimed to compare the effects of Yoga, Tai Chi, Qigong, Pilates, and Dance on quality of life, anxiety, and depression in breast cancer patients. METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 31, 2026. Pairwise meta-analyses were performed using random-effects models with Hedges' g. Bayesian…
Rank106.7
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors.
Journal of cancer survivorship : research and practice · 2025 · PMID 37906420
PURPOSE: Breast cancer survivors are more likely to report psychological distress and unmet need for support compared to healthy controls. Psychological mobile health interventions might be used in follow-up care of breast cancer patients to improve their mental health. METHODS: We searched MEDLINE, PsychINFO, Cochrane and PROSPERO for articles on controlled trials examining the effectiveness of psychological mobile health interventions compared to routine care regarding mental health outcomes of adult breast cance…
Rank104.5
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Annals of medicine · 2026 · PMID 41949990
BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…
Rank102.9
WeChat-Based Nursing Interventions in Women's Mobile Health: Systematic Review.
JMIR nursing · 2026 · PMID 42406877
BACKGROUND: Mobile health (mHealth) technology offers new approaches to improve women's health by providing personalized monitoring and real-time guidance. As one of the most widely used social media platforms in China, WeChat has shown great potential in mHealth practice, yet systematic evidence on its application in women's health care remains insufficient. OBJECTIVE: This study aims to systematically review WeChat-based nursing interventions in women's mHealth in order to clarify the application status, interven…
Rank100.6
RecoverEsupport-A Digital Health Intervention for Recovery After Breast Cancer Surgery: Feasibility and Acceptability Outcomes from a Pilot Randomized Controlled Trial.
JMIR formative research · 2026 · PMID 42424596
BACKGROUND: Optimizing recovery following breast cancer surgery is critical for restoring usual function, minimizing complications, and enabling timely initiation of adjuvant therapies. Enhanced Recovery After Surgery protocols are internationally endorsed recommendations and include patient-led behaviors such as early mobilization, early oral intake of fluids and food, postoperative rehabilitation exercises, and multimodal pain management. However, adherence to these behaviors is often suboptimal, and strategies t…
Rank100.5
The effect of different combinations of open invitations and timed appointments on breast screening attendance: service evaluation of invitation strategies in the NHS Breast Screening Programme.
British journal of cancer · 2026 · PMID 42129338
BACKGROUND: The NHS Breast Screening Programme invites eligible women using either a timed appointment letter (option to change), or an open invitation to make an appointment. Non-attenders receive a 'Timed' or 'Open' second invitation. NHS England commissioned a service evaluation to determine the effect of different combinations of timed and open invitations. METHODS: Seven services, selected to ensure adequate representation of diverse socio-economic, ethnic, urban/rural, and current uptake groups, participated.…
Rank100.5
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42508432
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. M…
Rank100.4
Association of mobile application information on multidisciplinary therapy and treatment compliance in early-stage breast cancer: A prospective multicenter randomized phase III study.
Breast (Edinburgh, Scotland) · 2026 · PMID 42150214
BACKGROUND: Multidisciplinary therapy (MDT) can improve early breast cancer outcome, while its treatment completion rate is critical. This study aimed to evaluate the association of a mobile health application (RJBC-APP) information on MDT and its treatment adherence, compared with standard clinical management. METHODS: The RJBC-APP study is a prospective, multicenter, randomized, phase 3 clinical trial that enrolled patients with early-stage breast cancer after MDT for adjuvant treatment. Eligible patients were ra…
Rank100.0
Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 41808362
BACKGROUND: Menopausal hormone therapy (MHT) is widely prescribed for alleviating menopausal symptoms. Prior studies have mainly focused on individual hormone therapy formulations. This meta-analysis comprehensively synthesized evidence across various regimens to systematically evaluate the association between MHT and breast cancer risk. MATERIALS AND METHODS: We systematically searched CNKI, Wanfang, PubMed, and Web of Science from inception through August 2024. Eligible studies examining breast cancer risk follow…
Rank100.0
Integrating Shared Decision-Making Into Breast Cancer Postmastectomy Reconstruction: A Systematic Review of Evidence, Barriers, and Real-World Implementation.
International journal of cancer · 2026 · PMID 42098969
This systematic review synthesizes empirical evidence on the development, effectiveness, patient experience, and implementation of decision aids (DAs) for postmastectomy breast reconstruction (PMBR) and to evaluate the role of pre-consultation educational interventions in supporting shared decision-making (SDM). Following PRISMA guidelines and a preregistered protocol (OSF: https://osf.io/mu9hv), six electronic databases and gray literature sources were searched for studies on PMBR DAs through November 2025. Eligib…
Rank100.0
The effects of exercise interventions on fatigue, body composition, physical fitness, and biomarkers in breast cancer patients during and after treatment: a systematic review and meta-analysis of randomized controlled trials.
Journal of cancer survivorship : research and practice · 2026 · PMID 40056311
BACKGROUND: Breast cancer is the leading cancer type among women, accounting for 24.5% of female cancer cases worldwide. OBJECTIVE: The purpose of this study is to systematically review and conduct a meta-analysis to evaluate the effects of exercise interventions on breast cancer patients at different stages of treatment. METHODS: Databases including PubMed, Cochrane Library, and Embase were searched for English-language randomized controlled trials (RCTs) published since 2000. The study included data from women ag…
Rank100.0
Pharmacological, psychosocial, and brain stimulation interventions in oncologic populations with mental disorders: An umbrella review.
Psychiatry research · 2026 · PMID 42184575
Mental health disorders frequently co-occur with oncological conditions, prompting an umbrella review(UR) to summarize meta-analytic evidence about the outcomes of pharmacological, psychosocial, and brain-stimulation interventions for psychiatric disorders in oncologic populations. We performed an UR of meta-analyses of randomized controlled trials(RCTs) documenting the efficacy of interventions for mental disorders in people with cancer(November 2, 2025). Re-calculated meta-analytic estimates employed the GRADE cr…
Rank100.0
Digital behavioural weight loss interventions for weight management in breast cancer survivors: A meta-analysis.
European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2026 · PMID 42385539
OBJECTIVE: This study aims to systematically evaluate the effectiveness of digital behavioural weight-loss interventions on body weight, BMI, waist circumference, physical activity, and quality of life in breast cancer survivors. METHODS: A comprehensive search was conducted across six databases, including PubMed, Scopus, Embase, Web of Science, CINAHL, and Cochrane Library, to identify eligible randomised controlled trials that investigated the effectiveness of digital behavioural weight loss interventions in weig…
Rank100.0
Application of patient navigation programs across the entire continuum of breast cancer care: a GRADE-assessed systematic review with meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42525303
BACKGROUND: Patient navigation programs (PNPs) have been increasingly applied in breast cancer (BC) care of underserved clients, as they can significantly assist them with coordinating services across the care continuum. However, existing evidence has produced inconclusive findings regarding the empirical adequacy of BC-related caring interventions developed from PNPs. Hence, the aim of the present systematic review and meta-analysis was to clarify the benefits of PNPs across all phases of the BC care continuum. Pr…
Rank100.0
Thermal ablation for early-stage breast cancer: cryoablation, microwave ablation, radiofrequency ablation, high-intensity focused ultrasound ablation, and laser ablation - a systematic review.
Breast (Edinburgh, Scotland) · 2026 · PMID 42322704
BACKGROUND: Thermal ablation techniques have been proposed as minimally invasive alternatives to surgery for early-stage breast cancer (BC), with the potential to reduce treatment burden while preserving oncological outcomes. The aim of this review was to evaluate the available evidence on the effectiveness and safety of thermal ablation techniques in patients with early-stage BC. METHODS: We conducted a systematic review and narrative synthesis in accordance with PRISMA guidelines. MEDLINE, Embase, the Cochrane Li…
Rank99.6
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41937088
BACKGROUND: Prognosis is poor, and treatment options are limited for patients with previously untreated, advanced triple-negative breast cancer (TNBC), especially for those who are not candidates for immunotherapy. PATIENTS AND METHODS: In the randomised, open-label, phase III TROPION-Breast02 trial, patients with previously untreated, locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option were randomly assigned 1:1 to datopotamab deruxtecan (Dato-DXd; 6 mg/kg intravenously every 3…
Rank99.6
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42150145
PURPOSE: The WSG TP-II trial (ClinicalTrials.gov identifier: NCT03272477) was designed to compare the impact of 12 weeks of neoadjuvant trastuzumab + pertuzumab combined with endocrine therapy (ET) versus chemotherapy (once per week paclitaxel) on the pathologic complete response (pCR) rate and survival in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC). Analysis of the primary end point revealed that the pCR rate in the paclitaxel + trastuzumab + pertuzu…
Rank99.4
24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 42070391
BACKGROUND: Aromatase inhibitor (AI) induced arthralgia/myalgia (AIA) is a frequent side-effect of adjuvant breast cancer (BC) endocrine therapy. We investigated the effect of a user-friendly activity tracker to accompany a 24-week walking program, from the start of adjuvant AI-therapy, on patient AIA symptom burden and medication adherence. METHODS: 320 early-stage BC patients were included and randomly allocated to the intervention (arm A, n = 158) or control arm (arm B, n = 162). The intervention in arm A was ai…
Rank99.2
Self-Management Support for Cancer Survivors at Risk of Cardiotoxicity: A Scoping Review.
Heart, lung & circulation · 2026 · PMID 42431760
BACKGROUND: Cancer survivorship has significantly increased globally. This success has brought new challenges, including the rise in cardiovascular complications due to cardiotoxic effects of cancer treatments. Self-management (SM) support is increasingly recognised as an important component in overcoming these challenges; however, its implementation into practice remains inconsistent. AIM: This scoping review aims to map the current landscape of SM for cancer survivors at risk of or experiencing cardiotoxicity, wi…
Rank98.2
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 42364416
BACKGROUND: Dose-dense (DD) adjuvant chemotherapy represents a standard treatment for patients with high-risk node-positive early-stage HER2-negative breast cancer (BC). In this exploratory analysis of the GIM2 trial, we investigated the efficacy of DD chemotherapy among patients with HER2-negative BC according to HER2 immunohistochemistry (IHC) score. METHODS: Patients with node-positive early BC were randomized to receive either DD or standard schedule anthracycline- and taxane-based chemotherapy. HER2 status was…
Rank98.1
The Effect of Yoga on Cancer-Related Fatigue and Quality of Life Among Racially and Ethnically Diverse Cancer Survivors: A Secondary Data Analysis.
Journal of integrative and complementary medicine · 2025 · PMID 40467527
Introduction: Survivors from racially and ethnically diverse backgrounds tend to experience cancer-related fatigue (CRF) at higher rates than non-Hispanic Whites (NHWs), often leading to a decline in quality of life (QOL). It is crucial to consider the impact their marginalized identities have on cancer outcomes. Although yoga has shown promise as a supportive intervention for CRF and QOL, existing research has largely centered on NHW populations. This study seeks to evaluate the impact of yoga on CRF and QOL among…
Rank97.8
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Annals of surgical oncology · 2026 · PMID 41739398
PURPOSE: We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study (NCT03036488). METHODS: Participants with previously untreated, early-stage TNBC (AJCC stage T1c N1-2 or T2-4 N0-2) were randomized 2:1 to neoadjuvant pembrolizumab/placebo plus paclitaxel-carboplatin for 4 cycles, followed by pembrolizumab/placebo plus doxorubicin/epirubicin an…
Rank97.0
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 40632989
PURPOSE: We investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor-positive (HR+) BC who had a live birth in the POSITIVE trial. PATIENTS AND METHODS: POSITIVE is a prospective trial that demonstrated no increased short-term risk of BC events in women with early HR+ BC who interrupted endocrine therapy (ET) to attempt pregnancy. We describe the frequency, duration, and laterality of breastfeeding and estimate the cumulative incidence of …
Safety And Adverse Effects134 records
Rank105.4
Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026 · PMID 42140114
BACKGROUND: Leptomeningeal disease (LMD) is an increasingly recognised late-stage complication of solid tumours (primarily melanoma, lung and breast cancers). It involves dissemination to the leptomeninges surrounding the brain and spinal cord and carries a poor prognosis ranging from 2-6 months. Recent advances in emerging therapies such as CNS-active targeted therapy, intrathecal agents, and early-phase immunotherapy necessitate an updated appraisal of prospective data. METHODS: A systematic search of MEDLINE, Em…
Rank104.5
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Annals of medicine · 2026 · PMID 41949990
BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…
Rank100.0
Per- and polyfluoroalkyl substances and the risk of thyroid and breast cancer: Evidence from a meta-analysis and computational toxicology.
Toxicology and applied pharmacology · 2026 · PMID 42392276
Per- and polyfluoroalkyl substances (PFAS) are persistent environmental pollutants with endocrine-disrupting and carcinogenic effects, but epidemiological evidence linking PFAS exposure to cancer remains inconsistent. We conducted a meta-analysis to systematically evaluate associations between PFAS exposure and risks of thyroid and breast cancer. Relevant literature published between January 2003 and May 2025 was retrieved from Web of Science and PubMed. The analysis showed that the pooled odds ratios (ORs) for per…
Rank100.0
Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42449201
OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in…
Rank100.0
Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 41808362
BACKGROUND: Menopausal hormone therapy (MHT) is widely prescribed for alleviating menopausal symptoms. Prior studies have mainly focused on individual hormone therapy formulations. This meta-analysis comprehensively synthesized evidence across various regimens to systematically evaluate the association between MHT and breast cancer risk. MATERIALS AND METHODS: We systematically searched CNKI, Wanfang, PubMed, and Web of Science from inception through August 2024. Eligible studies examining breast cancer risk follow…
Rank97.8
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Annals of surgical oncology · 2026 · PMID 41739398
PURPOSE: We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study (NCT03036488). METHODS: Participants with previously untreated, early-stage TNBC (AJCC stage T1c N1-2 or T2-4 N0-2) were randomized 2:1 to neoadjuvant pembrolizumab/placebo plus paclitaxel-carboplatin for 4 cycles, followed by pembrolizumab/placebo plus doxorubicin/epirubicin an…
Rank95.8
Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery.
Cancer biotherapy & radiopharmaceuticals · 2026 · PMID 41645929
OBJECTIVE: To assess the clinical impact of docetaxel and capecitabine administered under ultrasound-mediated enhancement in patients with advanced triple-negative breast cancer (TNBC), with an emphasis on safety, quality of life, immunological modulation, and therapeutic efficacy. METHODS: A total of 80 patients with advanced TNBC who received treatment at this institution between October 2021 and October 2022 were chosen at random and placed in either the control group (CG, n = 40) or the observation group (OG, n…
Rank94.8
Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.
Cancer chemotherapy and pharmacology · 2024 · PMID 38324036
PURPOSE: Myelosuppressive chemotherapy-induced neutropenia (CIN) remains a major limitation of cancer treatment efficacy, necessitating very expensive supportive care. Lithium carbonate, an inexpensive drug, can increase the number of neutrophils, possibly providing an efficacious and cost-effective alternative for treating CIN. The aim of this study was to determine whether lithium therapy can attenuate chemotherapy-induced neutropenia and leukopenia in breast cancer patients. METHODS: A total of 50 breast cancer …
Rank92.2
Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)].
EClinicalMedicine · 2026 · PMID 42541182
BACKGROUND: Postmastectomy radiation therapy (PMRT) improves locoregional control and survival in patients with early breast cancer, but it is unclear whether these benefits extend to human epidermal growth factor receptor 2 (HER2)-positive patients in the anti-HER2 era. METHODS: This was a retrospective cohort analysis of prospectively collected data from the phase III ALTTO trial and includes all ALTTO participants who underwent mastectomy regardless of randomisation arm. The phase III ALTTO trial enrolled patien…
Rank92.0
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.
Cancer chemotherapy and pharmacology · 2024 · PMID 38814343
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a treatment-limiting and debilitating neurotoxicity of many commonly used anti-cancer agents, including paclitaxel. The objective of this study was to confirm the previously found inverse association between pre-treatment blood concentrations of histidine and CIPN occurrence and examine relationships of other amino acids with CIPN severity. METHODS: Pre-treatment serum concentrations of 20 amino acids were measured in the SWOG S0221 (NCT00070564) tria…
Rank91.7
Acute adverse events of hypofractionated whole-breast radiotherapy with a simultaneous-integrated boost - Results from the randomized controlled HYPOSIB-trial (ARO 2013-05).
International journal of radiation oncology, biology, physics · 2026 · PMID 42537852
BACKGROUND: Moderate hypofractionation (HF) is standard of care for adjuvant whole-breast irradiation after breast-conserving surgery (BCS). While boost irradiation has traditionally been administered sequentially (seq) after whole-breast irradiation, a growing amount of data suggests that delivery of a simultaneous integrated boost (SIB) may be equally effective and tolerable. METHODS: HYPOSIB is a randomized controlled non-inferiority trial enrolling patients with breast cancer after BCS. Patients were randomized…
Rank89.4
Minimal incision-assisted endoscopic versus conventional open breast-conserving surgery: A multicentre randomized clinical trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 42497645
BACKGROUND: Compared with conventional open breast-conserving surgery (BCS), conventional endoscopic (E-BCS) mostly involves dual incisions, which provide an insignificant scarring benefit but increase the surgical difficulty and prolong the surgical time. In contrast, the novel minimal incision-assisted E-BCS (M-E-BCS) procedure enables a near-scarless operation with efficient and precise tumour resection through a single axillary incision. METHODS: This is a phase III, open-label, multicentre, superiority, random…
Rank85.0
Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program.
Maturitas · 2026 · PMID 42537360
Elinzanetant, a dual neurokinin-1/-3 receptor antagonist, is approved for the treatment of moderate-to-severe vasomotor symptoms. The double-blind, randomized, placebo-controlled Phase III OASIS-1-4 studies evaluated elinzanetant's efficacy and safety in diverse populations of women, including those with vasomotor symptoms associated with natural or surgical menopause (OASIS-1, -2, and -3) and caused by endocrine therapy for breast cancer (OASIS-4). Results were similar across all trials for the respective primary …
Rank85.0
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
Future oncology (London, England) · 2026 · PMID 42535874
Patients with advanced TNBC with PD-L1 CPS < 10 are typically treated with chemotherapy and experience poor outcomes. Sacituzumab tirumotecan (sac-TMT; MK-2870/SKB264) is a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate with a unique, bifunctional linker that maximizes payload delivery to tumor cells. Combining sac-TMT with immunotherapy may improve outcomes given their complementary respective direct cytotoxic and immune-mediated antitumor effects regardless of tumor PD-L1 expression. …
Rank85.0
Antioxidant Activity and Dose-Dependent Toxicity of a Traditionally Consumed Ipomoea pes-caprae Infusion Evaluated in a Triple-Negative Breast Cancer Xenograft Model.
Nutrients · 2026 · PMID 42514317
Background/Objectives: Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes and remains associated with limited therapeutic options and high systemic toxicity from conventional chemotherapy. Ipomoea pes-caprae is a coastal medicinal plant traditionally consumed in Mexico for inflammatory and renal disorders and contains bioactive metabolites with reported antioxidant and pharmacological properties. However, its antitumoral activity and systemic safety profile remain poorly under…
Rank77.4
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Cancer medicine · 2024 · PMID 38733172
BACKGROUND: Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial which demonstrated its efficacy and safety in HER2-positive metastatic/unresectable breast cancer after ≥2 anti-HER2-based regimens received at metastatic stage. METHODS: This multicenter real-world early access program included HER2-positive metastatic/unresectable breast patients pretreated with at least two lines of anti-HER2 regimens who rece…
Rank75.1
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.
Cancer biology & therapy · 2026 · PMID 42337391
BACKGROUND: CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions. MATERIALS: HR+/HER2- ABC patients who received CDK4/6i were enrolled from four cancer centers in China. RESULTS: A total of 350 patients were eligible for the study, involving 268 from the low-altitude group and 82 from the high-altitude group.…
Rank70.5
Air Pollution and Cardiac Remodeling and Function in Patients With Breast Cancer.
JAMA network open · 2026 · PMID 41538185
IMPORTANCE: The relationship between air pollution and cardiac remodeling in patients with cancer treated with cardiotoxic therapy is undefined. OBJECTIVE: To assess the associations between air pollutants and changes in cardiac function, structure, and remodeling in patients with breast cancer treated with anthracyclines and/or trastuzumab therapy. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal prospective cohort study included patients with breast cancer enrolled at multiple sites of a quaternary health car…
Rank63.6
Analysis of Lesion Shrinkage and Factors Influencing Shrinkage Following Radiofrequency Ablation of Breast Nodules: An Observational Study.
Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2026 · PMID 42454750
PURPOSE: To evaluate the reduction in ablated lesion volume after ultrasound-guided percutaneous radiofrequency ablation (RFA) for benign breast tumors and identify factors associated with shrinkage. METHODS: This retrospective study included 64 patients (244 benign breast tumors) treated with RFA from December 2014 to February 2021. All tumors were biopsy confirmed before ablation. Follow-up at 1, 3, 6, and 12 months measured nodule volume changes and recorded complications, with analyses at the individual nodule …
Rank62.3
[¹⁷⁷Lu]Lu-FAPI-2286 radioligand therapy in heavily pre-treated patients with advanced breast and gastrointestinal cancers: a single-center retrospective experience.
BMC cancer · 2026 · PMID 42215966
BACKGROUND: Breast and gastrointestinal (GI) cancers remain leading causes of cancer-related mortality worldwide, particularly in the metastatic setting, where therapeutic options are limited, and drug resistance inevitably develops. This study aims to evaluate the feasibility and safety of [177Lu]Lu-FAPI-2286 in patients with breast and GI cancers. METHODS: In this retrospective, single-center, observational analysis, we evaluated the safety, tolerability, and preliminary efficacy of [¹⁷⁷Lu]Lu-FAPI-2286 in 14 pati…
Rank55.0
Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients.
Cancer chemotherapy and pharmacology · 2024 · PMID 38678150
PURPOSE: The current candidate gene association study aims to investigate tag SNPs from the TACR1 gene as pharmacogenetic predictors of response to the antiemetic guidelines-recommended, NK-1 receptor antagonist-based, triple antiemetic regimens. METHODS: A set of eighteen tag SNPs of TACR1 were genotyped in breast cancer patients receiving anthracycline and cyclophosphamide (with/without docetaxel) applying real-time PCR-HRMA. Data analysis for 121 ultimately enrolled patients was initiated by defining haplotype b…
Rank53.3
Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.
Tumori · 2026 · PMID 42533373
Background and aimThere is limited data on the safety of switching between CDK4/6i to address toxicity-related permanent discontinuation in patients with HR+/HER2- advanced breast cancer (ABC).To overcome this issue, this international observational study included consecutive HR+/HER2- ABC patients treated with CDK4/6i at two cancer centers, who switched the CDK4/6i for toxicity. The study aimed to evaluate the safety, feasibility, and clinical impact of this approach.ResultsAmong 1413 patients, 67 (4.5%) switched …
Rank52.4
Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: a multicenter real-world study.
Therapeutic advances in medical oncology · 2026 · PMID 42539852
BACKGROUND: Dalpiciclib is the latest cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved in China. Real-world data regarding the efficacy and safety of dalpiciclib for metastatic breast cancer (MBC) are still insufficient. OBJECTIVES: This study aims to investigate the real-world outcomes of dalpiciclib in a more heterogeneous population of patients with MBC. DESIGN: We retrospectively collected data of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) MBC patients who re…
Rank52.2
Clinically interpretable machine-learning model for predicting heart mean dose using simple BEV-based metrics.
Medical dosimetry : official journal of the American Association of Medical Dosimetrists · 2026 · PMID 41724626
Radiation-induced cardiac toxicity remains a major concern in left-sided breast cancer radiotherapy, with mean heart dose (MHD) serving as a key predictor of long-term cardiac morbidity. This study aimed to develop a clinically interpretable machine-learning model to predict MHD using simple beam's-eye-view (BEV)-based heart-projection metrics. A retrospective cohort of 127 patients treated with postoperative left breast or chest wall radiotherapy including supraclavicular nodal irradiation was analyzed. Heart proj…
Rank51.6
The Impact of Neoadjuvant Chemotherapy on Implant-Based Breast Reconstruction Outcomes.
Plastic and reconstructive surgery · 2026 · PMID 40875534
BACKGROUND: Neoadjuvant chemotherapy (NACT) is a critical component of breast cancer treatment, yet its impact on tissue expander (TE)-based breast reconstruction remains unclear. The purpose of this study was to examine the impact of NACT on complication rates after immediate TE-based breast reconstruction and on the commencement of adjuvant radiotherapy. METHODS: Female patients who underwent immediate TE-based breast reconstruction between 2017 and 2022 were included. Inclusion criteria consisted of patients who…
Treatments That Failed Clinical Trials65 records
Rank100.5
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42508432
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. M…
Rank100.5
OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41833903
BACKGROUND: Intravenous (i.v.) paclitaxel (Taxol) requires prolonged infusion and is associated with hypersensitivity reactions and peripheral neuropathy. This study evaluated the efficacy and safety of DHP107, a novel oral formulation of paclitaxel, compared with i.v. paclitaxel in patients with HER2-negative, recurrent, or metastatic breast cancer. PATIENTS AND METHODS: This multinational, multicenter, open-label, randomized phase III trial evaluated the noninferiority of DHP107 compared with i.v. paclitaxel, wit…
Rank99.8
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41999978
BACKGROUND: Low Ki67 after short preoperative endocrine therapy (ET) indicates a favorable prognosis in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC). We investigated predictors of ET response in the West German Study Group (WSG) ADAPT-HR+/HER2- and ADAPTcycle trials. PATIENTS AND METHODS: ET response (Ki67 ≤10%) after 2- to 4-week standard ET, recurrence score (RS), and nodal status were used for treatment allocation. In ADAPT-HR+/HER2-, patients at hi…
Rank99.6
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41937088
BACKGROUND: Prognosis is poor, and treatment options are limited for patients with previously untreated, advanced triple-negative breast cancer (TNBC), especially for those who are not candidates for immunotherapy. PATIENTS AND METHODS: In the randomised, open-label, phase III TROPION-Breast02 trial, patients with previously untreated, locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option were randomly assigned 1:1 to datopotamab deruxtecan (Dato-DXd; 6 mg/kg intravenously every 3…
Rank99.2
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
Journal of the National Cancer Institute · 2026 · PMID 41712503
BACKGROUND: Patients with estrogen receptor-positive breast cancer have a substantial late risk of distant recurrence, but the long-term subtype-specific tamoxifen benefit remains poorly understood. METHODS: A secondary analysis of the Stockholm Tamoxifen randomized trials (1976-1997, n = 3930) with 20-year follow-up was conducted. Formalin-fixed, paraffin-embedded blocks were available for 2250 patients. A total of 952 patients with estrogen receptor-positive and HER2-negative tumors, classified as luminal A (n = …
Rank99.2
Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.
The Lancet. Oncology · 2026 · PMID 42372743
BACKGROUND: Results from several studies, including our 15-year analysis, showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on overall survival with the addition of partial or comprehensive regional lymph node irradiation after surgery in patients with breast cancer. Here, we present the scheduled 20-year analysis of the EORTC trial 22922/10925, evaluating the role of internal mammary and medial-supraclavicular (IM-MS) nodal irr…
Rank99.2
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
Nature medicine · 2026 · PMID 42350643
Patients with estrogen receptor-positive (ER+), HER2-negative, early breast cancer (BC) have low pathologic complete response (pCR) rates following neoadjuvant chemotherapy. Immune checkpoint inhibitors (ICIs) provide limited benefit in programmed death-ligand 1 (PD-L1)-negative tumors, characterized by an immune-cold tumor microenvironment. Here we hypothesized that immune-modulating stereotactic body radiation therapy (iSBRT; 3 × 8 Gy) could enhance response through tumor microenvironment reprogramming, and that …
Rank98.6
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.
ESMO open · 2026 · PMID 42275799
BACKGROUND: PADMA is a prospective, randomized, open-label, multicenter phase IV study comparing palbociclib and endocrine therapy (ET) with mono-chemotherapy (CT) +/- maintenance ET (at the discretion of the treating physician) as first-line therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (mBC). PATIENTS AND METHODS: Patients were randomly assigned 1:1 to receive first-line treatment with palbociclib + ET or i…
Rank98.2
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 42364416
BACKGROUND: Dose-dense (DD) adjuvant chemotherapy represents a standard treatment for patients with high-risk node-positive early-stage HER2-negative breast cancer (BC). In this exploratory analysis of the GIM2 trial, we investigated the efficacy of DD chemotherapy among patients with HER2-negative BC according to HER2 immunohistochemistry (IHC) score. METHODS: Patients with node-positive early BC were randomized to receive either DD or standard schedule anthracycline- and taxane-based chemotherapy. HER2 status was…
Rank98.0
Secondary Analysis of the CAN-Study, a Randomised Controlled Trial - Local Anaesthesia and Overall Survival.
Acta anaesthesiologica Scandinavica · 2026 · PMID 42210709
INTRODUCTION: This study investigates long-term survival in the Cancer and Anaesthesia (CAN) study, focusing on the potential impact of local anaesthetic infiltration during breast cancer surgery. A positive effect from peritumoral infiltration has recently been suggested. We conducted an exploratory data analysis to examine a possible association between uncontrolled exposure to local anaesthetics during breast cancer surgery and long-term survival. METHODS: Breast cancer patients were recruited to compare long-te…
Rank97.8
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Annals of surgical oncology · 2026 · PMID 41739398
PURPOSE: We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study (NCT03036488). METHODS: Participants with previously untreated, early-stage TNBC (AJCC stage T1c N1-2 or T2-4 N0-2) were randomized 2:1 to neoadjuvant pembrolizumab/placebo plus paclitaxel-carboplatin for 4 cycles, followed by pembrolizumab/placebo plus doxorubicin/epirubicin an…
Rank97.6
Should AI results be disclosed in mammography reports? A randomised survey study of patient responses to concordant and discordant interpretations.
European radiology · 2026 · PMID 41832929
OBJECTIVES: To assess how disclosing artificial intelligence (AI) results, particularly discordant findings, affects patient trust, anxiety, follow-up intentions, and attitudes toward AI in mammography. The study also assessed whether adding an explanatory note mitigates adverse reactions. MATERIALS AND METHODS: A cross-sectional randomised experimental survey was conducted among 600 women (mean age 55.4 ± 6.8 years) undergoing mammography in two academic centres in Milan, Italy, between January 2023 and January 20…
Rank97.6
Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).
Breast (Edinburgh, Scotland) · 2026 · PMID 41864056
BACKGROUND: Intensified anthracycline-based regimens are as effective as standard anthracycline-based chemotherapy with taxanes in unselected high-risk patients with early breast cancer and come with their own toxicity profiles. Many biomarkers linked to taxane resistance have been identified, but none are used clinically. A predictive biomarker for taxane resistance or sensitivity would help personalise treatment. METHODS: In the randomised controlled trial MATADOR (ISRCTN61893718), 664 patients with pT1-3, pN0-3 …
Rank97.3
Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42067068
PURPOSE/OBJECTIVE: The FAST-Forward randomised nodal sub-study primary analysis showed non-inferiority for 5-year patient-reported arm/hand swelling following adjuvant breast/chest wall and axillary radiotherapy given in 26 Gy in 5 fractions (Fr) over 1 week compared to 40 Gy in 15Fr over 3 weeks. This subsequent analysis investigates the association between patient, tumour and treatment factors and development of long-term arm/hand swelling. MATERIAL/METHODS: Data from 469 patients randomised to adjuvant radiother…
Rank97.2
Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis.
Breast cancer research and treatment · 2026 · PMID 42243522
INTRODUCTION: This study aims to evaluate the long-term skin-related patient-reported outcomes (PROs) of a randomized controlled trial (RCT) comparing Mepitel Film (MF) to standard of care (SOC) for the prevention of acute radiation dermatitis (ARD) in breast cancer patients undergoing radiation therapy (RT). METHODS: Patients were contacted via telephone at 6 months, 12 months, and 24 months post-RT to complete the Skin Symptom Assessment (SSA) and Radiation-induced Skin Reaction Assessment Scale (RISRAS). SSA and…
Rank97.1
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42372741
BACKGROUND: Patients with stage III, human epidermal-growth-factor-receptor 2 (HER2; also known as ERBB2)-negative breast cancer with homologous recombination deficiency (HRD) had a 4-year overall survival of 35% after anthracycline-based chemotherapy versus 78% after intensified alkylating chemotherapy with autologous stem cell rescue (IACT) in a post-hoc analysis of an earlier randomised controlled trial. In this study, we aimed to prospectively assess 4-year overall survival with IACT and establish whether this …
Rank96.8
A Prospective Randomized Trial Comparing Radioguided Occult Lesion Localization (ROLL) and Magnetic Seed Localization for the Localization of Nonpalpable Breast Lesions: Analysis of Surgical Outcomes, Patient's Perception, and Costs.
Annals of surgical oncology · 2026 · PMID 41936682
BACKGROUD: Accurate localization of nonpalpable breast lesions in breast-conserving surgery (BCS) is essential for achieving oncological radicality, preserving cosmetic outcomes, and reducing reinterventions for positive margins. Radioguided occult lesion localization (ROLL) and magnetic seed localization (MSL) are established alternatives to wire-guided methods, but comparative evidence remains limited. METHODS: This prospective, single-centre, randomized clinical trial evaluated the noninferiority of MSL compared…
Rank96.8
Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41915435
PURPOSE: Trastuzumab-based chemotherapy has improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, but treatment benefit varies among patients. Predictive signatures are needed to identify patients most likely to respond to these therapies. EXPERIMENTAL DESIGN: We developed Density and Spatial architecture of Tumor-Infiltrating Lymphocytes (DeSTIL), a computational signature derived from hematoxylin and eosin slides. The signature captures spatial organization of immune cells a…
Rank96.6
Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.
NEJM evidence · 2026 · PMID 42187551
BACKGROUND: Three-year data from a randomized trial comparing a single zoledronate infusion with infusions every 6 months were previously reported showing that a single infusion was associated with increased patient convenience, less toxicity, and lower rates of treatment discontinuation at 3 years. We now report the trial's final, prespecified 5-year follow-up data. METHODS: Patients who were postmenopausal (either naturally or treatment induced) with early breast cancer were randomly assigned to receive a single …
Rank96.3
Brief Post-Surgical Stress Management Intervention Effects on Positive Psychological Well-Being and Self-Efficacy in Women Being Treated With Adjuvant Endocrine Therapy for Hormone-Receptor Positive Breast Cancer.
Psycho-oncology · 2025 · PMID 40846861
BACKGROUND: Women prescribed adjuvant endocrine therapy (AET) for nonmetastatic breast cancer may experience a decline in positive psychological well-being (PPWB) and self-efficacy. Brief cognitive behavioral therapy (CBT) and relaxation training (RT) interventions have shown short-term efficacy in reducing distress, but their impact on PPWB and self-efficacy over longer periods among women prescribed AET is unknown. AIMS: We aimed to investigate longitudinal effects of CBT and RT on PPWB and self-efficacy among wo…
Rank96.2
Comparing Discharge Timing in Patients Undergoing Immediate Implant-Based Breast Reconstruction: A Randomized Controlled Trial.
Plastic and reconstructive surgery · 2026 · PMID 41247168
BACKGROUND: Implementation of enhanced recovery after surgery (ERAS) programs have shown that same-day discharge of patients undergoing immediate implant-based reconstruction following mastectomy is safe. The purpose of this study was to compare outcomes of patients in ERAS programs undergoing mastectomy with immediate implant-based breast reconstruction discharged on the day of the surgery (postoperative day [POD] 0) versus POD 1. METHODS: A randomized controlled trial was conducted on patients who underwent immed…
Rank95.9
The Effect of Life Coaching on Post-Traumatic Growth and Well-Being in Breast Cancer Survivors: A Randomized Controlled Trial.
Psycho-oncology · 2025 · PMID 41068064
BACKGROUND: Breast cancer survivors often experience psychosocial challenges, including fear of cancer recurrence, diminished quality of life, and are less aware of the potential for post-traumatic growth. Life coaching is a strengths-based, goal-directed approach that may promote adjustment and recovery after cancer. AIM: This randomized controlled trial evaluated the effects of a life coaching intervention on post-traumatic growth (PTG), fear of cancer recurrence (FCR), and quality of life (QoL) in breast cancer …
Rank95.8
Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery.
Cancer biotherapy & radiopharmaceuticals · 2026 · PMID 41645929
OBJECTIVE: To assess the clinical impact of docetaxel and capecitabine administered under ultrasound-mediated enhancement in patients with advanced triple-negative breast cancer (TNBC), with an emphasis on safety, quality of life, immunological modulation, and therapeutic efficacy. METHODS: A total of 80 patients with advanced TNBC who received treatment at this institution between October 2021 and October 2022 were chosen at random and placed in either the control group (CG, n = 40) or the observation group (OG, n…
Rank95.8
[Image-guided application of plant pigment patch and laser microdot ablation for surface marking in radiotherapy for breast cancer: a randomized controlled trial].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026 · PMID 42343850
OBJECTIVES: To validate the non-inferiority of plant-based pigment patches as surface markers for postoperative radiotherapy localization in breast cancer, evaluate their accuracy, durability and safety, and identify the factors influencing pigment fading to determine the patients eligible for these patches. METHODS: In this randomized controlled trial, 80 patients receiving their first course of postoperative radiotherapy for breast cancer were randomly assigned in a 1:1 ratio to plant-based pigment patch group (t…
Rank95.7
Investigating the effect of web-based education on positive mental health of family caregivers of breast cancer patients: a quasi-experimental study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42542461
BACKGROUND AND AIM: The increasing incidence of cancer and the fact that the family is an important factor in cancer care; attention to the positive mental health of cancer patients should be sought to provide solutions to improve the mental health of these caregivers. The present study aimed to investigate the effect of web-based education on positive mental health of family caregivers of breast cancer patients undergoing chemotherapy in educational and treatment centers of Zahedan University of Medical Sciences. …
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.